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I	
	
Abstract 
 
Myeloid and lymphoid malignancies are potentially curable through a graft versus 
leukaemia (GvL) effect following allogeneic haematopoietic stem cell transplantation. 
Whilst donor T cell are thought to be the main mediators of GvL, the effect of donor 
NK cells within HLA matched T cell depleted transplant setting is more unclear. 
Patient blood samples were analysed during the first month post-transplant, with 
higher reconstitution of NK cells at two weeks conferring a relapse protection 
association. Donor stem cell graft samples, from which NK cells within the patient at 
two weeks are thought to be derived, similarly displayed a strong association 
between high NK cell dose and protection from disease relapse. CD56dimDNAM+ NK 
cells were found to be the population with the most significant association. The ability 
of NK cells to kill AML blasts in a DNAM dependent manner was shown indicating 
that direct killing of residual tumour cells may be a valid mechanism of GvL. These 
findings suggest that optimising the number of NK cells within stem cell grafts should 
be considered as a means to prevent disease relapse.   
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Chapter 1 – Introduction 
 
This introduction aims to give the reader a background into the scientific areas 
investigated in this PhD project. The fundamental basis of immunology, and more 
specifically natural killer (NK) cells, are discussed first. The principles and application 
of allogeneic haematopoietic stem cell transplantation (allo-HSCT) is then defined, 
followed by a summary of the relevant literature concerning NK cell involvement 
within this setting. 
 
Adaptive and innate immunity 
 
The development of independent multicellular life some 800 million years ago 
brought with it the challenge of recognising self and non-self. The immune system 
has evolved with a primary role of protecting the body from infectious challenge and 
utilises a wide variety of cell types, tissues and organs that have developed to 
achieve this. Through the identification and removal of foreign or transformed cells, 
and the maintenance of a memory of past infections, the immune system acts as a 
vital regulator of body homeostasis. The reaction of the immune system when 
encountering foreign material can broadly be split into the more evolutionarily 
conserved innate response, driven by cells which recognise foreign or transformed 
molecules, and an adaptive response which develops to specifically eliminate and 
create a memory of an infection. 
The generation of an adaptive immune response, and subsequent expansion of 
antigen-specific cells, can take several days and the immediate innate immune 
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response is therefore important to initiate recognition, restrict the proliferation of an 
infected or transformed cell and promote an adaptive immune response (Figure 1.1). 
Lymphocytes are nucleated blood cells which act as the main mediators of the 
immune system. They form from haematopoietic stem cells within the bone marrow 
which can differentiate into many different subsets. For the purposes of this thesis, 
the three major lymphocyte cell types derived from the common lymphoid progenitor 
(CLP) are referenced. Natural killer cells and antibody producing B cells develop in 
the bone marrow. In contrast, CLPs which home to the thymus generate cells of the 
T lymphocyte lineage. Lymphocytes migrate out of these primary lymphoid organs 
into the bloodstream where they home to tissues and the lymphatic system. Lymph 
fluid transports lymphocytes to the secondary lymphatic tissues such as lymph 
nodes and the spleen. Lymphocytes are present in varying quantities throughout the 
body, within the lymphatic system, peripheral blood and various bodily tissues and 
are therefore suitably located to respond to antigenic challenge.  
Natural killer (NK) cells are considered to be a component of the innate immune 
system due to their ability to identify target cells through a broad repertoire of both 
activatory and inhibitory receptors on their cell surface. These receptors detect the 
presence or absence of ligands, rather than being ‘specific’ for an individual target 
structure as observed for T and B cell recognition (Lanier 2005; Moretta & Moretta 
2004b). This allows NK cells to become activated when they recognise targets that 
trigger an internal signalling reaction above a critical threshold (Holmes et al. 2011). 
The innate system response also includes macrophage, neutrophil and dendritic 
cells which mediate a range of functions, and have prominent phagocytic roles, 
engulfing dead and foreign molecules that they encounter. Dendritic cells are also 
known as antigen presenting cells (APC) and provide the main link between the 
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innate and adaptive responses. An innate response is vitally important upon initial 
infection to directly remove foreign material as well as initiating an inflammatory 
response and signalling through the release of cytokines to promote migration and 
activation of adaptive immune cells (Martinez et al. 2008). 
 
 
 
 
The adaptive immune system produces a specialised response against foreign (non-
self) cells as well as long lasting memory against specific pathogens. This process is 
initiated by immature APCs engulfing cells and proteins and presenting peptides on 
their surface using major histocompatibility complex (MHC) molecules. Almost all 
cells of the body present peptides on their surface through MHC molecules in this 
way. During synthesis, the MHC protein incorporates a short peptide onto its surface 
Figure 1.1 – Adaptive and innate immune response 
Infected or transformed cells can be recognised by members of the innate immune 
system. Natural killer cells may spontaneously eliminate cells if they are deemed “non-
self”. Antigen presenting cells can present peptides on the surface which can be 
recognised by adaptive immune T cells driving expansion of cytotoxic antigen specific 
CD8+ T cells. B cell response can also be initiated producing antibodies against the target 
cell, marking them for lysis.  
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which stabilizes its structure and allows it to be displayed on the surface of the cell. 
MHC class I molecules are found on most cell types and collect peptides from 
proteins made in the cytosol whilst MHC class II molecules are only found on 
subsets of cells within the immune system such as APC, and are recognised by 
CD4+ T cells  (Holling et al. 2004). 
Mature APC will migrate to lymphoid tissues and present peptides to cells of the 
adaptive immune system (Lim et al. 2012).  If a T lymphocyte expressing an antigen 
specific T cell receptor (TCR) engages with the MHC-peptide complex with sufficient 
affinity it will become activated and undergo proliferation and differentiation. A wide 
range of functional T cell subsets are generated in this process including CD8+ T 
lymphocytes (CTL) with cytotoxic function, CD4+ T helper cells and regulatory 
CD4+FoxP3+ T cells (Treg) which act to control immune responses (Ma et al. 2012; 
Murphy et al. 2008). Of note, B lymphocytes can also undergo somatic 
hypermutation to derive a surface immunoglobulin with increased affinity for the 
antigen. Broadly speaking, the primary role of CTL is to eliminate target cells whilst a 
subset of B cells can differentiate into plasma cells and relocate to the bone marrow 
where they secrete antibodies into the blood stream (Shulman et al. 2011; Murphy et 
al. 2008). The antibodies can then bind to their antigen and renders them susceptible 
to elimination through processes such as antibody-dependent cell-mediated 
cytotoxicity (ADCC) and complement fixation.  Most of the effector cells generated 
through a primary adaptive immune response will subsequently undergo apoptosis 
but a proportion are retained as memory cells to provide a more rapid response 
should re-encounter with the antigen occur (Gray 2002). 
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Tumour surveillance and immune evasion 
 
Cancer arises from the accumulation of somatic mutations and epigenetic 
modifications that leads to uncontrolled cellular proliferation. Cancer represents a 
significant threat for multicellular organisms and the immune system performs an 
important ‘surveillance’ role, monitoring the body for transformed cells and mediating 
their elimination.  
It is now clear that the rate of tumour development is greatly increased in many 
immunodeficient mouse strains (Swann & Smyth 2007). Immunodeficient mice are 
also more susceptible to tumours induced by chemical carcinogens (Engel et al. 
1997). Similarly, there is a higher risk of tumour development in immunosuppressed 
human patients although the range of tumours that is observed is of a more limited 
spectrum in comparison to the general population (Penn 1988; Buell et al. 2005).  
The development of spontaneous tumours in mice is also associated with 
impairment of immune function, such as loss of cytotoxic molecules or cytokine 
responses (Smyth et al. 2000; Street et al. 2002). Tumour cells are rejected in 
syngeneic transplantation models, indicating that ‘tumour-specific’ antigens are likely 
to be present (Burnet 1970).  
Both adaptive and innate immune systems are involved in tumour surveillance 
(Swann & Smyth 2007). Whilst T cells are considered the primary effector cells in 
this, the role of NK cells, which are capable of directly killing tumour cells, is also 
important to consider (Marcus et al. 2014). As discussed later, the expression of 
‘stress’ ligands can render tumour cells highly immunogenic, primarily for elimination 
by NK cells, whilst the generation of ‘neo-antigens’ from somatically mutated cancer 
genes is another dominant mechanism resulting in elimination by cytotoxic T cells 
6	
	
(Bauer et al. 1999; Diefenbach et al. 2001; Moretta et al. 2001). Despite this, cancer 
is highly prevalent in the population and cancers can evolve a range of mechanisms 
to evade detection by the immune system. 
Such mechanisms of immune evasion include the downregulation of antigens and 
cell adhesion molecules from the cell surface (Vinay et al. 2015; Beatty & Gladney 
2015). Many malignant cells downregulate MHC class I expression as a way to avoid 
T cell recognition (Garrido et al. 2016). Tumour cells can express ligands to 
suppress immune responses such as PD-L1, which engage with inhibitory 
‘checkpoint’ proteins on T cells and act to limit T cell function (Iwai et al. 2002). 
Secretion of immunosuppressive cytokines such as TGF-β, TNF-α and VEGF 
(Massagué 2008; Lind et al. 2004; Gabrilovich et al. 1996), recruitment of 
immunosuppressive cells such as Tregs, tumour-associated macrophages (TAMs), 
and myeloid-derived suppressor cells (MDSCs) and upregulation of phagocytic 
inhibition signals such as CD47 are additional mechanisms of immune evasion 
(Gajewski et al. 2013; Jaiswal et al. 2009).  
These mechanisms of immune evasion are commonly observed in haematological 
malignancies (Curran et al. 2017). Constitutive expression of PD-L1 and reduced 
expression of MHC class II molecules, caused by chromosomal changes, is seen in 
many cases of lymphoma (Green et al. 2010; Steidl et al. 2011). In leukaemia it is 
thought that the disseminated nature of the tumour means that danger associated 
molecular patterns (DAMPs) released upon immunogenic cancer cell death, which 
lead to the maturation of dendritic cells, are not present at a sufficient concentration 
to effectively produce a response (Zhang et al. 2013; Curran et al. 2016). 
Additionally haematological tumours generally have a lower mutational burden 
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compared to most solid malignancies and as such there may be a more limited 
repertoire of neo-antigens for presentation to T cells (Alexandrov et al. 2013). 
Understanding the mechanisms that lead to tumour immune evasion is one of the 
most important topics within medicine at the current time and may guide 
appropriately beneficial approaches for improving the effectiveness of tumour 
elimination through immunotherapeutic means (Gotwals et al. 2017). 
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Natural killer cells 
 
Natural killer cells are innate lymphocytes and play an important role in elimination of 
cells without prior sensitisation or activation. They are involved primarily in defence 
against viral infection and in tumour cell surveillance. Human NK cells are generally 
characterised as being CD3 negative (i.e. not T cells) and CD56 positive. CD56 is a 
140kDa isoform of neural cell adhesion molecule (NCAM), however the precise 
function of the protein on NK cells is not entirely clear. The degree of CD56 cell 
surface expression varies, such that NK cells either display high or low amounts. 
Generally, CD56bright NK cells are considered to be relatively immature and have a 
primary cytokine producing immunoregulatory function, whilst mature CD56dim NK 
cells display a cytotoxic effector function (Vivier et al. 2008). Further differentiation of 
NK cells using CD16 (FcRgIII), an Fc portion antibody receptor found on the majority 
of CD56dim cells, is also often used (Anegón et al. 1988; Cooper et al. 2001).  
Humans born with genetic disorders that impair NK cell function display susceptibility 
to viral infection and a high rate of premature death (Biron et al. 1989; Orange 2013). 
Similarly, in mice the artificial depletion of NK cells, through injection of rabbit 
antiserum against a glycosphingolipid present at the cell surface causing membrane 
damage and loss of function, results in impaired control of viral infection (Bukowski 
et al. 1983).  
NK cells represent 5-15% of circulating lymphocytes in human peripheral blood and 
they are also found in high numbers in lymphoid organs as well as throughout 
various tissues such as skin, gut, liver, lung, uterus, kidney, joints and breast tissue 
in normal physiological conditions (Carrega & Ferlazzo 2012). Murine models are 
often used to assess NK cell function however it is important to note the differences 
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between murine and human NK cells. NK cells represent only 2–7% of circulating 
lymphocytes in mouse peripheral blood and murine NK cells do not express CD56 
meaning comparative differentiation studies cannot therefore be done with accuracy. 
However, comparisons between CD11blowCD27high and CD11bhighCD27low NK cells 
in mice and CD56 subsets in humans are of value (Hayakawa & Smyth 2006). In 
contrast to the situation in humans, murine NK cells do not localise to lymph nodes in 
the resting state, but this can happen following activation (Martín-Fontecha et al. 
2004). Low levels of the cytotoxic proteins granzyme and perforin are found in 
resting murine NK cells compared to the constitutively high levels expressed in 
humans. Freshly isolated murine NK cells therefore display weaker cytotoxic activity 
compared to those isolated from humans (Fehniger et al. 2007; Leong & Fehniger 
2011). Whilst these considerations must be taken into account when translating 
murine data to that in humans, murine NK cells do share a large amount of ontogeny 
and functionality with human cells which has validated their use comparatively.  
 
 
NK cell development  
 
The origin of NK cells from haemopoietic tissue was first demonstrated with the 
observation that severely depleted NK cell numbers were found in mice with an 
impaired stem cell niche. Further work demonstrated that CD34+ haematopoietic 
stem cells (HSCs) cultured on bone marrow stroma could differentiate into NK cells 
in the presence of interleukin 15 (IL-15) and interleukin 2 (IL-2) (Kalland 1986). In 
humans, CD34+ NK cell precursors and differentiated NK cells leave the bone 
marrow to populate tissues throughout the body (Yu et al. 2013). These CD34+ NK 
cells precursors can establish themselves in secondary lymphoid tissues and 
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generate significant numbers of CD56bright NK cells (Freud et al. 2005). The presence 
of large numbers of dendritic cells expressing IL-15 in the secondary lymphoid 
tissues is thought to encourage this differentiation (Mattei et al. 2001; Mrózek et al. 
1996) as well as further maturation to a more cytotoxic CD56dim cell (Anguille et al. 
2015). IL-15 is also involved in NK cell homeostasis and survival, and mice devoid of 
IL-15 are unable to maintain mature NK cell numbers following adoptive transfer 
(Koka et al. 2003). 
The linear differentiation of human immature CD56bright into mature CD56dim NK cells 
has been proven both in vitro and in vivo through stimulation with fibroblasts or 
transfer to immune deficient mice (Chan et al. 2007). Additionally CD56bright cells 
have longer telomeres compared to CD56dim cells suggesting their relative 
immaturity (Romagnani et al. 2007). 
Chemokines are chemoattractant cytokines which act on G-protein coupled 
receptors to induce direct chemotaxis in nearby responsive cells. Most CD56bright NK 
cells express high levels of the chemokine receptors CXCR3, CXCR4, CCR5 and 
CCR7, as well as low levels of CX3CR1, and this maintains their preferential 
localisation within secondary lymphoid tissues such as peripheral lymph nodes and 
tonsils. CD56dim NK cells express high levels of CXCR1, CX3CR1 and CXCR4, as 
well as low levels of CXCR2 and CXCR3. They account for approximately 90% of 
NK cells in the circulating peripheral blood and are also present at higher proportions 
than CD56bright cells in the bone marrow and spleen. Both mature and immature NK 
cell subsets will migrate to sites of inflammation to assist in the innate immune 
response (Maghazachi 2010).  
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The maturity and functional status of NK cells can be assessed through the 
phenotypic expression of various extracellular and intracellular proteins (Figure 1.2). 
Immature cytokine producing NK cells are defined by high expression of the ‘neural 
cell adhesion molecule’ CD56 at the surface and are termed CD56bright. In general, 
during these immature stages of NK cell development CD161, 2B4 (CD244) and the 
activating receptor NKp44 are also expressed along with CD56 at the cell surface.  
 
 
 
 
 
Figure 1.2 –NK cell maturation 
Phenotypic differences between immature CD56bright NK cells which possess high 
proliferative capacity and are primarily involved in cytokine production, and mature 
CD56dim NK cells which have a primarily cytotoxic function through the release of 
cytotoxic granules.     
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As CD56bright NK cells mature and develop a more cytotoxic function their expression 
of CD56 decreases whilst expression of activatory receptors NKp46, NKp30, NKG2D 
and DNAM-1, as well as the inhibitory receptor CD94/NKG2A, are subsequently 
acquired (Moretta et al. 2001). CD16 and killer-cell immunoglobulin-like receptors 
(KIR) are expressed later on, and production of the cytotoxic molecules perforin and 
granzyme increases as cells develop a CD56dim phenotype. The levels of expression 
of these receptors determines the balance between stimulatory and inhibitory 
signalling that are received by the cell and the ultimate cytotoxic potential. An 
intermediate stage between CD56bright and CD56dim cells can be identified with the 
marker CD62L (Juelke et al. 2010). These cells possess the cytokine 
responsiveness of the CD56bright cells and the receptor mediated activation capacity 
of the CD56dim cells. Around half of the CD56dim NK cell population express CD57 
and display greater cytotoxic capacity, decreased responsiveness to cytokines and a 
reduced ability to proliferate, suggesting that it defines a population of terminally 
differentiated cells (Lopez-Vergès et al. 2010). 
NK cells proliferate relatively quickly and demonstrate a half-life of around 12 days in 
humans (Zhang et al. 2007). Active proliferation of cells can be detected by the 
presence of Ki-67, a nuclear protein which is present on the surface of chromosomes 
during all active phases of the cell cycle where it can be detected by intracellular 
staining (Scholzen & Gerdes 2000). In healthy individuals roughly 5% of peripheral 
blood NK cell express Ki-67 to maintain homeostatic conditions, however following 
infection or during tumour control NK cell proliferation can be increased to deal with 
the threat.  
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The functional state of an NK cell population is also an important consideration. The 
expression of activatory markers or the presence of cytotoxic molecules shows that 
an NK cell has the potential to be functionally cytotoxic. Expression of CD107 is a 
useful marker of recent cytotoxic activity (Alter. et al. 2004). This protein is also 
known as lysosomal-associated membrane glycoprotein 1 (LAMP-1) as it commonly 
resides on the lysosomal membranes of vesicles containing molecules ready to be 
secreted within NK cells. An active NK cell will undergo degranulation to release both 
cytokines and cytotoxic enzymes, requiring the lysosomes to fuse with the 
extracellular membrane, resulting in an increase in the expression of CD107 at the 
cell surface.    
Exhaustion of NK cell function has been associated with the clinical states of cancer 
and chronic infection (Bi & Tian 2017). Upregulation of the immune suppressor 
receptor PD-1 is associated with reduced anti-tumour activity by NK cells (Della 
Chiesa et al. 2016) and may be particularly prominent when seen in association with 
Tim-3 (Ndhlovu et al. 2012). Low levels of IFN-g production and decreased levels of 
activatory receptor and cytotoxic molecule expression are also seen in NK cells from 
human intratumoural sites (Bi & Tian 2017). The transcription factors T-bet and 
eomesodermin (Eomes) are crucial for NK cell development and maintenance of 
maturity as their deletion results in NK cell reversion to an immature phenotype 
(Simonetta et al. 2016). Both proteins are involved in the regulation of IFN-g 
production whilst T-bet is also thought to be important in regulating cytotoxic activity 
through production of perforin and granzyme B (Gordon et al. 2012). Loss of T-bet 
and Eomes has been shown to result in poor NK cell mediated tumour control in a 
murine model of melanoma, which could be recovered by adoptive transfer of wild 
type NK cells (Werneck et al. 2008). However these transferred NK cells are then 
14	
	
susceptible to T-bet and Eomes downregulation and rapid exhaustion of cellular 
function was shown in a lymphoma murine model (Gill et al. 2012). NK cell 
downregulation of T-bet and Eomes following human allo-HSCT has also been 
shown at around 8 months post-SCT and correlated with decreased NK function and 
increased non-relapse mortality (Simonetta et al. 2015). Collectively these studies 
highlight the important role that evasion of NK cell cytotoxic responses plays in the 
development of tumours and this may be achieved, at least partly, by differentiation 
of NK cells towards a more exhausted state. 
 
 
NK cell signalling receptors 
 
NK cells interact with their environment through expression of a wide range of 
activatory and inhibitory receptors present at the extracellular membrane. NK 
receptors are encoded by the germline and do not undergo RAG-mediated 
recombination as occurs with T and B lymphocytes (Lanier 1986). The presence or 
absence of ligands on the surface of stressed or transformed cells will induce 
intracellular signalling responses which, depending on the individual NK cell 
thresholds, will dictate its functional response (Lanier 2005) (Figure 1.3). Greater 
signalling is required to induce cytokine release compared to degranulation whilst 
chemokine induction requires the weakest signalling (Fauriat et al. 2010). 
Killer cell immunoglobulin-like receptors (KIR) are one such family of receptors 
whose intracellular domains confer inhibitory or activatory cytotoxic function. KIRs 
are part of the leukocyte receptor complex (LRC) gene cluster, which includes the 
killer lectin-like receptors (KLR), a group also containing both activatory and 
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inhibitory members (Moretta & Moretta 2004a). KIRs possess either two or three Ig-
like extracellular domains (KIR2D or KIR3D) and interact with HLA-Cw or HLA-A and 
HLA-B alleles respectively. Activatory KIRs possess a short cytoplasmic domain and 
a charged transmembrane region which associates with DAP12, an accessory 
signalling protein containing an immunoreceptor tyrosine-based activation motif 
(ITAM) (Radaev & Sun 2003). Upon ligand binding this ITAM becomes 
phosphorylated, stimulating intracellular signalling pathways. Inhibitory KIRs possess 
a long cytoplasmic domain containing an immunoreceptor tyrosine-based inhibition 
motif (ITIM). Ligand binding to these receptors causes phosphorylation of a tyrosine 
on the ITIM, which can then bind intracellular phosphatases itself. This localisation of 
phosphatases near the cell membrane causes inhibition of signalling from other 
activatory receptors by preventing stimulation of their ITAMs. Recent improvements 
in super high resolution imaging have identified that nanoclusters of KIR receptors 
are present at immune synapses between cells and that larger clusters result in 
stronger downstream signalling (Oszmiana et al. 2016). When activated through 
NKG2D ligands, the KIR nanoclusters reduce in size suggesting that the signalling 
threshold to convey inhibition is reduced and is a dynamic process constantly 
affected by changes in the environment. 
NKG2 proteins form heterodimers with CD94 to create a receptor. Both proteins are 
C-type lectins that together detect the presence of several MHC class I variants, 
most importantly HLA-E. CD94 is encoded by a single gene and is therefore 
invariant, whereas there are five NKG2 proteins (A, C, D, E and F) found in humans. 
CD94/NKG2 receptors are thought to promote cell survival, with NKG2A and B 
conferring an inhibitory cytotoxic influence and NKG2C, D and E an activatory one 
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(Gunturi et al. 2004). The function of NKG2F is not fully known, but it thought to 
associate with DAP12 and activate NK cells (Huang et al. 2010).  
NKG2D is an exception to the family as it does not dimerise with CD94 but forms a 
complex with adaptor protein DAP10 (Wu et al. 1999). NKG2D also has different 
ligands which are encoded from two different gene families, MIC and ULBP. This 
includes the MHC class I-like MIC-A and MIC-B proteins and the RAET1 protein 
family, three of which are ULBP proteins (Bauer et al. 1999). DAP10 does not 
contain an ITAM and therefore the PI3-kinase signalling cascade produced upon 
NKG2D ligand stimulation differs from that seen with most activatory receptors 
(Raulet et al. 2013). 
 
 
 
Figure 1.3 – NK cell receptors and ligands 
The activation of an NK cell is determined by a balance of signalling received from a 
repertoire of activatory and inhibitory receptors at the extracellular membrane. Ligands 
for activatory receptors are often upregulated on stressed or transformed cells.   
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The natural cytotoxicity receptor (NCR) family of activatory proteins, NKp30, NKp44 
and NKp46, were first identified in the late 1990s and named according to their 
molecular weight (Sivori et al. 1997; Vitale et al. 1998; Pende et al. 1999). The gene 
for NKp46 is located on chromosome 19 within the leukocyte receptor complex, 
while NKp30 and NKp44 are on chromosome 6. All three have a short cytoplasmic 
domain and associate with an ITAM. NKp46 expression is ubiquitous on NK cells, 
NKp44 is found only on activated cells and NKp30 on mature NKs (Kruse et al. 
2014). All three are capable of detecting viral ligands as well as those derived from 
bacterial and parasitic sources, but conclusive identification of cellular ligands is 
lacking. Tumour associated ligands have been shown for NKp44 and NKp30, but not 
for NKp46. Interestingly NKp46 ligands have been found in insulin granules of 
pancreatic β Langerhans cells (Gur et al. 2013). NK cells can kill β Langerhans cells 
expressing the ligand and could therefore be involved in the pathogenesis of type 1 
diabetes (Gur et al. 2010).  
 
The Fcγ receptor CD16 has an essential activatory signalling role in inducing 
antibody dependant cellular cytotoxicity (ADCC) against targets as well as some 
antibody independent cytotoxic functionality (Mandelboim et al. 1999). Its stimulation 
induces ITAM phosphorylation and can cause cell degranulation in resting NK cells 
alone, whereas other activatory receptors require co-activation (Bryceson et al. 
2005). 
DNAM-1 (CD226) is a DNAX accessory molecule which acts as an adhesion 
molecule and has been shown to confer cytotoxic functionality against a variety of 
tumour targets (Shibuya et al. 1996). Upon cellular stimulation, DNAM polarises 
towards the generating immunological synapse between an effector and target cell 
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and is thought assist lymphocyte function-associated protein 1 (LFA1) in creating 
adhesion points around the synapse and stabilising the cytoskeleton (Hou et al. 
2014; Martinet, Ferrari De Andrade, et al. 2015). DNAM does not associate with an 
ITAM molecule, rather the intracellular domain is directly phosphorylated upon 
activation to induce downstream phosphorylation of SLP-76 and Vav1, leading to 
cytotoxic granule exocytosis as well as IFN-γ secretion (de Andrade et al. 2014; 
Martinet, Ferrari De Andrade, et al. 2015). 
The pattern of intracellular signalling that is induced by receptor engagement is 
integrated in order to determine the cellular response. If the threshold for cytotoxic 
activation is reached, NK cells can then secrete cytotoxic granules containing 
granzyme and perforin by exocytosis (Smyth et al. 2005). Perforin proteins can 
oligomerise to form membrane spanning pores on the target cell, at a neutral pH and 
in the presence of Ca2+ (Voskoboinik et al. 2015). The pores formed by perforin 
assist in the diffusion of granzymes into the cell, however the precise mechanism is 
not fully understood. Once within the cytosol granzymes can induce target cell 
apoptosis through cleavage of target cell proteins and initiation of cell death 
pathways.  
Alternatively, NK cells can kill a target through death receptor pathways. TNF family 
proteins Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) 
expressed on NK cells can induce caspase dependent apoptosis when formation of 
an immune synapse results in contact with their receptor on the surface of a target 
cell (Smyth et al. 2005). Expression of FASL and TRAIL is regulated by IFN-γ, an 
important cytokine in NK cell function.  
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CD56bright NK cells play an important immunoregulatory role within the immune 
system. They comprise the major NK cell population within the secondary lymphoid 
organs and are in contact with APCs and T cells (Caligiuri 2008). Activation of NK 
cells by interleukins or activatory receptors results in the production of pro-
inflammatory cytokines such as IFN-γ and TNF-α. IFN-γ can activate APCs to induce 
a cytotoxic T cell response providing an important link between the innate and 
adaptive immune systems (Mocikat et al. 2003; Kelly et al. 2002).   
 
 
NK cell self-tolerance and education 
	
NK cells were first identified in mice during the 1970’s due to their ability to 
spontaneously kill tumour cells, as shown through antibody-independent in vitro 
cytotoxicity assays against lymphoma cell lines (Kiessling, Klein, et al. 1975; 
Herberman et al. 1975).  The “missing self” hypothesis was proposed as a 
mechanism to explain how NK cells could identify target cells due to a lack in 
expression of normal “self” markers (Ljunggren & Kärre 1990). This was based upon 
the observed rejection of parental MHC homozygous bone marrow grafts and the 
elimination of tumour cell lines expressing low amounts of MHC class I molecules 
(Kiessling, Petranyi, et al. 1975; Kärre et al. 1986). This hypothesis was backed up 
by the identification of inhibitory murine Ly49 receptors and killer immunoglobulin-like 
receptors (KIRs) and CD94/NKG2A in humans, at the surface of NK cells which 
could bind to MHC class I molecules (Moretta et al. 1996; Braud et al. 1998; 
Yokoyama & Seaman 1993).  
However, it has also been observed in both mice and humans that not all NK cells 
within an individual express an MHC inhibitory receptor (Fernandez et al. 2005; 
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Anfossi et al. 2006). Interestingly these NK cells were still self-tolerant but also less 
responsive to tumour cell killing. Similarly, in mice mutated to be MHC Class I null 
the NK cell populations are normal in number and self-tolerant but displayed low 
efficiency in tumour cell killing (Liao et al. 1991; Dorfman et al. 1997). It has also 
been shown that the responsiveness of NK cells is directly proportional to the 
number of different self-specific inhibitory receptors they display (Joncker et al. 
2009). Therefore, a greater repertoire of receptors on each NK cell gives greater 
sensitivity. Whether NK cells are initially highly responsive but become “disarmed” 
when minimal interaction with MHC molecules occurs in normal situations, or if the 
NK cells are originally poorly responsive but become “armed” through interaction 
with MHC molecules, is not clear (Raulet & Vance 2006). Either way NK cells which 
have experienced this MHC class I education are often termed ‘licenced’, whilst 
those which have not, and are less responsive, are termed ‘unlicensed’.  
NK cells also express a wide variety of activatory receptors on the cell surface which 
recognise stress ligands that are only expressed or are upregulated on unhealthy 
cells (Raulet et al. 2013; Marcus et al. 2014). The presence of these ligands is also 
thought to be involved in NK cell education. Mice with mutations in NKG2D and 
NKp46 receptors displayed increased killing of certain targets (Zafirova et al. 2009; 
Narni-Mancinelli et al. 2012). Additionally, sustained NKG2D or Ly49H ligand 
expression in transgenic mice has been shown to produce decreased functionality of 
the NK cells in some cases (Oppenheim et al. 2005; Sun & Lanier 2008).   
Therefore, the steady state inhibitory and activatory inputs that NK cells receive in 
the normal environment are thought to set the ‘responsiveness’ level of the cell. 
Interestingly this threshold can change when in a different MHC environment. 
Wildtype NK cells transferred to a MHC class I deficient mouse become less 
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responsive after a few days (Joncker et al. 2010).  The opposite is also found with 
NK cell responsiveness increasing following transfer from MHC class I deficient 
mouse into a wildtype host (Elliott et al. 2010). This NK cell “tuning” helps to create 
an NK cell population suitably poised to detect any abnormalities in the environments 
it encounters (Shifrin et al. 2014).  
 
Mechanism of NK cell cytotoxic function 
 
The primary function of mature CD56dim NK cells is to eliminate cells that are 
identified as foreign or transformed, through natural cytotoxicity or antibody-mediated 
cytotoxicity. To do this NK cells must receive sufficient stimulus from a target cell 
through the expression of stress ligands and the lack of MHC class I molecules. 
Apoptosis of the target cell is then induced through the release of cytotoxic granules 
or the engagement of death receptors (Smyth et al. 2005). 
The release of these cytotoxic granules is complexly regulated by a variety of 
proteins which are required for effective lysosome release (Topham & Hewitt 2009; 
Bryceson et al. 2011). Upon contact with a target cell, interactions with activatory 
and inhibitory receptors determine whether signalling induces LFA-1, a cellular 
adhesion molecule, to promote adhesion (Bryceson et al. 2009). The NK cell 
reorganises its actin cytoskeleton to form an immunological synapse with the target 
(Vyas et al. 2001). Further signalling between ligands and receptors happens with 
the resultant signalling cascade determining whether a cytolytic or non-cytolytic 
event will occur. In resting NK cells these signal from individual receptors can 
separately induce polarisation of cytotoxic granules to the immunological synapse or 
their exocytosis, indicating that a combination of receptor activation is required to 
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induce NK cell cytotoxicity (Bryceson et al. 2005). Signalling of several NK cell 
activating receptors, including NKG2D and NKp46, which stimulate the ERK2 and 
JNK1 pathways are required to induce polarisation of the microtubule-organizing 
centre (MTOC) towards the immunological synapse (Chen et al. 2007). Recruitment 
of the MTOC is necessary for the cytotoxic granules to polarise as well. At the 
extracellular membrane the cytotoxic granules dock, but complete fusion and release 
of the contents of the granules requires the formation of a soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) complex between the two 
membranes (Jahn & Scheller 2006).  
Upon their release across the immunological synapse, perforin is thought to assist 
the entrance of granzymes into the target cell by punching holes though the 
extracellular membrane. Once inside the granzymes help induce apoptosis by 
activating several different forms of programmed cell death signalling. Granzyme B 
in particular activates caspases within the cell and cleaves proteins of its own to 
induce a mitochondrial apoptotic pathway and cause DNA damage (Lieberman 
2003).  
Following death of the target the NK cell can go on to serially kill multiple target cells 
before their levels of perforin and granzyme become significantly reduced (Bhat & 
Watzl 2007a). Dependent upon the susceptibility of the target cells and the prowess 
of an individual NK cell, serial killing of up to 14 target cells has been observed in 
vitro in a 6-hour assay (Choi & Mitchison 2013). In these experiments a genetically 
encoded reporter of granzyme B activity was used to assess single cell killing 
dynamics. Following the relatively slow identification and subsequent killing of an 
initial target cell, NK cells are then able to rapidly kill other cells nearby. It is thought 
that this is achieved due to the NK cell making another immunological synapse 
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connection with a new target cell before detaching from the initial one, resulting in 
cross over of the signalling instigated by the initial target, priming the NK cell for 
further killing (Choi & Mitchison 2013).   
After reaching a point of ‘exhaustion’ following serial killing a small fraction of NK 
cells will not survive and undergo apoptosis themselves. Most NK cells however will 
survive and can recover their stocks of cytotoxic granules and functional ability 
following culture with IL-2 (Bhat & Watzl 2007a). 
Whilst certain tumour cell lines can be killed by freshly isolated resting human NK 
cells, many are resistant to NK cell killing, and those susceptible can be made 
resistant through the transfection of HLA molecules (Hasenkamp et al. 2006; 
Ciccone et al. 1992). Individual stimulation of natural cytotoxicity receptors, including 
NKp46, NKG2D and DNAM, is not sufficient to induce cytotoxic granule polarisation 
and release in resting NK cells to produce target cell lysis, but a combination of 
coactivatory receptors can be (Bryceson et al. 2006). 
The ability of NK cells to kill target cells can, however, be greatly enhanced through 
stimulation via cytokines or inflammatory stimuli, most notably IL-2 (Kehrl et al. 
1988). These “lymphokine-activated killer cells” are capable of eliminating NK 
resistant tumour cell lines (Pisani et al. 1989; Lehmann et al. 2001) and it is thought 
that IL-2 stimulation may provide an independent signal to induce cytotoxic granule 
exocytosis. Partial restoration of this function can be achieved in NK cells taken from 
patients with a loss of function SNARE mutation when cultured in high levels of IL-2 
(Bryceson et al. 2007). Similarly “tumour primed” NK cells, those which have been 
pre-incubated with certain leukaemia cell lines, are then able to kill NK cell resistant 
tumour cells (North et al. 2007; Sabry et al. 2011). 
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A two-step process of NK cell activation occurs where both the priming and 
triggering of an NK cell is required, with the initial signalling potentially provided by 
appropriate ligands or by cytokine stimulation (North et al. 2007). NK cell susceptible 
cell lines induce both the priming and triggering of resting NK cells whereas NK cell-
resistant cell lines often do not induce an initial priming signal, but can become 
susceptible when a priming signal is provided from another source.  
In patients with established tumours it is clear that the autologous NK cell response 
has proven unable to control the transformed cells. Aberrant NK cell function has 
been associated with impaired prognosis in many different cancer patients 
(Tratkiewicz & Szer 1990; Brenner et al. 2010.; Larsen et al. 2014; Vitale et al. 
2014). Interestingly many cancer treatments, such as chemotherapy, radiotherapy or 
autologous bone marrow transplant, act to reduce the tumour burden and it is 
believed that this may help a induce a protective immune response (Lowdell et al. 
2002). 
In the setting of allogeneic transplantation, a potential HLA mismatch between the 
donor and recipient may allow the development of alloreactive NK cells. Indeed, 
these cells are thought to contribute to the curative potential of haematopoietic stem 
cell transplantation (Ruggeri et al. 2002) and the use of primed NK cells as an 
adoptive immunotherapy has been demonstrated (Ruggeri et al. 2015a).  
 
NK cell repertoire diversity  
 
Recent investigations are revealing a high level of diversity within the NK cell 
repertoire. Populations of self-renewing “memory” NK cells have features in common 
with adaptive immunity function (O’Leary et al. 2006; Sun et al. 2009). This 
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CD56dimNKG2C+CD57+ population increases with age, although in those infected 
with cytomegalovirus (CMV) there is a large increase of NKG2C+ NK cells which 
also acquire a CD57 phenotype (Solana et al. 2014). In CMV seropositive children 
an initial increase in frequency of such NK cells occurs up to around 12 years but 
then plateaus off with an increased proportion of CD56dim cells expressing CD57 and 
expansion of NKG2C+ cells (Goodier et al. 2014). Of note, children with 
homozygous absence of the NKG2C gene demonstrate elevated anti-HCMV IgG 
titres suggesting poorly controlled infection which may be secondary to impaired NK 
cell function. These observations reveal that the NK cell repertoire is substantially 
dependent upon the history of environmental infectious challenge. 
Significant variation in the expression of cell surface receptors between individuals 
has been shown using mass cytometry to analyse NK cells from monozygotic twins 
as well as unrelated individuals (Horowitz, et al. 2013). Inhibitory receptor expression 
was found to be determined primarily by genotype whilst activation receptor 
expression was substantially influenced by environmental factors. Over 100,000 
different NK cell phenotypes were identified and around 6,000-30,000 of these were 
expressed within each individual. The diversity of an individual’s NK cell repertoire 
increases both with ageing and previous exposure to viral infections and this may 
result in less efficient response to subsequent infections (Strauss-Albee et al. 2015). 
Additionally the constantly changing receptor expression at the NK cell surface and 
changes in their spatial distribution may produce differential signalling responses 
(Pageon et al. 2013). 
The diversity of receptors on NK cells within an individual also creates a range of 
responsiveness of those NK cells through their NK cell education to the steady state 
(Shifrin et al. 2014). As such they are likely to be able to play different roles within 
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innate immune responses. NK cells which do not express MHC class I inhibitory 
receptors are considered to have a lower responsiveness to target cells than those 
which do. However, within the context of mice experiencing viral infection, and the 
cytokine and inflammatory stimuli produced, these NK cells were found to 
preferentially expand and provide greater protection than NK cells expressing 
inhibitory receptors (Orr et al. 2010). This enhancement is thought to override the 
usual NK cell tuning adaption to a new environment, allowing the NK cells to remain 
functionally active against the infected cells. NK cells which express MHC inhibitory 
receptors and have been educated are considered as ‘licenced’ and highly 
responsive. These NK cells are more adept at recognising decreased expression of 
MHC class I molecules on unhealthy cells and are therefore thought to be more 
beneficial in tumour surveillance. (Kusunoki et al. 2000; Shifrin et al. 2014).  
The diversity of the NK cell repertoire, its dynamically responsive capacity and ability 
to eliminate tumour cells gives them the potential to be profoundly beneficial for anti-
cancer responses.  
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Haematopoietic stem cell transplantation 
 
Haematological malignancies represent around 10% of all cancers and, despite 
recent improvements in immune-chemotherapy, many patients are not cured with 
standard treatment.  Allogeneic haematopoietic stem cell transplantation (allo-HSCT) 
may represent an effective curative treatment in this setting (Figure 1.4). Patients 
receive chemotherapy and/or irradiation in an effort to provide space for the donor 
cells and also to eliminate residual malignant cells. Following this ‘conditioning’ 
therapy, haematopoietic stem cells are then collected from a donor and delivered 
through intravenous infusion. Engraftment of donor stem cells and establishment of 
haemopoiesis usually occurs within two to three weeks post-transplantation. 
However, it can take years for full reconstitution of the immune system to occur 
(Ogonek et al. 2016). Importantly donor cells may act to eliminate residual tumour 
cells within the host, in a process termed a ‘graft versus leukaemia’ (GvL) response, 
which can effectively cure the patient (Horowitz et al. 1990). However, this is usually 
accompanied by a donor cell response against healthy host tissues, termed ‘graft 
versus host disease’ (GvHD), which remains a major post-transplant complication.  
 
Donor selection and apheresis  
	
Most patients and donors are closely matched for major histocompatibility antigens 
such as HLA-A, -B, -C, -DR, -DQ and –DP (Nowak 2008; Howard et al. 2015). This 
is usually achieved through the use of sibling or matched unrelated donors although 
the use of haploidentical transplantation is increasing (Koh & Chao 2008). Close 
matching of HLA alleles limits the intensity of the donor-mediated alloreactive 
immune response and also ensures that the graft itself is not rejected.  
28	
	
 
 
The donor cells that are critical to establish donor haemopoiesis are CD34+ 
haematopoietic stem cells which are found within bone marrow. These cells can be 
obtained directly from the donor by bone marrow aspiration from the pelvis. Umbilical 
cord blood is another source of stem cells and was initially demonstrated to be 
efficacious in a paediatric setting before translation to adults (Kurtzberg et al. 1996; 
Laughlin et al. 2001). However low stem cell number and expense are limiting 
factors along with slower engraftment and immune reconstitution following infusion 
resulting in an increased risk of infection (Brunstein et al. 2010; Ballen 2017).  
The most common source of CD34+ haemopoietic stem cells is now from mobilised 
peripheral blood. Peripheral administration of a mobilising drug leads to movement of 
Figure 1.4 - Allogeneic haematopoietic stem cell transplantation 
Patients undergoing allogeneic haematopoietic stem cell transplantation receive 
chemotherapy conditioning to significantly eradicate their tumour and haematopoietic 
cells. Cells from a HLA matched donor are infused and engraftment of progenitor cells 
and the reconstitution of the immune environment occurs. The curative nature of this 
treatment is achieved if donor haematopoietic cells confer a graft versus leukaemia effect 
and eliminate any residual tumour within the host. 
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CD34+ cells from the bone marrow such that they migrate into the peripheral blood, 
where they can be collected by a process of apheresis (Gyger et al. 2000). Stem cell 
processing acts to concentrate the leucocyte fraction containing the CD34+ cellular 
fraction (Reddy 2005). The graft can be stored for up to a day without greatly 
affecting cell viability before being infused into the patient (Sugrue et al. 1998). 
 
G-CSF mobilised grafts 
 
The most common drug used to mobilise the haematopoietic stem cells is 
granulocyte-colony stimulating factor (G-CSF). Knock-out of G-CSF in mice results in 
severe neutropenia and led to studies that revealed the importance of G-CSF for 
stimulation and proliferation of haematopoietic progenitor cells (Lieschke et al. 1994). 
The use of G-CSF clinically to improve haemopoietic recovery after chemotherapy is 
valuable to reduce infection risk and is associated with minimal long term effects 
(Welte 2012). The observation that CD34+ progenitor cell frequency in the peripheral 
blood increased significantly unexpectedly indicated the potential use of G-CSF to 
mobilise stem cells in healthy adult donors for allo-HSCT, as an alternative to bone 
marrow stem cell collection (Lane et al. 1995; Bensinger et al. 1993).  
G-CSF mobilisation results in a significantly higher yield of CD34+ progenitor cells 
and substantial increase in the frequency of lymphocytes within the apheresis 
product in comparison to bone marrow derived grafts (Theilgaard-Mönch et al. 2001; 
Körbling & Freireich 2011). Analysis of 3465 patients with acute leukaemia has 
shown that the use of peripheral blood derived grafts is associated with an increased 
rate of chronic GvHD in comparison to bone marrow, however effects on disease 
free survival and overall survival are considered to be relatively similar (Körbling & 
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Freireich 2011; Ringdén et al. 2002). Bone marrow grafts are preferred for patients 
with aplastic anaemia as they carry a lower acute GvHD risk (Eapen et al. 2011). As 
a beneficial GvL response is not required in these patients the lower frequency of 
lymphocytes infused with a bone marrow derived source of stem cells makes it the 
safer option for those patients. Peripheral blood derived stem cell grafts generate a 
faster post-transplant neutrophil and platelet recovery time compared to grafts 
sourced directly from the bone marrow, and are considered safer and cause less 
discomfort for donors (Körbling et al. 1995; Bensinger 2012).  Therefore G-CSF 
mobilised peripheral blood has become the most common source of stem cell grafts 
in Europe (Baldomero et al. 2011). 
 
The receptor for G-CSF (CD114/G-CSFR) is expressed on CD34+ haematopoietic 
progenitor cells as well as neutrophils, monocytes and endothelial cells. Surprisingly 
murine studies have shown that binding of G-CSF to the receptor on progenitor cells 
is not required for mobilisation (Liu et al. 2000). It is thought that G-CSF acts by 
disrupting the (VLA)-4/VCAM1 and CXCL12/CXCR4 interactions which retain 
progenitors in the bone marrow (Bendall & Bradstock 2014). Treating healthy 
individuals with G-CSF results in increased numbers of lymphocytes, 
polymorphonuclear and CD34+ cells in the peripheral blood (Körbling et al. 1995). 
However, the precise number of cells collected from adult donors will vary due to 
weight, gender and G-CSF dose scheduling, as well as genetic polymorphisms in the 
molecules used to mobilise haematopoietic stem cells, and previous chemotherapy 
treatments. Ultimately this means that there is variation in both the number of CD34+ 
haemopoietic stem cells collected from each donor and in the dose of other lymphoid 
effector cells patients will receive in their stem cell graft (Chatta et al. 1994). It is 
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known that such effector cells mount the allogeneic immune responses required for 
both GvL and GvHD and the use of in vivo T cell depletion (alemtuzumab and ATG) 
has abrogated the clinical manifestations of donor T cell mediated GvHD (Kanda et 
al. 2011; Bacigalupo et al. 2001).  
 
Conditioning and T cell depletion 
 
Prior to transplantation patients are given a one to two week course of chemotherapy 
in an attempt to eradicate residual tumour and host haemopoietic cells. Full intensity 
myeloablative conditioning carries the risk of damaging other major organs in the 
body and producing significant side effects which may be especially harmful to older 
patients or those with pre-existing conditions and therefore is not always a viable 
option. Within the past two decades reduced intensity conditioning (RIC) using 
primarily fludarabine and dose reductions of other drugs or total body irradiation 
(TBI) has allowed HSCT to be given to a far greater range of patients. The 
effectiveness of RIC in producing sustained disease free survival and reducing non-
relapse mortality in AML patients who would otherwise not have been treated has 
now been proven (Tauro et al. 2005; Sengsayadeth et al. 2015). Whilst the 
comparative effectiveness of RIC over fully myeloablative conditioning is difficult to 
ascertain due to their use in different transplant settings, the benefits and broad 
application of the reduced treatment has made it the most common form of 
conditioning therapy at our institution (Russell et al. 2015).    
In the UK most patients will also receive drugs to mediate T cell depletion as a 
measure to limit the development of GvHD (Waldmann et al. 1984; Kanda et al. 
2011). However this also leads to higher risk of disease relapse in patients (Soiffer et 
al. 2011). Commonly at our institution the drug alemtuzumab (Campath-1H), a 
32	
	
humanised CD52 monoclonal antibody is used. The physiological role of CD52 is 
uncertain but it is expressed at varying levels on T, B and NK lymphocytes as well as 
most monocytes, macrophages and a subpopulation of granulocytes (Domagała & 
Kurpisz 2001). Alemtuzumab binds to CD52 and can induce lysis of T cells, resulting 
in lower GvHD rates although there is inevitably an associated increase in the rate of 
relapse (Hale et al. 1998; Kanda et al. 2011). The density of expression of CD52 on 
the surface of cells directly correlates with the cytolytic effect of Alemtuzumab in vitro 
(Rao et al. 2012). Therefore T cells, which have a relatively high CD52 density, are 
more effectively killed than the lower density expressing NK cells. Anti-thymocyte 
globulin (ATG) is a polyclonal antibody, which depletes T cell primarily through 
complement dependent lysis and activation-associated apoptosis, and is also used 
for T cell depletion in some conditioning regimens (Mohty 2007).  
Following infusion of the stem cell graft, recipients usually require inpatient hospital 
care for approximately two weeks prior to stem cell engraftment and the production 
of granulocytes (neutrophils) and platelets. In their immunocompromised state 
patients are prone to infection and are therefore carefully monitored and require 
blood product support. 
 
Immune reconstitution following allo-HSCT 
 
Successful allo-HSCT will result in engraftment of donor haematopoietic progenitor 
cells within the host bone marrow where they will initiate proliferation and 
differentiation of an immune repertoire. Cells of the innate immune system 
reconstitute rapidly and dictate the duration of inpatient care. Neutrophils and 
platelets often reach clinically ‘safe’ levels (1 x 109/L neutrophils and 30 x 109/L 
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platelets) within 2-3 weeks, whilst T and B cell reconstitution can take up to 2 years 
to reach normal levels (Keever-Taylor et al. 2001; Fry & Mackall 2005; Storek et al. 
2008). T cell recovery occurs through two mechanisms, initial homeostatic 
proliferation of donor T cells from the stem cell graft and then more gradually through 
de novo generation of T cells from donor derived CD34+ cells and subsequent 
maturation in the residual thymus (Roux et al. 2000). The homeostatically expanded 
population of T cells is limited in the diversity of its repertoire (Mackall et al. 1996). 
Additionally the T cell depletion, which is used to reduce GvHD, decreases the donor 
T cell pool and limits T cell proliferation, resulting in a profound restriction of the early 
T cell repertoire, that may therefore mount a less effective allogeneic immune 
response (Soiffer et al. 2011; van Heijst et al. 2013). Similarly, B cell recovery takes 
several months and low B cell numbers post allo-HSCT associate with the presence 
of GvHD (Storek et al. 2001; Corre et al. 2010). 
NK cell reconstitution is also driven by both homeostatic proliferation and maturation 
of CD34+ progenitor cells, but occurs far more rapidly meaning that NK cells 
dominate the lymphocyte population within the first month (Ullah et al. 2016). The 
differentiation of NK cells from donor haemopoietic stem cells is swift and produces a 
large increase in immature CD56bright NK cells by 6-8 weeks post-transplant. 
Recovery of a normal NK cell phenotypic repertoire can take 3-6 months with full 
cytokine and cytotoxic capabilities achieved after at least 6 months (Björklund et al. 
2010; Ullah et al. 2016). 
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Graft versus leukaemia and graft versus host disease 
 
Chemo/radiotherapy treatment is given to patients before transplantation with the 
aim of reaching complete remission. Unfortunately, residual tumour cells are likely to 
remain and patients may experience disease relapse if these cells are able to 
develop. The ability of transplanted lymphocytes to kill tumour cells has been known 
for several decades with murine models used to prove the principle in the 1950s 
(Barnes et al. 1956) and then clinically in the 1960s (Mathe et al. 1965). Horowitz et 
al, showed that graft versus host disease was associated with reduced rates of 
disease relapse after transplantation  (Horowitz et al. 1990). Marmont et al also 
showed that the difference in relapse rates between T cell replete and T cell deplete 
transplants was due to a less aggressive GvL and GvHD effect in the T cell depleted 
patients (Marmont et al. 1991). It has since been found that in HLA matched 
allogeneic transplants T cells confer a GvL effect through identification of 
mismatched haematopoietic restricted minor histocompatibility antigens on residual 
host cells (Marijt et al. 2003). Killing of these host cells results in the elimination of 
any lingering tumour, as long as the leukemic cells express antigen (Bleakley & 
Riddell 2004). However, donor T cells will also respond to more broadly expressed 
minor histocompatibility antigens in epithelial tissues such as the skin, gut and liver 
resulting in GvHD.  
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Figure 1.5 – Timeline of allo-HSCT 
Patients undergoing allogeneic haematopoietic stem cell transplantation at the Queen 
Elizabeth Hospital Birmingham receive pre-transplant conditioning during the two weeks 
prior to infusion of the transplant (A). Donor G-CSF mobilisation and subsequent stem 
cell graft collection occurs in the week prior to patient transplantation. Patients are 
usually discharged by two weeks post stem cell graft infusion. Post-transplant immune 
reconstitution occurs more rapidly for NK cells than T cells and may impact upon patient 
GvHD and relapse outcomes during the first 12 months (B).  
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GvHD arising within 100 days of transplant is described as ‘acute’ (aGvHD). It is 
characterised by skin, gastrointestinal and liver involvement. Cases are classically 
graded according to Glucksberg criteria and can last weeks, months or even years 
and may be fatal in the setting of steroid refractory gut GvHD (Glucksberg et al. 
1974). The initial conditioning regimen causes tissue damage and therefore an 
inflammatory response triggering the release of pro-inflammatory cytokines. This in 
turn promotes APC maturation and the presentation of minor antigens which activate 
donor CD8+ T cells. Chemokines are produced which recruit CXCR3+ T cells into 
patient tissues such as the skin, gut and liver where they damage healthy cells 
(Piper et al. 2007). This causes more inflammation and a cycle of cytokine release 
continues (Socié & Blazar 2009; Ferrara et al. 2009).  
Chronic GvHD is a separate clinical entity which generally develops after day 100 
and is a much more diverse clinical syndrome (Jagasia et al. 2015). It can overlap 
with acute GvHD or occur independently and is a major cause of long-term morbidity 
and mortality following allo-HSCT. The pathophysiology is complicated and current 
murine models suggest that a multifaceted network involving T and B lymphocytes is 
involved (Socié & Ritz 2014; Croudace et al. 2012).   
Risk factors include the level of donor mismatch, age, sex and CMV infection but 
GvHD is observed in between 20-80% of patients in most SCT regimens (Weisdorf 
et al. 1991). The occurrence of GvHD indicates the presence of an alloreactive 
immune response and is usually associated with reduced relapse rates indicating a 
more effective GvL response (Weiden et al. 1979). Understanding if separate 
mechanisms are behind GvL and GvHD, or if an ideal equilibrium can be achieved 
between the two, will greatly help in improving patient outcomes after allo-HSCT.  
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Patient and donor influences on allo-HSCT outcome 
 
Allogeneic haematopoietic stem cell transplantation is a potentially curative 
treatment for lymphoid and myeloid malignancies. Chemotherapy depletes the 
recipient bone marrow, making ‘space’ for an infusion of stem cell progenitors from 
the donor. Engraftment of these cells provide recovery of a competent 
haematopoietic system. Additionally, lymphocytes derived from the donor may have 
a GvL effect, killing off any residual tumour and effectively curing the patient. 
However, disease relapse is now the single major reason for treatment failure and 
‘relapse mortality’ is a key cause of death (Barrett & Battiwalla 2010). A relapse rate 
of 30% by 12 months post-transplant was reported in reduced intensity-conditioned 
allo-HSCT with alemtuzumab T cell depletion (Tauro et al. 2005). Identifying ways to 
improve disease free survival in transplant settings is an important research 
objective to increase the efficiency of allo-HSCT.  
The major ‘transplant related mortality’ (TRM) risks related to allo-HSCT are due to 
the effects of drug-related toxicity (van Besien et al. 2003), increased susceptibility to 
viral infections (Gratwohl et al. 2005), early risk of sinusoidal obstructive syndrome 
(Carreras 2000) as well as acute and chronic GvHD (Jagasia et al. 2012; Wingard et 
al. 2011). Therefore greater understanding the mechanisms involved in allo-HSCT in 
order to improve patient outcome is important. 
Whilst animal models provide an insight into the mechanistic processes involved in 
allogeneic transplantation (Boieri et al. 2016) translation of these findings into the 
clinical setting is challenging because of the inevitable genetic and immunological 
variability present in the human system. Differences in patient gender, age, ethnicity, 
co-morbidities and previously acquired viral infections all impact upon an individual’s 
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haematopoietic cell repertoire and therefore upon outcomes. Similarly, donor age, 
gender and relationship to the patient have all been found to influence outcome 
following allo-HSCT. Additionally, the conditioning regimen used, whether T cell 
depletion has been applied and the source of the stem cell product can influence the 
effectiveness of the procedure. Although these complicate the process, allo-HSCT 
can be delivered to fit patients up to approximately the age of 70 with an acceptable 
TRM of less than 20% (Gratwohl 2012).  
Allo-HSCT can be given to treat a multitude of malignancies, all of which have 
differing ontologies, susceptibility to chemotherapy and immune evasion 
mechanisms. Therefore, the overall survival from one disease can differ greatly 
compared to another. The potential benefit of the transplantation procedure is also 
dependent on the patient remission status at the point of diagnosis (Armand et al. 
2012). The risk of transplant-related mortality can often be predicted based upon an 
individual patient’s pre-existing comorbidities. The haematopoietic cell 
transplantation score comorbidity index (HCT-CI) developed by Sorror et al can be 
used to identify patients at high risk of non-relapse related mortality and overall 
mortality based upon factors such as obesity, diabetes or heart conditions (Sorror et 
al. 2005).  
Obtaining a suitable HLA donor is also necessary for the success of the transplant. A 
sibling is the obvious first ‘point of call’ when trying to find a HLA matched individual, 
but if this is not possible an unrelated donor can be sourced. Receiving cells from a 
sibling is also more beneficial in terms of lower graft rejection rates and lower 
aGvHD risk due to fewer minor mismatches between patient and donor (Weisdorf et 
al. 2002; Alousi et al. 2013). Whilst fully HLA matched individuals are the ideal donor 
source, in some instances donors with a single or multiple HLA mismatch can be 
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given. This however is usually associated with higher mortality risk due to 
engraftment failure (Lee et al. 2007; Madrigal & Shaw 2008; Nowak 2008).      
Additionally, patient age is important.  Younger AML patients (<40 years  old) 
receiving allografts from matched siblings are found to have better overall survival 
outcomes compared to older patients (Cornelissen et al. 2007; Suciu et al. 2003). 
Similarly transplant-related mortality and complications are thought to be increased 
with age, however the use of reduced intensity conditioning and general 
improvements in transplant application is reducing this (Frassoni et al. 1996; 
Bacigalupo et al. 2004). The age of the stem cell graft donor also plays an important 
role. This has been shown in a large cohort of almost 7000 patients, where receiving 
unrelated donor cell infusions from younger donors (<30 years old) resulted in 
improved five year overall survival, as well as reduced rates of grade III or IV acute 
GvHD and chronic GvHD (Kollman et al. 2001). In a smaller primarily HLA matched 
sibling cohort the beneficial effect of younger donor age was seen in a lower relapse 
risk and overall survival (Mehta et al. 2006).  Immune senescence is the 
deterioration of immune function as individuals age which is thought to be due to a 
combination of defective bone marrow haematopoiesis, immune cell maturation, 
migration and functional efficiency (Gruver et al. 2007). As individuals and their 
immune systems age they are exposed to more environmental pressures and 
antigens, which can modify the immune repertoire making them less tolerant and 
responsive (Miller 1996; Strauss-Albee et al. 2015).  
A matched sibling donor will usually be chosen if available because of the reduced 
rates of graft rejection, and transplant related mortality. However, the difference 
between this and a young matched unrelated donor is now almost negligible (Saber 
et al. 2012; Robin et al. 2013). Registries primarily use donors that are under 30 
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years of age. Together this means that at Queen Elizabeth Hospital Birmingham 
approximately 60% of all allo-HSCT are now from matched unrelated donors.   
Chronic cytomegalovirus (CMV) infection may also contribute to immune 
senescence as virus-specific T cells comprise a very large proportion of the T cell 
repertoire and may explain the association between CMV infection and increased 
mortality in older individuals (Hosie et al. 2017; Savva et al. 2013). In the context of 
allo-HSCT, CMV can be both beneficial and detrimental and the ‘CMV match’ 
between patient and donor is one determinant. CMV seronegative patients receiving 
a stem cell infusion from a CMV seropositive donor are at high risk of a primary CMV 
infection and subsequently higher risk of mortality, potentially due to bacterial and 
fungal infection (Nichols et al. 2002). In contrast, CMV mismatch between a 
seropositive patient and a seronegative donor has also been associated with 
increased mortality in a cohort of matched unrelated donors (Ayuk et al. 2016). 
Interestingly however, it has recently become apparent that CMV reactivation in AML 
patients following allo-HSCT is associated with reduced relapse risk, suggesting that 
residual disease is also identified for elimination in the immune response (Green et 
al. 2013). This however did not lead to improvements in overall survival due to an 
increase in non-relapse mortality. 
Another source of potential mismatch between patient and donor is in terms of 
gender. It is thought that male patients receiving stem cells from a female donor 
benefit from donor T cells that are specific to minor histocompatibility antigens 
encoded by the Y chromosome. This is due to the lower relapse and higher GvHD 
incidence seen in female to male transplants, with a beneficial GvL effect seen in 
both myeloid and lymphoid malignancies (Randolph et al. 2004). However male 
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recipients in general are more at risk of mortality when undergoing allo-HSCT 
compared to females (Kim et al. 2016). 
The issue with many of these findings is that what may be significant in one cohort is 
often not in another, especially considering the heterogeneity of patients included. 
Distinguishing the similarities and differences between the different studies and 
pulling out the useful information is complicated. Furthermore, the process of allo-
HSCT is also constantly changing and common practices a decade ago are vastly 
different to those now. Importantly though patient outcomes are getting better and 
there is potential to improve them even further. 
 
Impact of stem cell graft composition on transplant outcomes 
 
The CD34+ haemopoietic stem cell graft does not consist solely of stem cells but 
also contains a substantial number of mature donor immune cells. As donor 
lymphocytes are known to provide both a GvHD and a GvL response it is already 
appreciated that graft composition can impact upon transplant outcome. Sufficient 
CD34+ HSCs are required to prevent graft rejection, and a dose of at least 2-3 x 106 
CD34+ cells per kg is considered necessary to achieve this. High CD34 dose (>8 
x106 cells/kg) has been implicated in the development of GvHD (Zaucha et al. 2001; 
Mielcarek et al. 2004). On the other hand low CD34+ doses (<4 x106 cells/kg), were 
also found to associate with higher non-relapse mortality and reduced overall 
survival in a study examining the outcomes of over 1000 AML and MDS patients 
(Törlén et al. 2014; Mavroudis et al. 1996). An adequate dose of CD34+ cells is 
required for neutrophil and platelet engraftment (Keever-Taylor et al. 2001), which 
are important to fend off bacterial or fungal infections and provide adequate blood 
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clotting and red blood cells to perfuse tissues. High doses are thought to result in a 
quicker and stronger alloreactive T cell response increasing the incidence of GvHD, 
however this remains controversial (Baron et al. 2005; Gõmez-Almaguer et al. 2013). 
A balance between the two (4-8 x106 cells/kg) is therefore recommended for most 
allo-HSCT (Mehta et al. 2009). 
Other graft components have also been associated with improvements in transplant 
outcome in various settings. High frequency of T, B and dendritic cells within the 
graft have been found to correlate with increased acute GVHD in a cohort of AML 
patients who received mainly matched unrelated donor grafts (Impola et al. 2016). 
However, studies have also suggested no such associations between T cell dose 
and acute GvHD or overall survival (Cao et al. 2005). Studies of T cell replete HLA 
matched sibling donor transplants have found associations between NK cell number 
and patient outcome. Receiving an NK cell dose below 7 x 107 cells/kg was 
associated with increased acute GvHD in a small cohort (n=27) of patients receiving 
G-CSF mobilised grafts (Yamasaki et al. 2003). Additionally an NK cell dose above 5 
x 107 cells/kg has also been associated with reduced non-relapse mortality in a 
cohort of 61 patients, thought to be due to greater post-transplant infection control 
(D. H. Kim et al. 2005). Also low numbers of both regulatory T cells (Tregs) and 
invariant natural killer T cells (iNKT cells) in the stem cell graft have been shown to 
correlate with aGvHD incidence (Rezvani et al. 2006; Chaidos et al. 2012; Malard et 
al. 2016).  
The effect of graft composition upon relapse is somewhat unclear. Reduced relapse 
rates have been shown in patients receiving more than 4 x106 CD34+ cells/kg from 
unrelated donors (Nakamura et al. 2008). A successful GvL response will be 
conducted by effector lymphocyte populations and recently in a RIC T cell replete 
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setting, stem cell graft CD8 T cell dose above 0.72 × 108 cells per kg were found to 
associate with lower relapse risk (Reshef et al. 2015). The potential role of donor NK 
cells in the stem cell graft is thought to be beneficial by contributing to GvL, but not 
necessarily mediating GvHD (Ruggeri et al. 1999; L. Ruggeri et al. 2002; Dickinson 
et al. 2017). 
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NK cells in HSCT  
 
NK cells are present in considerable numbers within stem cell grafts received by 
patients (Martínez et al. 1996). Along with T cells they can undergo homeostatic 
proliferation within the lymphopenic environment of the patient, rapidly producing a 
large number of cells (Surh 2000; Prlic et al. 2003). They are the first lymphocyte 
population to re-emerge post allo-HSCT and they usually dominate the lymphocyte 
population during the first month, particularly so with T cell depleted transplants 
(Ogonek et al. 2016). They are thought to provide beneficial effects in terms of GvL, 
whilst not contributing towards or even protecting from GvHD.    
 
NK cell immune reconstitution following allo-HSCT 
 
In healthy individuals the lymphocyte population is in continual turnover. Assessment 
of normal NK cell kinetics through in vivo labelling with deuterium-labelled glucose in 
both young (19-34 years) and elderly (65-85 years) healthy individuals found that 
CD3-CD16+ NK cell half-life is around 12 days (Zhang et al. 2007). A production rate 
of roughly 15 CD3-CD16+ NK cells per μl blood per day was found in young 
individuals however this decreased to 7 cells per μl in elderly individuals. Similar 
experiments examining homeostatic T cell kinetics in young healthy individuals 
suggest that CD4+ and CD8+ T cells have half-lives of just less than 3 months with a 
production rate of 10 CD4+ T cells and 6 CD8+ T cells per μl of peripheral blood per 
day (Hellerstein et al. 1999). The CD4 and CD8 subpopulations can further be 
broken down into memory and naïve populations which display differing cell 
dynamics. Shorter 14 and 26 day doubling times are seen in “memory” T cells 
(CD45RO+CD8+ and CD45RO+CD4+ cells respectively), whilst a much longer 4-5 
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month doubling time was found in “naïve” T cells (CD45RA+CD8 and 
CD45RA+CD4+) (Macallan et al. 2003).  
Furthermore, in healthy individuals mature NK cell proliferation, assessed by Ki67 
staining, is found in 5.3% of the whole NK cell population compared to 1.2% in T 
cells. Combined with swifter apoptosis, a 3-4 fold greater turnover rate of NK cells 
compared to T cells is produced (Lutz et al. 2011). Therefore, within a 
lymphodepleted environment following allo-HSCT, NK cells are expected to 
reconstitute faster.  
Indeed, in murine models of adoptive cell transfer mature NK cell turnover takes 7-10 
days with homeostatic proliferation shown to occur in lymphodepleted environments 
(Wang et al. 2002; Jamieson et al. 2004; Prlic et al. 2003). Proliferation does not 
occur when cells are transferred to a host with an adequate NK cell pool, indicating 
that the availability of physiological niches and regulatory cytokines is necessary for 
survival of adoptively transferred NK cells. Additionally murine models also suggest 
that the NK cells present following allo-HSCT can be long lived and persist for 
greater than 6 months without diminished functionality (Sun et al. 2011). Whether 
similar dynamics are involved in humans following allo-HSCT is more difficult to 
ascertain without being able to label the cells of interest.   
Following allo-HSCT in humans NK cell reconstitution is rapid and NK cells dominate 
the lymphocyte population within the first month, being capable of reaching normal 
numbers during this time irrespective of the donor stem cell graft source (Ullah et al. 
2016). However, these NK cells express a far more immature phenotype with a 
significantly higher percentage of CD56bright NK cells present in the peripheral blood 
of patients compared to healthy individuals (Pical-Izard et al. 2015). This is 
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accompanied by higher expression of NKG2A and lower expression of CD56dim, 
CD57 and KIRs. It is therefore suggested that the rapid expansion of NK cells is due 
to differentiation of progenitor cells rather than proliferation of mature cells infused 
with the stem cell graft. This is supported by the similar reconstitution kinetics 
measured post-transplant in patients receiving large differences in NK cell dose. 
Although, NK cell reconstitution does occur more rapidly in patients receiving T and 
B cell depleted stem cell grafts as opposed to CD34+ selected grafts, indicating that 
expansion of the donated NK cell population does play a part (Eissens et al. 2010). 
Interestingly the timing of NK cell reconstitution in T cell replete or T cell deplete 
transplant settings has been found to be generally similar given the use of 
cyclosporine to dampen any T cell reconstitution (Ullah et al. 2016).  
The overall immature NK cell phenotype post-transplant gradually returns to 
comparable levels with healthy donors by around 4-6 months following infusion. 
Functional recovery of the NK cell population takes at least 6 months post-transplant 
with the reestablishment of cytokine production and cytotoxicity occurring separately 
(Björklund et al. 2010; Foley et al. 2011).  
 
NK cell impact on patient outcomes 
 
The effectiveness of NK cell reconstitution following HLA matched allo-HSCT has 
been shown to associate with some clinical outcomes. In a T cell replete setting of 
allo-HSCT greater NK cell reconstitution at one-month post-transplant has been 
shown to associate with enhanced overall survival due to lower transplant related 
mortality and lower infection rates in a cohort of nearly 300 AML, ALL and MDS 
patients (Minculescu et al. 2016). No effect on disease relapse was found in this 
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cohort suggesting that beneficial effects NK cells may have in HLA matched 
transplant setting are only mediated when T cell depletion is used.  
High lymphocyte numbers (predominantly NK cells) at one month following T cell 
deplete myeloablative transplants from matched sibling, as well as matched 
unrelated donors, associated with improved survival (Savani et al. 2007; Le Blanc et 
al. 2009). Savani et al corroborated this by showing in a small cohort (n=54) that NK 
cell number at day 30 associated with less relapse, acute GvHD, lower NRM and 
greater overall survival for myeloid leukaemia patients receiving donor infusions from 
fully HLA matched siblings (Savani et al. 2007b). Interestingly though NK cell 
reconstitution did not impact upon ALL patient relapse or survival. This was also 
seen in patients receiving reduced intensity conditioning allo-HSCT at day 60 post-
transplant, but not in those with fully myeloablative treatment (Dunbar et al. 2008).  
In a cohort of HLA matched RIC patients (n=45) who received ATG T cell depletion 
NK cell reconstitution at one month with high TNF-a production associated with less 
relapse and greater overall survival (Pical-Izard et al. 2015). Additionally, patients 
expressing lower CD107a and CD56dim NK cells showed non-significant trends 
towards greater relapse and mortality within a year post-transplant.  
Together these findings suggest that any NK cell mediated effects on patient 
outcome are established early on in HLA matched allo-HSCT, however small 
differences in transplant procedure, conditioning and follow up may have a 
significant impact upon this effect.     
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NK cell GvL effect 
 
Given the cytotoxic and cytokine producing functional ability of NK cells it is clear 
that they may play a role in GvL by directly killing residual tumour cells or indirectly 
affecting the immune environment post allo-HSCT. To do this the donated NK cells 
must produce an alloreactive response against the host. This is primarily thought to 
be achieved due to the absence of MHC class I ligands for inhibitory KIR receptors 
on donor NK cells, but may also be driven by the repertoire of activatory receptors 
and the expression of their related ligands within the host (Benjamin et al. 2010). 
As described above inhibitory KIRs recognise HLA-A, B and C molecules while HLA-
E is recognised by the CD94/NKG2A receptor. The expression of these receptors 
throughout an individual’s NK cell population is stochastic, yet necessary for proper 
cell education and the production of mature, self-tolerant yet responsive NK cells that 
are able to detect cells expressing MHC class I molecules at low levels or none at 
all. As inhibitory KIR and HLA expression varies within the human population 
mismatches are likely when performing allo-HSCT which would result in a 
subpopulation of donor NK cells that are alloreactive. Additionally, the 
proinflammatory environment produced by myeloablative conditioning provides a 
source of stimulatory molecules which can increase the responsiveness of 
‘unlicensed’ NK cells (S. Kim et al. 2005).  
 
NK cell alloreactivity has been most notably shown through the beneficial effect of 
KIR ligand mismatch between donor and recipients of haploidentical transplantation 
in providing a protective GvL response (Velardi 2008; Ruggeri et al. 1999). This was 
effective for patients with AML but not ALL. The beneficial advantage of alloreactive 
NK cells in this context is also associated with reduced GvHD risk, thought to be 
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mediated by the killing of recipient APC (L. Ruggeri et al. 2002). However, in the 
context of unrelated allo-HSCT the role of NK cell alloreactivity is more controversial. 
KIR ligand mismatch has been found to associate with reduced relapse rates and 
greater overall survival in a study of 130 patients receiving T cell depleted unrelated 
donor transplants (Giebel et al. 2003). However similar studies in unrelated donors 
with and without T cell depletion did not find the same beneficial effect on patient 
outcomes (Davies et al. 2002; Bornhäuser et al. 2004). Patients missing a KIR ligand 
have been found to associate with lower relapse when being treated for early 
myeloid leukaemia in both HLA matched and mismatched allo-HSCT (Miller et al. 
2007). Additionally differences in donor KIR haplotypes have been found to impact 
on relapse rates for AML patients receiving T cell replete transplants (Cooley et al. 
2009). Patients receiving cells from donors with KIR group B haplotype, containing 
predominantly activatory KIR receptors, had reduced incidence of relapse and a 
significantly higher three year overall survival compared to those with donors 
expressing KIR group A haplotype. Specific KIR ligand mismatch between donor and 
recipient was identified as the cause of this protective effect as recipients who had 
one or two C1- bearing HLA-C allotypes, compared to those with C2 only showed 
improved survival when receiving cells from a KIR B haplotype donor (Cooley et al. 
2010). 
Whilst the “missing self” is adequate to engage an NK cell an activatory signal is also 
necessary to elicit cytotoxic functionality. Again differences in receptor and ligand 
expression have been shown to impact upon patient outcomes. Patients expressing 
the NKG2D ligand ULBP06*02 polymorphism rather than ULBP06*01 showed better 
overall survival and relapse free survival in a cohort of 371 patients receiving HLA 
matched sibling transplants for both myeloid and lymphoid malignancies (Antoun et 
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al. 2012). Structural transformations in the protein cause changes in the binding 
affinity of the ligand with its receptor (Zuo et al. 2017). ULBP06*02 has a higher 
affinity for NKG2D potentially causing a lower rate of NKG2D dependent NK killing of 
cells expressing *02 compared to *01 by preventing serial binding. ULBP06*01 also 
triggers stronger downstream signalling. 
Favourable differences in donor NK cells and patient targets help to improve clinical 
outcomes following allo-HSCT and therefore suggest that the cytotoxic ability of NK 
cells could play a role in GvL. A precise mechanism for NK cell involvement in GvL 
however remains unclear. NK cells may eliminate residual tumour cells that express 
ligands for detection directly. Sanchez-Correa et al., found that in many cases of 
AML, leukemic blasts express ligands that are able to stimulate NK cell activation 
(Sanchez-Correa et al. 2011). However, there is also decreased expression of 
activating receptors NKp46, NKp30, DNAM-1 and NKG2C on autologous NK cells, 
potentially due to ligand overexposure. Therefore, in allogeneic transplantation newly 
infused NK cells with full cytotoxicity capabilities may prove more efficient at 
eliminating target cells. In vitro experiments have shown that KIR mismatched 
alloreactive NK clones can kill myeloid leukaemia cells, however only a minority of 
lymphoblastic leukaemia cells had the same response (Ruggeri et al. 1999). This 
mechanism is therefore highly dependent upon the disease and susceptibility of 
tumour cells to NK cell killing. 
Alternatively NK cells may promote the GvL effect of alloreactive T cells, by killing 
immune cells and potentially regulating the GvHD response (Olson et al. 2010). 
Ghadially et al., found that in a murine model of HSCT the absence of NKp46 
expressing NK cells resulted in a much higher prevalence of GvHD (Ghadially et al. 
2014)..This was due to ligands on immature dendritic cells activating NKp46 
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expressing NK cells, resulting in their lysis and leading to a reduction in T cell 
stimulation. Additionally greater reconstitution of NK cells expressing IL-10 at two 
weeks following allo-HSCT associates with protection from aGvHD which may 
indicate a mechanism of alloreactive T cell suppression (Chan et al. 2017).  
Therefore, if a GvL effect occurs early post-transplant it may be mediated by NK 
cells directly from the donated stem cell graft. Interestingly though G-CSF has been 
shown to reduce the cytotoxic capacity of NK cells (Miller et al. 1997). Isolated NK 
cells from G-CSF treated donors showed significantly poorer killing of the K562 
target cell line in vitro, along with a reduced ability for IL-2 induced proliferation. The 
reduced cytotoxicity is also exacerbated by the apheresis collection of the stem cell 
graft.  Using G-CSF mobilisation and aphaeresis is therefore likely to affect the 
phenotype and function of NK cells infused with the CD34+ haemopoietic stem cell 
product, however their usefulness in allo-HSCT is still clear and has the potential to 
be improved. 
 
NK cell immunotherapy in allo-HSCT 
 
The potential of NK cells to promote GvL, whilst suppressing GvHD, makes them 
attractive as a cell therapy in allo-HSCT. Initial attempts to increase NK cell 
activation in the autologous transplant setting through injections of IL-2 or infusion of 
IL-2 activated NK cells however did not yield any clinical benefit for patients (Miller, 
et al. 1997; Burns et al. 2003). Allogeneic transfer of enriched haploidentical NK cells 
is also feasible and was shown to induce remission in 27% of a small cohort of AML 
patients and could be improved with the addition of IL-2 (Miller et al. 2005; 
Bachanova & Miller 2014). However, for donor NK cells to persist and expand within 
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the host, lymphodepletion, adequate levels of IL-15 and the infusion of CD34+ 
haematopoietic progenitor cells are also recommended. 
Further studies have continued to show that the adoptive transfer of alloreactive NK 
cells is feasible, however significant improvements in long term patient outcomes are 
difficult to achieve (Rubnitz et al. 2010; Curti et al. 2011; Stern et al. 2013). Attempts 
to make adoptive transfer of NK cells more successful involve identifying the optimal 
source, purity and priming of NK cells for use as an immunotherapy. Low NK cell 
numbers can be sourced from peripheral or umbilical cord blood. These numbers 
can be increased when NK cells are enriched from the apheresis product of a G-CSF 
mobilised individual, however these NK cells are functionally less efficient than those 
in normal healthy peripheral blood (Miller et al. 1997). Additionally, NK cells can also 
be expanded in vitro from human embryonic stem cells, bone marrow CD34+ cells or 
umbilical cord blood CD34+ cells with functional cytotoxic killing capacity (Knorr & 
Kaufman 2010; Domogala et al. 2017). NK cell lines such as NK-92 and NKL which 
show cytotoxicity against malignancies are also considered as viable sources of 
immunotherapeutic NK cells (Tonn et al. 2001; Robertson et al. 1996).  
Whilst progress is being made in this area understanding the role of NK cells within 
the context of current allo-HSCT methodology is important and will help to identify 
how alloreactive NK cells can be optimally utilised.  
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Aims and objectives 
 
There are gaps in our current understanding of NK cell involvement within HLA 
matched T cell deplete allo-HSCT. The large variability of an individual’s NK cell 
repertoire suggests that within the allo-HSCT setting NK cells received from different 
donors will ultimately have differing impacts upon patients. A beneficial effect from 
donor NK cells within this transplant context has not been definitively proven.  
It was hypothesised that the impact of stem cell graft NK cells on HLA matched allo-
HSCT transplant outcome was most likely to be observed early on in patients who 
received T cell depleted transplantation. With access to donor stem cell graft 
samples and patient peripheral blood in the first month post-transplant we therefore 
set out to appraise the following: 
• How T and NK cells reconstitute during the first month post allo-HSCT and 
how this associates with patient outcomes.  
• Whether NK cells in G-CSF mobilised stem cell grafts are phenotypically and 
functionally different to NK cells from healthy individual peripheral blood. 
• If the cellular composition of the stem cell graft impacts upon clinical outcome 
following allo-HSCT. 
• If the variability in phenotype and function of NK cells within the stem cell graft 
impacts upon clinical outcome following allo-HSCT. 
Findings are described in detail with short discussions following each chapter. A 
general discussion summarises the project and its impact upon the scientific area.
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Chapter 2 – Materials and Methods  
Reagents 
Media and solutions 
• Freezing media - Foetal bovine serum (Sigma-Aldrich); 10% Dimethyl 
sulfoxide (DMSO) (Thermoscientific) 
• MACS buffer – 1x PBS (University of Birmingham); 0.5% Bovine serum 
albumin (Sigma-Aldrich); 2mM EDTA (Sigma-Aldrich) 
• Wash media - RPMI 1640 (Sigma-Aldrich); 1% penicillin-streptomycin 
(Thermoscientific); 2mM L-glutamine (Thermoscientific). 
• Growth media (GM) - RPMI 1640 (Sigma-Aldrich); 10% Foetal bovine serum 
(Sigma-Aldrich); 1% penicillin-streptomycin (Thermoscientific); 2mM L-
glutamine (Thermoscientific). 
• TBE buffer – 89nM Tris HCl (Geneflow); 89nM Boric Acid (Geneflow); 3mM 
EDTA (Geneflow)  
Commercial kits and beads 
• BD Trucount™ tubes (BD Biosciences - Catalogue Number: 340334) 
• BD Biosciences transcription factor intracellular staining kit (BD Biosciences - 
Catalogue Number: 565575) 
• DNEasy isolation kit (Qiagen – Catalogue number: 69504) 
• EasySepTM Human NK enrichment kit (Stem Cell Technologies – Catalogue 
number: 19055). 
• FlowCheck beads (Beckman Coulter – Catalogue number: A63493) 
• FlowSet beads (Beckman Coulter – Catalogue number: A63492) 
• VersaComp antibody capture beads (Beckman Coulter – Catalogue number: 
B22804)  
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Patient sample collection 
 
Peripheral blood sample collection and patient cohort 
 
Written consent was obtained from patients undergoing allogeneic haematopoietic 
stem cell transplantation for the treatment of haematological malignancies at the 
Queen Elizabeth Hospital Birmingham (Biological Correlates of Stem Cell 
Transplantation (BCOST) study ethics code: 051Q7071175). 
Peripheral blood samples were collected from 158 consecutive patients receiving 
allo-HSCT at several time points during the transplantation process (Figure 2.1). Up 
to 36ml of blood was collected into heparinised vacutainers on the day of 
transplantation, prior to infusion of the stem cell graft. Subsequent peripheral blood 
samples (36ml) were taken from the patients at one, two, three and four weeks post-
transplant. In total 387 samples were collected and processed within 24 hours. 
 
 
 
 
Transplant	
Date 
Week -2 -1 0 +1 +2 +3 +4 
Conditioning 
Day	7 Day	14 Week	3 Week	4 Day	0 
+ 
Post-transplant 
Figure 2.1 – Samples taken from patients undergoing allo-HSCT 
Up to 36ml of peripheral blood was collected from allo-HSCT patients on the day of 
transplantation, before infusion of the stem cell graft. Further blood samples of 36ml 
were collected at one, two, three and four weeks post-transplant. The bag containing 
the stem cell graft was also collected post infusion.  
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The 158 patients from which peripheral blood samples were collected during the first 
month post-transplant were primarily male (63%) with a median age of 56 years old 
(Table 2.1). There was a variety of malignancies within the patient cohort which 
could be classified into two groups. The majority of patients had myeloid (primarily 
AML or MDS) (66%) rather than lymphoid disease (primarily ALL). Most patients 
received reduced intensity conditioning (85%), whilst only 15% received fully 
myeloablative treatment. T cell depletion was given to most patients (89%), usually 
in the form of Alemtuzumab (52%) at 10mg per day for 5 days from day -5. Patients 
whose conditioning involved anti-thymocyte globulin (ATG) (37%) either received 
1mg/kg for 1 day then 2mg/kg for 2 days if combined with FLAMSA and Busulfan 
(Bu) or 2.5mg/kg for 2 days if combined with just Fludarabine and Busulfan. The 
primary source of stem cell graft infusions for these patients was the apheresis 
product collected from G-CSF mobilised donors (91%). Most of these donors were 
10/10 HLA matched (HLA-A, -B, -C, -DRB1 and –DRQ1) siblings (30%) or unrelated 
donors (60%), with 10% of patients receiving cells from a 9/10 HLA mismatched 
unrelated donor.  
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Patients Number 
 Total 158 
 Median Age (Years; Range) 56 (16-75) 
Male 99 63% 
CMV Seropositive 88 56% 
Disease 
  Myeloid 104 66% 
Lymphoid 53 34% 
Conditioning 
  Myeloablative 24 15% 
Reduced intensity 134 85% 
T Cell Depletion 
  Alemtuzumab 82 52% 
ATG 59 37% 
None given 17 11% 
Stem Cell Source 
  PBMC 144 91% 
Bone Marrow 10 6% 
Umbilical Cord 4 3% 
Transplant Type 
  HLA Matched Sibling 47 30% 
HLA Matched Unrelated Donor 95 60% 
Mismatched Unrelated Donor 16 10% 
 
 
 
 
  
Table 2.1 – Post-transplant patient cohort characteristics 
CMV – Cytomegalovirus; ATG – Anti-Thymocyte Globulin; HLA – Human Leukocyte 
Antigen; PBMC – Peripheral Blood Mononuclear Cells. 
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Stem cell graft sample collection and patient cohorts 
 
Following infusion of the donor apheresis product the bag containing the stem cell 
graft is deemed a waste product and was therefore ethically collected for analysis 
without further patient consent required. Stem cell grafts received by patients 
undergoing allo-HSCT at the Queen Elizabeth Hospital Birmingham between 2012-
2017 were assessed. Following infusion into the patient the bag was placed on ice 
for collection and processing within 16 hours. 
Initially, residual mononuclear cells from 107 stem cell graft samples were acquired 
to assess differences between NK cells collected through the process of G-CSF 
mobilisation and apheresis processing compared to those found in the peripheral 
blood of healthy individuals (Table 2.2). These stem cell grafts were collected from 
primarily male donors (64%) with a median age of 38 years old. Nearly half of donors 
were CMV seropositive (47%). All donors received G-CSF mobilisation (10μg/kg for 
five days) and then underwent apheresis to collect the stem cell graft. Most donors 
were unrelated to the patient with 5% having a major histocompatibility mismatch 
with the recipient. The remainder of patients received donations from a matched 
sibling (37%). Comparisons were made against PBMC isolated from the peripheral 
blood of 15 healthy individuals who had not undergone G-CSF treatment. A similar 
proportion of male donors (60%) were used, however the median age of these 
individuals was 8 years below that of the stem cell graft donors.    
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Stem Cell Grafts Number 
 Total 107 
 Median Age (Years; Range) 38 (18-67) 
Male 69 64% 
CMV Seropositive 50 47% 
Source 
  PBMC 107 100% 
Transplant Type 
  HLA Matched Sibling 39 37% 
HLA Matched Unrelated Donor 62 58% 
Mismatched Unrelated Donor 6 5% 
   Healthy Donors 
  Total 15 
 Median Age (Years: Range) 30 (24-45) 
Male 9 60% 
Stem Cell Source 
  PBMC 15 100% 
 
 
 
 
 
 
Another cohort of 107 consecutive patients all receiving T cell depleted allo-HSCT 
was used to identify associations with clinical outcomes (Table 2.3). Rare disease 
diagnoses were excluded and therefore patients within the cohort were divided into a 
myeloid category (63%) containing acute myeloid leukaemia (AML), Chronic myeloid 
leukaemia (CML), myelodysplastic syndrome (MDS) and myelofibrosis (MF) 
diagnoses or a lymphoid category containing acute lymphoid leukaemia (ALL), 
Hodgkin lymphoma and Non-Hodgkin lymphoma. Median patient and donor ages 
Table 2.2 – Stem cell graft and healthy donor comparison cohort characteristics 
Cohort of donor stem cell grafts used to assess the phenotype and functional profile of NK 
cells in comparison to NK cells from peripheral blood of healthy individuals. CMV – 
cytomegalovirus; HLA – human leukocyte antigen; PBMC - peripheral blood mononuclear 
cells. 
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were 56 years and 48 years respectively. The majority of both patients and donors 
were male (64% and 65% respectively) with only 22% of patients receiving a female 
graft. If a cytomegalovirus (CMV) seronegative patient received a stem cell graft from 
a CMV seropositive donor they were considered ‘at risk’ (36%). A total of 70 patients 
(65%) underwent matched unrelated donor transplant with a further 10 patients (9%) 
undergoing a single antigen mismatched transplant from an unrelated donor. Only 27 
patients (25%) received transplants from matched sibling donors. Of the entire 
cohort, 93 patients (87%) received reduced intensity conditioning whereas only 14 
patients (13%) underwent full myeloablative conditioning. All patients received in vivo 
T cell depletion, with most receiving a five day course of 10mg per day Alemtuzumab 
(n=79, 74%). Patients whose conditioning involved anti-thymocyte globulin (ATG) 
(n=28, 26%) either received 1mg/kg for 1 day then 2mg/kg for 2 days if combined 
with FLAMSA and Busulfan (Bu) or 2.5mg/kg for 2 days if combined with just 
Fludarabine and Busulfan.  
 
A smaller validation cohort of 30 patients was also selected comprising of patients 
receiving allo-HSCT donor grafts for treatment of myeloid (57%) or lymphoid (43%) 
malignancies (Table 2.4). This cohort had a slightly lower median age (54 years) and 
a smaller proportion of patients over 60 years (27%). Slightly more male patients 
were assessed (53%). Only 3 patients (10%) were at risk of developing a primary 
CMV infection. A similar majority of the patients received reduced intensity 
conditioning (80%) and 17% received ‘T replete’ grafts. Again, most donors were 
fully HLA matched with the patient with only 2 patients (7%) mismatched.    
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Population Characteristics Value Percentage 
Total Number in Cohort 107   
Patient Age, median (range) 56 (19-73)   
Patient >60 years 44 41% 
Patient Gender (Male) 69 64% 
CMV at risk (D+/R-) 39 36% 
Disease     
Myeloid (AML; CML; MDS; MF) 67 63% 
Lymphoid (ALL) 14 13% 
Non-Hodgkin Lymphoma 19 18% 
Hodgkin Lymphoma 7 7% 
Conditioning Regimen     
Full intensity     
Cyclo/TBI 14 13% 
Reduced intensity     
Flu/Melph 53 50% 
FLAMSA 14 13% 
Flu/Bu 12 11% 
BEAM 11 10% 
Flu/BEAM 3 3% 
T Cell Depletion     
Alemtuzumab 79 74% 
ATG 28 26% 
Donor Characteristics     
Donor Age, median (range) 48 (21-66)   
Donor Gender (male) 70 65% 
Female donor to male patient  22 21% 
Donor Type     
HLA Matched Sibling (10/10) 27 25% 
HLA Matched Unrelated Donor (10/10) 70 65% 
Mismatched unrelated donor (9/10) 10 9% 
 
   
  
Table 2.3 – Stem cell graft composition association with outcomes cohort characteristics 
CMV at risk - CMV seronegative patient receiving stem cell graft from a CMV seropositive 
donor. Disease: ALL – Acute Lymphoblastic Leukaemia; AML – Acute Myeloid Leukaemia; CML 
– Chronic Myeloid Leukaemia; MDS -  Myelodysplastic Syndrome; MF - Myelofibrosis. 
Conditioning: Flu – Fludarabine; Melph – Melphalan; FLAMSA - Fludarabine, Ara-C and 
Amsacrine; Cyclo – Cyclophosphamide; TBI – Total Body Irradiation ; Bu – Busulfan; ATG – 
Anti-Thymocyte Globulin; BEAM - BCNU Etoposide Ara-C Melphalan. Alemtuzumab dose – 
50mg (10mg per day for 5 days). ATG dose - FLAMSA/BU receive 1mg/kg for 1 day then 
2mg/kg for 2 days; Flu/Bu receive 2.5mg/kg for 2 days, 
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Population Characteristics Value Percentage 
Total Number in Cohort 30   
Patient Age, median (range) 54 (22-72)   
Patient >60 years 8 27% 
Patient Gender (Male) 16 53% 
CMV at risk (D+/R-) 3 10% 
Disease     
Myeloid 17 57% 
Lymphoid 13 43% 
Conditioning Regimen     
Full intensity     
Cyclo/TBI 6 20% 
Reduced intensity     
Flu/Melph 12 40% 
FLAMSA/Bu 3 10% 
Flu/Bu 4 13% 
BEAM 2 7% 
Flu/Cyclo 3 10% 
T Cell Depletion     
Alemtuzumab 15 50% 
ATG 10 33% 
None 5 17% 
Donor Type     
HLA Matched Sibling (10/10) 10 33% 
HLA Matched Unrelated Donor (10/10) 18 60% 
Mismatched unrelated donor (9/10) 2 7% 
Table 2.4 – Characteristics of patients within the secondary cohort 
CMV at risk - CMV seronegative patient receiving stem cell graft from a CMV 
seropositive donor. Conditioning: Flu – Fludarabine; Melph – Melphalan; Cyclo – 
Cyclophosphamide; TBI – Total Body Irradiation ; Bu – Busulfan; ATG – Anti-
Thymocyte Globulin; BEAM - BCNU Etoposide Ara-C Melphalan.  
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Absolute counts 
 
Absolute counts of mononuclear and CD34+ cells within the stem cell grafts were 
obtained from the NHS blood and transplant unit (NHSBT). Further 
immunophenotyping measurements of the percentages of cell populations within the 
stem cell graft allowed calculations of absolute counts for the individual cellular 
components (see flow cytometry section). Viable lymphocytes could be identified 
based upon their size and granularity in a flow plot and then taken as a fraction of 
the mononuclear cell count to calculate the absolute number of lymphocytes. NK and 
T cells were identified by CD56+CD3- and CD56-CD3+ phenotypes respectively 
from a “lymphocyte gate” in which non-viable, B cells and monocytes had been 
removed (Figure 2.2). The populations were applied as fractions of the lymphocyte 
count to calculate absolute numbers of NK and T cells. These values were then 
divided by the patient weight in order to determine the ‘cell dose’ per kg for each 
patient. 
 
 
 
 
  
Figure 2.2 – Measurement of T and NK cell populations within the stem cell graft 
Forward scatter plot (FS height v FS area) was used to gate on single cells and remove 
doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot identified the 
lymphocyte population. Live cells were identified by negative PI expression. NK cells were 
identified as CD56+CD3- with CD56
dim
 and CD56
bright 
cells distinguished by the intensity of 
CD56 expression. T cells were identified as CD56-CD3+.  
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Absolute counts of lymphocytes in patient peripheral blood following allo-HSCT were 
calculated using BD Trucount™ tubes (BD Biosciences). At room temperature, 20μl 
MACS buffer was reverse pipetted into the tube above the stainless-steel retainer. 
Then 50μl anticoagulated whole blood was also added to the tube by reverse pipette 
technique. The tube was vortexed and then incubated in the dark at room 
temperature for 15 minutes. Following this 450μL 1x BD FACS lysing solution was 
added to the tube which was again vortexed and incubated in the dark at room 
temperature for 15 minutes. The sample was then analysed on a Gallios flow 
cytometer (Beckman Coulter). The lymphocyte population was identified as a bright, 
compact cluster with low side scatter. Lymphocyte numbers were negligible in 
patients in the very early period after transplant and therefore calculation of exact 
numbers was less accurate (Figure 2.3). The number of cells was calculated as:   
(Number of cell events / number of bead events) x (Number of beads per test / 
volume of sample) = concentration of sample 
E.g: Healthy donor: (11460/4798) x (50950/50) = 2.436 cells/ml or 2433 cells/µl 
Patient Day 14: (1927/5374) x (50950/50) = 3.655 cells/ml or 365 cells/µl 
 
 
  
Healthy Donor Patient – Week 1 Patient – Week 4 
Figure 2.3 – Calculation of lymphocyte number using Trucount™ beads 
Plots showing identification of the lymphocyte populations in whole blood samples from a 
healthy donor and a patient at week 1 and week 4 following allo-HSCT. The Trucount™ tube 
beads are gated in the top left of each plot.    
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PBMC isolation and tissue culture 
 
PBMC isolation from peripheral blood 
 
Patient peripheral blood samples were processed under sterile conditions within 24 
hours of collection in order to isolate peripheral blood mononuclear cells (PBMCs). 
Whole blood, collected in heparinised vacutainers, was diluted at a 1:1 ratio with 
wash media. Up to 30ml of diluted peripheral blood was layered over 15ml 
Lymphoprep™ density gradient medium (Axis-Shield) in a 50ml conical centrifuge 
tube and spun at 400xg for 30 minutes with no brake to separate out the cellular 
fractions. The resultant PBMC layer was removed with a Pasteur pipette into another 
50ml tube. An additional 30ml wash media was added and the PBMC were 
centrifuged again at 300xg for 10 minutes (with brake) as a wash step. The 
supernatant was discarded and the re-suspended PBMC pellet was then either used 
fresh or cryopreserved. 
 
Mononuclear cell isolation from stem cell graft 
 
Donor stem cell graft mononuclear cells were also collected within 16 hours post 
transplantation. The discarded stem cell bag containing residual donor cells was 
washed out with 50ml MACS buffer and collected in a 50ml conical centrifuge tube. 
The cells were centrifuged at 300xg for 10 minutes, the supernatant discarded and 
the cell pellet re-suspended. An additional red blood cell lysis step was performed if 
necessary where 15ml Pharm Lyse™ red blood cell lysis buffer (BD Biosciences) 
was added and cells incubated at room temperature for 15 minutes. The stem cell 
graft mononuclear cells then had 35ml MACS buffer added and the sample was 
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centrifuged again at 300xg for 10 minutes. The supernatant was discarded and the 
suspended PBMC were used fresh or cryopreserved. 
 
Cell counting 
 
Cell counting was performed by placing 10µl of the PBMC sample on to a 
FastRead102® haemocytometer (Biosigma). An Olympus CK30 microscope with a 
CK10 objective lens (Olympus) was used to visualise the cells. Live cells within three 
4x4 grids were counted and an average taken. This value was multiplied by 104 to 
give the cell count per ml of the original sample. 
 
Cryopreservation and recovery of cells 
 
Cryopreservation was performed by adding freezing media to the samples which 
were subsequently aliquoted in 5-10x106 cells per 1ml cryovial. Samples were frozen 
to -800C in a ‘Mr. Frosty™’ freezing container holding isopropanol to cool the cells 
down at a rate of 10C per minute. Cells were either kept at -800C for short term 
storage or moved to liquid nitrogen storage at between -1400C to -1800C if longer 
term storage was necessary.  
When thawing samples for use, cryovials were placed in a 370C water bath for 1 
minute and then transferred to 10ml growth media (GM) at the same temperature. 
The PBMC were centrifuged at 300xg for 10 minutes and then washed again in 10ml 
GM and centrifuged (300xg for 5 minutes) before use.  
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Cell culture 
Two commonly used MHC class I null cell lines were used as target cell lines to 
assess NK cell cytotoxic killing. K562 is a erythromyeloblastic leukaemia cell line 
derived from a CML patient (Klein et al. 1976). The 721.221 B cell lymphoblastoid 
cell line was produced through gamma-ray irradiation-induced mutagenesis (Shimizu 
& DeMars 1989).  Established AML cell lines, kindly donated by Professor 
Constanze Bonifer’s lab, were also used as target cells. Kasumi was derived from 
the peripheral blood of a seven year old male AML patient and has a 8;21 
chromosome translocation (Asou et al. 1991). PL-21 was derived from the peripheral 
blood of a 23 year old male AML patient (Kubonishi et al. 1984). 
K562 and 721.221 cell lines were maintained in RPMI 1640 (Sigma-Aldrich) 
containing 10% Foetal bovine serum (Sigma-Aldrich); 1% pen-strep 
(Thermoscientific); 2mM L-glutamine (Thermoscientific) and incubated at 370C and 
5% CO2. K562 cells were maintained at 0.4-0.8 x106 cells/ml and 721.221 cells were 
maintained at 0.2 – 1x106 cells/ ml. 
Kasumi and PL-21 cell lines were cultured in RPMI 1640 (Sigma-Aldrich) containing; 
20% Foetal bovine serum (Sigma-Aldrich); 1% pen-strep (Thermoscientific); 2mM L-
glutamine (Thermoscientific). Kasumi cells were initialled obtained at 2 x106 cells/ml 
and maintained at 0.3 – 3 x106 cells/ml. PL-21 cells were initially obtained at 0.5 x106 
cells/ml and maintained at 0.5-0.8 x106 cells/ml. 
 
All cell suspensions were maintained in 25 cm2 corning flasks at a volume of 6-8ml 
media. Cells were split by partial removal of the cell suspension and addition of 370C 
fresh media. If media appeared yellow (acidic) the entire media was replaced.  This 
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was accomplished by adding the suspended cells to a 15ml conical tube and 
centrifuging at 300xg for 5 min. The supernatant was removed and cells re-
suspended in 370C growth media. 
	
	
Flow cytometry 
 
Immunophenotyping 
 
Analysis of PBMC from peripheral blood or the stem cell graft was conducted using 
flow cytometric immunophenotyping (Full antibody panels – Tables 2.5; 2.6; 2.7; 2.8; 
2.9). PBMC were counted and 1 x106 cells were added to a polypropylene FACS 
tube. Cells were washed in 5ml MACS buffer and centrifuged at 300xg for 5 minutes. 
The supernatant was removed and the cell pellet re-suspended in 100µl MACS 
buffer. Extracellular staining was performed by adding an excess of fluorochrome 
labelled antibodies which were then incubated on ice in the dark for 30 minutes. 
Following this, cells were washed twice with 5ml MACS buffer and centrifugation at 
300xg for 5 minutes. The cell pellet was re-suspended in 200µl MACS buffer and 2µl 
propidium iodide (PI) viability dye (100µg/ml - Miltenyi) was added to each sample 
tube immediately prior to flow cytometric analysis. 
 
Two panels required additional intracellular staining. This process fixes the cells and 
permeabilises the cellular membrane allowing subsequent staining with antibodies to 
reach intracellular antigens. For PBMC undergoing additional intracellular staining 
the initial surface stain was performed as above using LIVE/DEAD® Fixable Red 
Dead Cell Stain viability dye (Life Technologies) rather than PI. Following the surface 
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stain the “functionality” panel cells were then washed in 5ml MACS and 100μl 4% 
PFA was added to the suspended pellet for 15minutes at room temperature in the 
dark. Cells were washed again in 5ml MACS buffer and 100μl 0.5% saponin was 
added for 5 minutes at room temperature in the dark. An excess of the intracellular 
fluorochrome-labelled antibodies was then added and incubated at room 
temperature for 30 minutes in the dark. A final wash step with 5ml MACS buffer was 
performed and the cell pellet was resuspended in 200μl MACS buffer to be run on 
the flow cytometer.  
For the “exhaustion” panel cells were stained using the BD Biosciences transcription 
factor intracellular staining kit which enables detection of intranuclear transcription 
factors. Staining was conducted by following the suggested BD Biosciences protocol. 
1 ml of 1x Fix/Perm buffer was added to the resuspended cell pellet which was 
incubated on ice in the dark for 45 minutes. Following this 1ml 1x Perm/Wash buffer 
was added and the tube was centrifuged at 300xg for 5 minutes. The supernatant 
was discarded and another wash step with 2ml 1x Perm/Wash buffer was performed. 
The resuspended cell pellet had a further 100μl Perm/Wash buffer added along with 
the intracellular antibodies. The tube was then incubated on ice in the dark for 
another 40 minutes. Finally, two wash steps adding 2ml 1x Perm/Wash buffer and 
centrifuging at 300xg for 5 minutes were performed.  The cell pellet was 
resuspended in 200μl MACS buffer to be run on the flow cytometer 
 
Flow cytometry 
 
Data collection was performed on a three laser, ten colour, Gallios flow cytometer 
(Beckman Coulter). Unstained cells were run initially to set the voltages and gains on 
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the machine suitable for visualisation of the cellular populations of interest. 
Compensation was performed using VersaComp antibody capture beads (Beckman 
Coulter) prior to testing samples in order to determine the spectral overlap of the 
fluorophores used in each panel. Quality control checks were also completed each 
day before samples were run using FlowCheck and FlowSet beads (Beckman 
Coulter) to ensure the maintenance of laser position and intensity. 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 – Post-transplant reconstitution panel 
Table 2.6 – NK signalling receptor panel 
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Table 2.7 – NK functionality marker panel 
Table 2.8 – NK exhaustion marker panel 
Table 2.9 – NK chemokine receptor panel 
FITC – Fluorescein isothiocyanate; PE – Phycoerythrin; PI – Propidium iodide; PerCP-
Cy5.5 – Peridinin chlorophyll protein; APC – Allophycocyanin; AF700 – Alexa Fluor® 
700; PB – Pacific Blue. 
72	
	
	
Gating strategies 
 
Kaluza Analysis Software 1.3/1.5 (Beckman Coulter) was used to analyse the flow 
data acquired. When identifying lymphocytes an initial forward scatter plot was used 
to gate on single cells and remove doublets or clumped cells passing through. Then, 
based on the size and granularity of the cells (forward versus side scatter), the 
lymphocyte population could be identified. Expression of PI or LIVE/DEAD® Fixable 
Red Dead Cell Stain was used to distinguish viable and non-viable cells.  
NK cells were identified as CD56+CD3- and T cells as CD56-CD3+. Populations of 
CD56bright and CD56dim cells were easily distinguishable on a flow plot to subgroup 
the NK cell population. Individual receptors were identified through flow plots and 
their expression was assessed on total NK cells, and on CD56bright or CD56dim 
subsets. Gating strategies employed on total NK cells are shown in Figures 2.5, 2.6, 
2.7, 2.8 and 2.9. Gating strategies were applied after thorough back gating and 
comparison with unstained and healthy controls to set the gates. Each gating 
strategy was validated by blind assessment of a healthy donor sample in triplicate 
(Figure 2.4).  
 
Figure 2.4 – Gating strategy validation 
Graph displaying the variation in analysis of a healthy donor sample assessed in 
triplicate through the same gating strategies.  
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Figure 2.5 – Post-transplant reconstitution panel gating strategy 
Forward scatter plot (FS height v FS area) was used to gate on single cells and 
remove doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot 
identified the lymphocyte population. Live cells were identified by negative PI 
expression (A). NK cells were identified as CD56+CD3- with CD56
dim
 and CD56
bright 
cells distinguished by the intensity of CD56 expression (B). The NK cells were further 
classified by gating on NKG2D and CD57 on CD56
dim
 and CD56
bright 
NK cells 
respectively (C). T cells were classified into CD4+, CD8+, or double positive or 
negative cells (D). All subsets of T cells were then classified by CD45RA and CCR7 
expression (E).  
A 
B C 
D E 
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Figure 2.6 – NK signalling receptor panel gating strategy 
Forward scatter plot (FS height v FS area) was used to gate on single cells and remove 
doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot identified the 
lymphocyte population. Live cells were identified by negative PI expression (A). NK cells were 
identified as CD56+CD3- with CD56
dim
 and CD56
bright 
cells distinguished by the intensity of 
CD56 expression (B). Expression of surface receptors NKp46, NKG2D, DNAM and KIR 
(CD158a/h, CD158b, CD158e) on total NK cells, CD56
dim
 and CD56
bright
 were then assessed 
(C).  
A 
B 
C 
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Figure 2.7 – NK functionality marker panel gating strategy 
Forward scatter plot (FS height v FS area) was used to gate on single cells and remove 
doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot identified the 
lymphocyte population. Live cells were identified by negative LIVE/DEAD red stain 
expression (A). NK cells were identified as CD56+CD3- with CD56
dim
 and CD56
bright 
cells 
distinguished by the intensity of CD56 expression. Further differentiation using a CD56 v 
CD16 plot could distinguish CD56
dim
 and CD56
bright
 CD16 negative or positive NK cells 
(B). Expression of markers was assessed on total NK cells, CD56
dim
 and CD56
bright
  NK 
cells (C). Maturity markers CD57 and NKG2C were assessed together, as were the 
cytotoxic proteins granzyme and perforin as well as activation marker CD107 and 
proliferation marker Ki-67. 
A 
B 
C 
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Figure 2.8 – NK exhaustion marker panel gating strategy 
Forward scatter plot (FS height v FS area) was used to gate on single cells and remove 
doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot identified the 
lymphocyte population. Live cells were identified by negative LIVE/DEAD red stain 
expression (A). NK cells were identified as CD56+CD3- with CD56
dim
 and CD56
bright 
cells 
distinguished by the intensity of CD56 expression (B). Expression of markers was assessed 
on total NK cells, CD56
dim
 and CD56
bright
  NK cells (B). Expression of the markers Tim-3 and 
PD-1, as well as the transcription factors Eomes and T-bet, were assessed (C). 
A 
B 
C 
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Figure 2.9 – NK chemokine receptor panel gating strategy 
Forward scatter plot (FS height v FS area) was used to gate on single cells and remove 
doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot identified the 
lymphocyte population (A). Live NK cells were identified as CD56+CD3-LIVE/DEAD red 
stain- expression (B). Chemokine receptor markers were assessed on NK cells by 
comparison with CD56 expression to determine expression on CD56
bright
 and CD56
dim
 NK 
cells (C).  
A 
C 
B 
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Cellular assays 
 
G-CSF assay 
 
To assess the effect of granulocyte colony stimulating factor (G-CSF) directly on 
PBMC, samples were acquired from the peripheral blood of three healthy individuals. 
The PBMC were isolated using Lymphoprep™ density gradient medium as 
described above. A total of 1x106 cells in 250μl growth media were added to 
individual wells of a 48 well plate. The cells were incubated at 370C with 5% CO2 for 
five days. At 24 hour intervals, G-CSF (Miltenyi) was added in varying concentrations 
(0.1ng/ml, 1ng/ml, 10ng/ml or 100ng/ml). After five days cells were removed via 
pipette and placed in a 5ml round bottom FACS tube. Cells were washed in 5ml 
MACS buffer, centrifuged at 300xg for 5minutes and the cell pellet re-suspended in 
200μl of MACS buffer. Cells were stained with antibodies to CD56 (APC-Cy7 – 
Biolegend), CD3 (AF700 – Biolegend), NKG2D (PerCP-Cy5.5 – Biolegend), DNAM 
(APC – Biolegend) and NKp46 (PB – Biolegend) for 30 minutes on ice in the dark. 
Cells were then washed in 5ml MACS buffer 300xg for 5 minutes and the cell pellet 
re-suspended in 200μl of MACS buffer. PI was added at a concentration of 1μg/ml 
and cells were run on a Gallios flow cytometer to assess the cell populations 
(Beckman Coulter). Analysis of flow cytometric data was conducted using Kaluza 
Analysis Software 1.3/1.5 (Beckman Coulter) as per the NK cell signalling receptor 
gating strategy (Figure 2.6). 
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Justification of NK cell assay 
 
Assessment of NK cell cytotoxic function in vitro is usually measured by their ability 
to kill target cells. Previously the 4 hour chromium release assay with a high E:T ratio 
has been considered the gold standard of NK cell cytotoxic assessment. The use of 
flow cytometric, rather than a traditional chromium release assays, has now become 
well established as a method to detect NK cell cytotoxicity (Hatam et al. 1994; 
Jedema et al. 2004; Valiathan et al. 2012). The hazardous nature of handling 
radioactive material, high expense, short usage period and disposal complications 
make the chromium release assay difficult to perform. Flow cytometry-based 
methods provide a simpler and more efficient way of assessing NK cell cytotoxicity, 
however they have limitations of their own.    
NK cell isolation from a PBMC sample is required to perform such an assay. Often 
the residual cells collected from the stem cell graft bag were found to exhibit some 
adhesion to one another and were therefore filtered before use. NK cell isolation 
from stem cell graft samples was difficult and obtaining over 90% pure NK cells was 
rarely possible with the NK cell enrichment kit. Using enrichment and ‘MoFlo’ cell 
sorting enabled >98% NK cell purity however use of this technique required staining 
of NK cells and the low numbers that were obtained made multiple cytotoxicity 
assays unfeasible. Therefore, I elected to use the NK cell enrichment kit for assays, 
however the threshold for use with stem cell graft-derived NK cells was lowered to 
70%. The NK cell yield from stem cell graft samples was relatively low, usually 
around 30,000-75,000 NK cells per sample. Therefore, to perform the experiment in 
triplicate for each sample the number of effectors was maintained at 10,000 cells per 
well.  
80	
	
	
Our flow cytometry measurement technique necessitated the recording of at least 
20,000 target cell events to ensure that measurement of target cell killing would be 
accurate. Therefore an initial 2 target cells to 1 NK cell ratio was used (0.5:1 E:T). 
However, incubating unstimulated NK cells with the 721.221 target cell line for four 
hours and measuring target cell number reduction did not yield sufficiently 
measurable target cell killing. Increasing the incubation time of the NK cells to 16 
hours did improve the killing of percentage but not to satisfactory levels (Figure 
2.10).  
Stimulation with IL-2 is known to enhance NK cell cytotoxic activity (Henney et al. 
1981; Becknell & Caligiuri 2005). This cytokine is commonly used in assays to 
increase the cytotoxic potential of the NK cells, particularly when the cells in question 
produce weaker than normal cytotoxicity, such as with stem cell graft NK cells (Miller 
et al. 1997). In this assay the killing percentage of 721.221 cells could be increased 
to around 80% when NK cells stimulated with 1000iu/ml were incubated with the 
target cells for 16 hours (Miller et al 1997) at a 0.5:1 effector to target ratio (Figure 
2.10). Using a lower 0.1:1 effector to target cell ratio reduced this killing percentage 
to a median of 42% and also improved the accuracy of functional measurement 
through the calculation of target cell numbers as 100,000 target cells were used. 
Additionally, using more target than effector cells and a long-term incubation allowed 
assessment of NK cell ability to kill multiple cell targets (Bhat & Watzl 2007b). This 
killing frequency was calculated by dividing the number of target cells killed by the 
number of effector cells used to estimate the average number of target cells killed by 
each individual NK cell. 
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The combination of these factors led to the development of an assay of NK cell 
function that performed consistently and allowed relative assessment between 
donors. Importantly, this approach facilitated measurement of the cytotoxic potential 
of the low numbers of NK cells that were obtained from the stem cell graft.  
 
 
 
 
 
 
 
 
 
 
 
 
NK cell functional assay 
 
A novel in vitro cytotoxicity assay was developed to assess the functional response 
of NK cells from the stem cell graft following recognition of target cells lines (Figure 
2.13A). Between 5-20 x106 peripheral blood or stem cell graft mononuclear cells 
were added to a 5ml polystyrene round bottomed tube, washed in 5ml Robosep™ 
buffer (Stem Cell Technologies) and centrifuged at 300xg for 5 minutes. The cell 
pellet was re-suspended at 5x107 cells/ml Robosep™ buffer. NK cells were 
negatively selected for using an EasySepTM Human NK enrichment kit (Stem Cell 
Figure 2.10 – Optimisation of assays of NK cell function 
Healthy peripheral blood NK cells were isolated and combined with 721.221 target cells in a 
16 hour incubation. Unstimulated NK cells were incubated with fluorescent-labelled target 
cells at a 0.5:1 E: T ratio whereas IL-2-primed NK cells (1000iu/ml for 16 hours) were 
incubated at 0.5:1 and 0.1:1 E:T. Bars display median with interquartile range (n=4 for all 
bars).  
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Technologies). EasySep™ Human NK Cell Enrichment Cocktail was added at 
50μl/ml, mixed and incubated at room temperature for 10 minutes. EasySep™ D 
Magnetic Particles were vortexed for 30 seconds, added at 100µl/ml and incubated 
at room temperature for 5 minutes. Robosep™ buffer was then added to make up 
the sample to 2.5ml with gentle pipette mixing. The tube was placed into an 
EasySep™ magnet and incubated for 2.5 minutes at room temperature. The magnet 
and tube were tipped in one motion to pour out the unbound cell suspension into a 
new 5ml round bottomed tube.  
A small amount (50μl) was taken to test purity of the sample. These cells were 
added to 150μl MACS buffer and stained with CD3 (AF700 – Biolegend) and 
CD56(APC-Cy7 - Biolegend) antibodies for 30 minutes on ice in the dark. The cells 
were then washed with 5ml MACS buffer, centrifuged at 300xg for 5 minutes and re-
suspended in 200μl MACS buffer. PI was added at a concentration of 1μg/ml and 
cells were run on a Gallios flow cytometer (Beckman Coulter). The percentage of 
CD3-CD56+ NK cells as a proportion of the live lymphocyte population was 
assessed (Figure 2.11). 
 
 
  
Figure 2.11 – NK cell purity following enrichment 
Cell suspension was assessed for NK cell purity following EasySep
TM
 Human NK cell 
enrichment. A forward scatter (FS) vs side scatter (SS) plot identified the lymphocyte 
population. Live cells were identified by negative PI expression. NK cells were identified 
as CD56+CD3- and the percentage of the lymphocyte gate was calculated.  
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The remaining NK cells were counted and then washed in 5ml growth media. Cells 
were re-suspended in 500μl growth media and added to a 24 well plate. 1000 iu/ml 
IL-2 (Preprotech) was added to the NK cells which were incubated at 370C and 5% 
CO2 for 18 hours. The NK cells were then washed in 5ml growth media, re-
suspended at a concentration of 1x105 NK cells/ml (taking purity into account) and 
plated into a 96 well U-bottomed well plate with 10,000 NK cells per well (100μl).  
Target cells were counted and a suitable number were removed into a 15ml tube, 
washed in PBS and centrifuged for 10 minutes at 300xg. The supernatant was 
removed and cells re-suspended in 200μl PBS with 1μM Carboxyfluorescein 
succinimidyl ester (CSFE) (eBioscience) added to label the cells, which were then 
incubated at 370C; 5% CO2 for 10 minutes. The cells were then washed in 10ml 
growth media, re-suspended in a volume of 1x106cells/ml and incubated for a further 
hour at 370C; 5% CO2. Target cells were added to the 96 well plate in 100µl aliquots 
creating a 1:10 effector to target cell ratio (10,000: 100,000). The plate was 
incubated at 370C; 5% CO2 for 16 hours.  
Cells were removed from the well via pipette and placed in a 5ml polypropylene 
round bottomed FACS tube, stained with 1μg/ml PI (Miltenyi) and 25μl CountBright™ 
beads (Life Technologies) were added for calculating absolute counts. 
Samples were run on the Gallios flow cytometer (Beckman Coulter) for 2 minutes at 
high flow speed. Validation that the same volume of sample was analysed could be 
shown by the minimal variation in the number of bead events measured between 
samples (Figure 2.12). 
Calculation of the number of viable target cells was performed by gating on the 
CSFE+PI- cells and the CountBrightTM beads (Figure 2.13B and C) and using the 
equation: 
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(Number of cell events / number of bead events) x (Bead count per 25µl / volume of 
sample) = concentration of sample as cells/μl 
These values were compared to control wells into which no effector cells were added 
to calculate the percentage of target cell killing achieved by the NK cells.  
In instances where PD-1 or DNAM inhibition were used an additional step was taken 
to block the NK cells 30 minutes prior to the addition of the target cells to the 96 well 
plate. Purified anti-PD1 (Biologend [EH12.2H7]) or purified anti-DNAM (Biolegend 
[11A8]) was added at a concentration of 20μl/ml.   
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Figure 2.12 – Variation in bead number between samples 
Tubes containing 200µl sample and 25µl CountBright beads were run for two minutes at 
high flow speed on a Gallios flow cytometer. Variation between bead counts within the 
same experiment were minimal. Bars show mean bead counts from three separate 
experiments, with standard deviation error bars. Variation in the bead number between 
experiments are caused by different lot bead concentrations of the CountBright beads 
used (Exp1 n=23, Exp2 n=15, Exp3 n=14). 
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Figure 2.13 – NK cell functionality assay 
NK cells were isolated and stimulated with 1000iu/ml IL-2 for 16 hours. Target cells were 
stained with CSFE and combined with NK cells at a 0.1:1 effector to target ratio. Cells were 
incubated for 16 hours, harvested and analysed using flow cytometry (A). Target cells and 
counting beads were gated based upon size using a forward scatter (FS) vs side scatter (SS) 
plot. True viable target cells were then identified as CSFE+PI-. Plots show a control tube with 
no NK cell effectors (B) and a tube with NK cells at a 0.1:1 ratio with target cells (C).   
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Molecular Assays 
 
ULBP06 genotyping and patient cohort 
 
Patient DNA was genotyped to identify presence of the ULBP06 allele. Initially the 
ULBP alleles of 27 patients were identified in house by assessing the presence of 
eight single-nucleotide polymorphisms (SNPs) (737A; 737G; 1232C; 1232T; 5037C; 
5037T; 5729A; 5729G). ULBP6 genotyping was performed by polymerase chain 
reaction (PCR) amplification of patient DNA and gel electrophoresis.  
DNA was extracted from patient PBMC samples using a DNEasy isolation kit 
(Qiagen). Roughly 3-5x106 cells per sample were resuspended in 200μl PBS, to 
which 20μl proteinase K was added to lyse the cells. A further 200μl of the kit buffer 
(AL) was added, the sample was vortexed and incubated at 56oC for 10 minutes. 
Then 200μl ethanol was added and the sample vortexed. The sample was spun 
through a DNeasy Mini spin column at 6000xg for 1 minute during which the DNA is 
selectively bound to the DNeasy membrane, with the flow through discarded. 500μl 
of the second kit buffer (AW1) was added to the column which was spun again at 
6000xg for 1 minute with the flow through discarded. A final flush through stage with 
500μl of kit buffer (AW2) added and the column spun at 20,000xg for 3 minutes was 
performed. To elute the DNA 200μl of the kit buffer (AE) was added. The sample 
was incubated at room temperature for 1 minute and then spun at 6000xg for 1 
minute with the flow through collected.  
The concentration of DNA was assessed in triplicate using a NanoDrop-1000 
spectrophotometer (Thermo Scientific). Samples were diluted to approximately 
50ng/μl DNA per sample for subsequent PCR preparation. 
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Eight primers were used to identify the ULBP haplotype of patients (Table 2.10). 
Samples were made up to a total reaction volume of 13μl in RNase-free water with a 
master mix containing 67 mM Tris; 16.6 mM ammonium sulphate, 2 mM magnesium 
chloride, 0.01% Tween-20, 200 μM of each deoxyribonucleoside triphos-phate 
(dNTP), 0.3 μM control primer, and 0.325 units Taq polymerase (Bioline). Primers 
were used at 0.75μM. 
PCR was performed with a GeneAmp PCR system 9700 (PE Applied BioSysyems), 
with thermal cycling conditions as follows: (180s, 950C) x 1 cycle; (25s, 950C; 45s, 
700C; 30s, 720C) x 5 cycles; (25s, 950C; 45s, 650C; 30s, 720C) x 21 cycles; (25s, 
950C; 60s, 550C; 120s, 720C) x 1 cycle.  
A 1.5% agarose gel was prepared by mixing 1.5g of agarose (Bioline) in 100ml 1x 
TBE buffer and then heating to boiling point in a microwave to dissolve the agarose. 
After the gel had cooled to 55oC, 0.5μg/ml ethidium bromide (Sigma-Aldrich) was 
added to the gel solution which was then poured into a tray with an appropriate gel 
comb in. After the gel had cooled the comb was removed and the tank filled with 1x 
TBE buffer. The amplified samples were loaded into the wells along with a 100 base 
pair DNA marker ladder (Invitrogen). 
Electrophoresis was performed at 120V for 45 minutes. Images of the gels were 
taken under UV light (Spectroline UV Illuminator TVC-312A) with a Kodak 
Electrophoresis Documentation and Analysis System (EDAS) 290. 
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Thirteen patients were heterozygous (01/02) and ten homozygous for the 01 and 02 
alleles (Four 01; Six 02). A further four patients were unidentifiable either due to poor 
quality DNA or inaccuracies in the PCR controls (Figure 2.14). 
To validate our polymorphism classifications and increase patient numbers a total of 
68 DNA sample were sent for independent genotyping performed by LGC Genomics 
Ltd (Hoddesdon, England) (Table 2.11).  
These patients were predominantly male (66%), with a median age of 51 years old 
and 74% CMV seropositivity. Most patients were receiving allo-HSCT for treatment 
of a myeloid (65%) or lymphoid malignancy (32%). Two patients with aplastic 
anaemia were also included in the cohort. Only one patient received their stem cell 
graft directly from patient bone marrow rather than a G-CSF mobilised individual. 
The majority of patients received reduced intensity conditioning (84%) and T cell 
Table 2.10 – Primer sequences used to identify ULBP06 SNPs  
Two forward oligonucleotide primers were used to discriminate the SNPs, in 
combination with a common reverse primer. The asterisk highlights the base 
substitution in the primer sequence. 
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depletion (94%). Four patients received cells from a mismatched unrelated donor 
(6%) with the majority of fully matched individuals receiving cells from an unrelated 
donor (59%) rather than a sibling (35%).    
For each patient a 25μl  >5ng/μl DNA sample was sent for analysis. Just under 40% 
of patients were heterozygous (23) with 19 ULPB06*01 and 20 ULPB06*02 
homozygotes, with 90% of our initial genotyping validated. Six samples were 
unidentifiable.  
 
 
 
 
Figure 2.14 – ULBP06 genotype associations with patient outcome 
ULPB alleles of 27 patients were assessed by eight single nucleotide polymorphisms 
(Gray = positive; Dark Grey = negative; Light Grey = ambiguous). 
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Table 2.11 – ULBP06 genotyped patient characteristics 
CMV – cytomegalovirus; ATG – Anti-Thymocyte Globulin; PBMC – peripheral blood 
mononuclear cells. 
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Microarray 
 
Assessment of NK cell RNA transcriptomes were acquired by microarray analysis. 
NK cells were negatively isolated from five healthy individual and five stem cell graft 
sample PBMCs using an EasySep™ Human NK cell enrichment kit (Stem Cell 
Technologies). The EasySep™ Human NK Cell Enrichment Cocktail was added at 
50µl/ml to a cell suspension of 5-20 x106 PBMC to label the other cellular 
components. After incubation at room temperature for 10 minutes vortexed 
EasySep™ D Magnetic Particles were added at 100µl/ml. Following incubation at 
room temperature for 5 minutes Robosep™ buffer was added to make the sample 
up to 2.5ml. The sample tube was placed into an EasySep™ magnet and incubated 
for a further 2.5 minutes at room temperature to mobilise the beads. Finally, the 
magnet and tube were tipped in one motion to pour out the unbound cell suspension 
into a fresh 5ml round bottomed tube. 
The isolated NK cells were stained with anti-CD3 (PE - Biolegend) and anti-CD56 
(APC-Cy7 - Biolegend) on ice in the dark for 30 minutes. Cells were washed in 
MACS buffer and the CD3- CD56+ live cells were sorted with an Astrios cell sorter 
(BD Biosciences) to <99% purity as an added enrichment step. The sorted NK cell 
populations were sent to AROS Applied Biotechnology A/S (Aarhus N, Denmark) as 
dry cell pellets. Total RNA was extracted, labelled and hybridized to GeneChip® 
Human Transcriptome Array 2.0 (Affymetrix, USA). Raw data was processed using 
Affymetrix’s Expression Console software with default RNA parameters. Gene set 
enrichment analysis was conducted by Dr Wayne Croft using the hallmark and 
canonical gene sets from the molecular signatures database (MSigDB database 
v6.0).  
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Statistical analysis 
	
Clinical outcomes 
 
Clinical outcomes assessed post allo-HSCT were overall survival (OS), non-relapse 
mortality (NRM), relapse incidence (RI) and incidence of acute graft versus host 
disease (aGvHD). OS was defined as time to death, of any cause, post 
transplantation. NRM was defined as death without prior relapse, with a competing 
risk of death following relapse. RI was defined as time to relapse with a competing 
risk of death without relapse. Incidence of aGvHD was determined by the diagnosis 
of grade 2 or above aGvHD within 100 days post transplantation and a competing 
risk of death before 100 days without aGvHD incidence. (Iacobelli & EBMT Statistical 
Committee 2013).  
Overall survival is a binary outcome, the patient is either alive or deceased at the 
end of the follow-up period. The effect of all baseline variables upon OS was 
estimated using the Kaplan-Meier method. Statistical analysis of these survival 
curves was performed by Log-Rank tests. This test measures the difference between 
the expected and observed events at different time points to see if the null 
hypothesis, that there is no difference between two populations in terms of the 
probability of an event, is correct. To calculate a regression analysis using these 
outcomes a Cox proportional hazards model was suitable. This test estimates the 
individual effect of several different independent variables on the differences 
between two groups. 
Relapse incidence, graft versus host incidence and non-relapse mortality are all 
patient outcomes which can provide useful information. However with these 
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outcomes there is a possibility that another unrelated event could occur before the 
event of interest. For example when investigating relapse incidence following allo-
HSCT there will be patients who reach censorship without relapse, patients who 
relapse and additionally a group of patients who will die from non-relapse related 
causes, but whom could have relapsed if that had not occurred. Without taking this 
competing risk into account any analysis will be skewed as the “died before relapse 
could occur” group would be included in the censorship group. The outputs of theses 
patient outcomes are therefore not binary. 
Gray developed a statistical test to compare the cumulative incidence of an event 
whilst taking a competing risk into account (Gray 1988). This can be performed using 
the ‘cmprsk’ package in R program for statistical computing. Following on from this 
Fine and Gray developed a regression model in order to correctly assess multiple 
variables whilst also taking the competing risk into account (Fine & Gray 1999). 
 
Clinical outcome statistical analysis 
 
Associations between cell numbers and patient outcomes were assessed using R 
project for statistical computing 3.2.2.  
The binary outcome of overall survival was assessed for significance by a log rank 
test, with multivariate regression analysis performed using a Cox proportional 
hazards model.  
Clinical outcomes with a competing risk were assessed with a Gray test using the 
‘cmprsk’ package in R program (Gray 1988). Further multivariate regression analysis 
was performed using the Fine and Gray model, also available through the ‘cmprsk’ 
package (Fine & Gray 1999).  
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Baseline variables with a cut-off point of p < 0.2 were included in multivariate 
analyses. 
R programming code for tests and plots: 
Log rank test – survdiff(Surv(time, status)~x, rho=o 
Kaplan-Meier – formula >a=survfit(Surv(time, status)~variable) 
>plot(a, conf.int=”none”, mark.time=FALSE, col=c(“red”, “black”), xlab=””, ylab=””) 
Grey test: > cuminc(time_a, status_a, variable, cencode=0) 
>plot(cuminc(time_a, status_a, variable, cencode=0), xlab=, ylab=, col=c(“1”,”2”…), 
lty=1, lwd=2) 
Fine and Grey test: > x=cbind(variable_1, variable_2, variable_3…) 
                                   > mod1=crr(time_a, status_a, x) 
Comprehensive instructions on performing the analysis have been published by 
Scrucca et al (Scrucca et al. 2007; Scrucca et al. 2010).  
 
 
General statistical analysis 
 
Statistical analyses were performed using GraphPad Prism (7.0), IBM SPSS 
Statistics (21) and R (the R project for statistical computing 3.2.2). Appropriate 
statistical testing was used, depending upon the data being parametric or non-
parametric, and taking competing risks into account.  
For flow cytometric phenotypic analyses data normalcy was assessed via a 
D'Agostino-Pearson normality test. The majority of cases data did not follow a 
Gaussian distribution and therefore a Mann-Whitney test was performed to compare 
the two groups. Statistical significance was determined with a p value lower than 
0.05. Where the p value is not stated in the figure, significance is displayed by 
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asterisks where * indicates <0.05, ** indicates <0.01 and *** indicates <0.001. All 
significant p values are recorded in the figure legend.      
In the instance where multiple significance tests were performed on the same data 
set (i.e. comparisons with multiple clinical outcomes) a Bonferroni correction was 
used to set a more stringent significance value (0.05/4 = significant p value <0.0125).  
Data is primarily presented with bar charts displaying the median value and error 
bars demonstrating the interquartile range, but each is specified in the figure 
legends.   
In instances where correlation between two quantitative variables was assessed a 
Pearson coefficient of determination was calculated. This is presented as an R2 
value between 0 and 1 and defines the percentage variation in variable g caused by 
variable c. An accompanying p value determines whether the correlation coefficient 
is significantly different than the null hypothesis that there is no correlation between 
the two variables. A p value less 0.05 was used to indicate a significant correlation.  
 
To determine the optimum cell dose thresholds to distinguish between patient 
outcomes receiver operating characteristic (ROC) curve analysis was used. The true 
positive rate (sensitivity) was plotted against the false positive rate (100-specificity) 
to create a graph of which the area under the curve (AUC) is a measure of how well 
the variable can separate between the two outcomes. The point with the highest 
sensitivity and specificity (i.e. closest to the top left corner of the graph) indicates the 
most suitable discriminatory threshold.  
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Chapter 3 - Lymphocyte reconstitution within the first month 
following allo-HSCT 
 
Allogeneic haematopoietic stem cell transplantation is a potentially curative 
treatment for a range of myeloid and lymphoid malignancies. Haematopoietic stem 
cells transferred from a donor will hopefully engraft into a lymphodepleted host to 
restore a functional immune system as well as contributing towards an allo-immune 
response against any residual tumour. Risks of acute GvHD and transplant related 
mortality are also present with the effectiveness of the donor derived immune 
repertoire reconstitution playing a role in these outcomes. 
Whilst full recovery of a functional immune repertoire will take over a year post-
transplant, reconstitution of immune cells begins immediately. Cells directly 
transferred with the stem cell graft will populate the host while de novo cells will be 
generated following engraftment of the haematopoietic stem cells. NK cells are the 
initial population to recover and dominate the immune environment during the first 
month post-transplant. They are also associated with producing a GvL response in 
certain transplant settings, however at which point this is established is not entirely 
clear. 
Immune reconstitution during the first month post-transplant has not been 
extensively studied due to the difficulties in obtaining samples and the low numbers 
of cells available to examine when collected. Here cell populations within peripheral 
blood samples of patients undergoing T cell depleted allo-HSCT were assessed 
during the first month post-transplant and correlated with subsequent clinical 
outcomes.	  
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Results 
	
 
Cellular reconstitution during the first month following allo-HSCT 
	
Absolute counts and cellular phenotypes of 158 patient peripheral blood samples, 
collected during the first month following allo-HSCT, were analysed to assess 
lymphocyte reconstitution (Table 2.1). Patient samples were pooled for each weekly 
time point to assess the average cell composition across all patients (Table 3.1).  
Healthy adult peripheral blood contains roughly 2000 lymphocytes per μl with around 
three quarters (~1500) compromising of T cells, whilst NK cells represent up to 15% 
of the lymphocyte population (~250 NK cells/μl) (Apoil et al. 2017). These values 
were calculated form a study looking at 253 healthy individuals aged between 19 and 
67 years old. Similarly, within our healthy donor cohort, which represent a younger 
demographic aged between 24 to 45 years old, the mean lymphocyte number within 
the peripheral blood was 2591 cells/µl (Figure 3.1A). T cells made up roughly 60% of 
the lymphocyte population and NK cells a further 15% (Figure 3.1B).  
 
 
Table 3.1 – Post-transplant samples assessed 
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Within the cohort of patients assessed following full or reduced intensity conditioning 
their lymphocyte pool was severely depleted (Figure 3.2A). In the majority of 
patients, numbers of T and NK cells were negligible on the day of donor graft 
infusion, with median values of less than 1 cell per µl of peripheral blood (Table 3.1; 
Figure 3.2B). By two weeks post-transplant both T and NK cell numbers began to 
increase. At one-month post-transplant total lymphocyte count was still well below 
normal values with T cell reconstitution at a median of 19 cells per µl of blood, 
around 75 fold lower than expected in healthy individuals. Contrastingly NK cell 
reconstitution was far greater than in T cells with a median of 160 cells per µl of 
blood at one month, with some patients almost reaching normal values within this 
short time period. 
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A B
C D
 
Figure 3.1 – Lymphoid subsets in healthy peripheral blood  
Peripheral blood was collected from healthy individuals and PBMC isolated as described. 
Lymphocyte count per µl of blood was calculated using the Trucount method (A). T and NK 
cell populations were identified by flow cytometric immunophenotyping as CD3+CD56- and 
CD3-CD56+ respectively (B). The subpopulations of CD4+/CD8+ T cells (C) and 
CD56
bight/dim
 NK cells (D) were also assessed. Bars display mean and standard deviation. (A 
n=8, B n=15, C n=8, D n=15).  
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NK Cell subset reconstitution dynamics 
 
Having demonstrated a predominance of NK cells within the first month, the 
composition of this NK compartment was assessed in more detail. Mature and 
immature NK cells can be identified on the basis of dim or bright CD56 expression 
respectively (Cooper et al. 2001). In healthy individuals the CD56bright population 
makes up only 5-10% of the NK cell repertoire of the peripheral blood (Figure 3.1C). 
Interestingly the reconstitution of both subsets increased simultaneously over the 
first month reaching similar median values within the peripheral blood by day 28 
(55.4 CD56dim NK cells/µl; 58.1 CD56bright NK cells//µl) (Figure 3.2C). This is either 
indicative of homeostatic proliferation of the NK cell population received in the donor 
stem cell graft or indicates the production of de novo NK cells from engrafted donor 
CD34+ haematopoietic progenitor cells. 
 
T cell subset reconstitution dynamics 
The two major subgroups of T cells are CD4+ T cells and CD8+ T cells which 
represent roughly 65% and 25% of the total T cell population in healthy individual 
peripheral blood respectively (Apoil et al. 2017) (Figure 3.1C). At the point of 
transplantation the T cell depletion received by patients had eliminated both CD4+ 
and CD8+ T cells to similarly low numbers. No significant difference between the 
absolute number of peripheral blood CD4+ T cells (median 3.5 cells per µl) and 
CD8+ T cells (median 4.5 cells per µl) was found within the first month following allo-
HSCT (Figure 3.2C).  
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Populations of naïve (CD45RA+CCR7+), central memory (CD45RA-CCR7+), 
effector memory (CD45RA+CCR7-) and EMRA (CD45RA-CCR7-) cells can be used 
to subgroup T cells further. In healthy individuals these populations represent 43.1%, 
32.8%, 16.7% and 1.6% of CD4 T cells respectively and 36.0%, 9.6%, 23.6% and 
23.2% of CD8 T cells (Apoil et al. 2017). 
On the day of transplantation, within the severely T cell depleted individuals, the 
remaining CD4+ T cells were predominantly effector memory or central memory with 
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Figure 3.2 – Immune reconstitution during first month post allo-HSCT 
Peripheral blood samples were collected from patients during the first month following allo-
HSCT. PBMC were measured and analysed phenotypically. Total lymphocyte reconstitution 
increased over the month (A), with NK cell reconstitution greater than T cells (median with bars 
indicating interquartile range) (B). Reconstitution of peripheral blood CD8+ and CD4+ T cells in 
patients following allo-HSCT. Absolute number of CD8+ and CD4+ T cell reconstitution (C) 
(median with interquartile range). Median numbers of reconstituting CD56
bright
 and CD56
dim
 NK 
cells in the circulating peripheral blood, with interquartile range shown (D). D0 n=87; D7 
n=105; D14 n=88; D21 n=43; D28 n=64. 
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averages of 7.55% naïve, 29.73% central memory, 59.20% effector memory and 
3.52% EMRA (Figure 3.3A). This suggests that naïve and central memory CD4+ T 
cells are more selectively killed off during conditioning. Within the CD8+ T cell 
subgroup effector memory and EMRA were the main groups remaining (13.03% 
naïve, 7.21% central memory, 48.81% effector memory and 30.95% EMRA) (Figure 
3.3B). This also suggests an increased drop off in mainly the naïve T cells as well as 
the central memory T cells. Over the course of the first month post-transplant these 
populations did not significantly change. 
Together these data indicates that the infused donor product did not have a major 
effect on the host T cell population and that notable production of novel naïve T cells 
does not begin to occur within this early time period.   
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Figure 3.3 – T cell reconstitution dynamics 
Subgroup percentages of peripheral blood CD4+ (A) and CD8+ (B) T cells were 
assessed over the first month of reconstitution post-transplant. Bars display mean 
values for each subgroup. Memory subsets are defined as naïve (CD45RA+CCR7+), 
central memory (CD45RA-CCR7+), effector memory (CD45RA+CCR7-) and EMRA 
(CD45RA-CCR7-). (D0 n=87; D7 n=105; D14 n=88; D21 n=43; D28 n=64). 
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Patient Outcomes 
 
To identify whether reconstitution of T and NK cells during the first month post allo-
HSCT is predictive of subsequent clinical course the cohort was next assessed in 
relation to clinical outcome events (Table 3.2). In total 104 patients in the cohort 
were over two years post-transplant and therefore included in the analysis. The 
overall survival of these patients at two years was 59%. Relapse incidence by two-
years post-transplant was 30% when the competing risk of death before one year 
was taken into account. Acute GvHD incidence within the first 100 days post-
transplant was 40% when the competing risk of death within the first 100 days was 
taken into account. Finally, the non-relapse mortality at two years post-transplant 
was 32% when the competing risk of death due to disease relapse was taken into 
account.  
 
Assessment of T and NK cell reconstitution associations with patient outcome 
 
Initially to assess whether there was any effect between the reconstitution of T and 
NK lymphocytes and clinical outcome post allo-HSCT, patients were split based 
upon whether an event occurred or not and the pooled cell counts (per ul peripheral 
blood) were calculated over the first month (Figure 3.4). Overall T cell reconstitution 
was relatively low during the first month post-transplant. Whilst there was some 
variation between patients no significant differences in the numbers of T cells 
reconstituted were found to associate with patient outcomes (Figure 3.4A; 3.4C; 
3.4E; 3.4G). At the two week and one month time points similar numbers of T cells in 
the circulating peripheral blood were measured in patients who were alive at one 
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year post transplant and those that were deceased (Day 14: 0.88 – 1.11 cells/μl; p – 
0.4907. Day 28: 18.45 – 2.88 cells/μl; p – 0.2761) (Figure 3.4A). Comparable T cell 
numbers within the peripheral blood were observed between patients who did not 
relapse and those that did (Day 14 0.58 – 1.08 cells/μl; p – 0.9743. Day 28 19.11 – 
2.90 cells/μl; p - 0.2534) (Figure 3.4C) as well as patients who developed aGvHD 
(Day 14: 1.12 – 0.75 cells/μl; p – 0.9643. Day 28: 10.33 – 21.08 cells/μl; p – 0.6648) 
or died from NRM (Day 14: 0.65 – 0.91 cells/μl; p – 0.6463. Day 28: 19.11 – 2.66 
cells/μl; p – 0.2927). 
There was much greater heterogeneity in patient NK cell reconstitution during the 
first month post-transplant, suggesting that there could be a discernible impact on 
patient outcome. However, patients who were alive at one year post transplant and 
those that were deceased had no significant difference in NK cell reconstitution (Day 
14: 14.08 – 13.49 cells/μl; p – 0.8648. Day 28: 99.94 – 159.4 cells/μl; p – 0.5925) 
(Figure 3.4B). 
A possible trend towards inferior reconstitution of NK cells at two weeks post-
transplant occurred in patients who went on to relapse (Day 14 14.08 – 3.76 cells/μl; 
p – 0.1843) (Figure 3.4D). However this trend was not maintained at one month 
post-transplant (Day 28 109.0 – 45.52 cells/μl; p - 0.443). 
No differences in NK cell reconstitution and the incidence of acute GvHD within the 
first 100 days post-transplant were observed (Day 14: 8.27 – 21.03 cells/μl; p – 
0.1031. Day 28: 161.9 – 157.3 cells/μl; p – 0.2639) (Figure 3.4F). Similarly no effect 
on NRM was found (Day 14: 10.65 – 57.39 cells/μl; p – 0.3133. Day 28: 98.16 – 
213.7 cells/μl; p – 0.2927) (Figure 3.4H). 
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Table 3.2 – Clinical outcomes of patients at two years post-transplant 
Overall number and percentages of patients for each clinical outcome assessed. 
Overall survival was measured as patients who were alive or deceased at 2 years post-
transplant. Relapse incidence was measured as an event of disease relapse by 2 years 
post transplant. Acute GvHD incidence was measured as an event of grade 2+ acute 
GvHD within100 days post-transplant. Non-relapse mortality was measured as death 
caused by non-disease relapse related causes within two years post-transplant. 
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Figure 3.4 – Association of T and NK cell reconstitution with clinical outcome 
The potential association of T and NK cell reconstitution during the first month post allo-HSCT with 
patient outcomes was analysed. Patients were split based upon whether they were alive or 
deceased at two years post transplant (A/B), had relapsed or not at one year post transplant (C/D), 
had acquired aGvHD or not after 100 days post transplant (E/F) or died from non-relapse related 
mortality or not at two years post transplant (G/H) (medians with interquartile range). n=OS 
Deceased/Alive: D0 22/35; D7 27/37; D14 26/34; D21 11/13; D28 14/25. RI Non-relapse/Relapse: 
D0 39/15; D7 41/16; D14 40/15; D21 17/5; D28 26/7. aGvHD No/Yes, D0 34/43; D7 49/47; D14 
37/47; D21 21/18; D28 27/31. NRM Alive/NRM D0 33/11; D7 36/16; D14 33/18; D21 14/7; D28 
24/18.  
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Association of high or low T cell reconstitution with patient outcomes  
 
To try to distinguish any differences between patients the cohort was then split 
based upon patients who had ‘high’ (> median) and ‘low’ (< median) T cells in the 
peripheral blood at two weeks (median – 0.97 cells/μl) and one month post-
transplant (median – 19.1 cells/μl). These groups were compared in relation to 
clinical outcome (Figure 3.5). No difference in terms of overall survival was observed 
(p – 0.508; p – 0.201) (Figure 3.5A; 3.5B). However, ‘high’ T cell reconstitution at 
one month was associated with a trend towards protection from disease relapse (p: 
0.0952) (Figure 3.5D). No relapses were observed in 5 patients with very high T cell 
reconstitution (> 35 cells/μl) at two weeks post-transplant. This association also 
appeared to be maintained at one month post-transplant although there was one 
outlier. Reconstituting ‘high’ or ‘low’ T cells within the first month post-transplant did 
not significantly associate with acute GvHD incidence or with NRM. Interestingly 
higher numbers of T cells by one month post-transplant trended towards higher 
aGvHD incidence and may therefore indicate an alloreactive T cell response being 
activated. 
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Figure 3.5 – The association of early T cell reconstitution with clinical outcome 
The potential association of T cell number in the peripheral blood at two and four weeks post 
allo-HSCT with patient outcomes was analysed. Patients were assessed based upon whether 
they were alive at two years post-transplant (A/B), had relapsed by two years post-transplant 
(C/D), had acquired aGvHD by 100 days post-transplant (E/F) or died from non-relapse related 
mortality at two years post-transplant (G/H). Patients were divided based upon reconstitution of 
either above (black) or below (red) the median T cell number in the cohort at two or four weeks. 
Cumulative incidence analysis was tested using the Gray method. Log-Rank tests were used 
to analyse Kaplan-Meier survival curves. D14 n=64, D28 n=40. 
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Association of high or low NK cell reconstitution with patient outcome 
 
When split based upon patients who had ‘high’ (> median) and ‘low’ (< median) NK 
cells in the peripheral blood at two weeks (median – 15.9 cells/μl) and one month 
post-transplant (median – 159.4 cells/μl) there was no difference in terms of overall 
survival (p – 0.811; p – 0.308) (Figure 3.6A; 3.6B).       
However, when split by median values, ‘low’ NK cell reconstitution was associated 
with almost 35% relapse probability compared to only 15% in ‘high’ patients by two 
weeks post-transplant (p – 0.0777) (Figure 3.6C). By one month post-transplant 
however low or high NK cell numbers in the peripheral blood did not associate with 
relapse risk (p – 0.5475) (Figure 3.6D). As such, a beneficial effect of ‘high’ NK cell 
reconstitution and protection from disease relapse may be established very early on 
during the first two weeks post-transplant.  
High or low NK cell reconstitution during the first month post-transplant did not 
significantly affect aGvHD incidence (p – 0.4098; p – 0.6381) (Figure 3.6E; 3.6F). 
Interestingly high NK cell reconstitution trended towards an association with more 
non-relapse mortality both at two (p – 0.2593) and four weeks (p – 0.1287) post-
transplant (Figure 3.6G; 3.6H).   
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Figure 3.6 – The association of early NK cell reconstitution with clinical outcome 
The potential association of NK cell number in the peripheral blood at two and four weeks post 
allo-HSCT with patient outcomes was analysed. Patients assessed based upon whether they 
were alive at two years post-transplant (A/B), had relapsed by two years post-transplant (C/D), 
had acquired aGvHD by 100 days post-transplant (E/F) or died from non-relapse related 
mortality at two years post-transplant (G/H). Patients were divided based upon reconstitution of 
either above (black) or below (red) the median NK cell number in the cohort at two or four 
weeks. Cumulative incidence analysis was tested using the Gray method. Log-Rank tests were 
used to analyse Kaplan-Meier survival curves. D14 n=64, D28 n=40. 
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CD56bright and CD56dim NK cell reconstitution associates with protection from 
relapse 
 
As a trend was observed between high NK cell reconstitution at day 14 and low 
incidence of disease relapse further examination of the CD56bright and CD56dim NK 
cell subsets split by the median values (3.87 and 7.87 cells/μl respectively) was 
conducted. High numbers of both immature and mature NK cells were similarly 
associated with a protective disease relapse effect at two weeks post-transplant 
(CD56bright p: 0.0457; CD56dim p: 0.0529) (Figure 3.7A). Interestingly high numbers of 
CD56bright NK cells at one month post-transplant maintained this protective 
association (> 58.06 cells/μl; p – 0.0139) whilst CD56dim NK cells did not (55.4 
cells/μl; p – 0.4913) (Figure 3.7B). Data suggest that within the first two weeks post-
transplant the function of mature CD56dim NK cells may be important, but following 
this the production of new immature cytokine producing CD56bright NK cells is more 
relevant in preventing relapse.   
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Figure 3.7 –NK cell subset reconstitution may be protective from relapse 
Relationship between number of peripheral blood CD56
dim
 and CD56
bright
 NK cells in 
patients following allo-HSCT and incidence of relapse (RI) by two years post-
transplant. The median number of cells was defined and transplants were divided into 
those where the number of cells in the peripheral blood was either above (black) or 
below (red) this median value. Values at two weeks post-transplant (A), and one month 
(B) were assessed. Cumulative incidence analysis was tested using the Gray method. 
D14 n=64, D28 n=40. 
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Myeloid and lymphoid disease split 
		
The beneficial effects of NK cell reconstitution in relation to protection against 
disease relapse in allo-HSCT have been seen predominantly in myeloid disease 
(Savani et al 2007; Dunbar et al. 2008). As CD56bright and CD56dim NK cell 
reconstitution associated with disease relapse incidence at day 14 post-transplant I 
next separated patients according to myeloid or lymphoid disease (Figure 3.8).  
In myeloid disease a trend was observed between ‘high’ reconstitution of both 
CD56bright and CD56dim NK cells and relative protection from disease relapse 
(CD56bright p: 0.1837; CD56dim p: 0.1204) (Figure 3.8A). Within patients with lymphoid 
disease high numbers of the immature CD56bright NK cells showed a stronger 
association with relapse protection than the mature subset (CD56bright p: 0.1040; 
CD56dim p: 0.3775) (Figure 3.8B) but none of these values reached statistical 
significance. 
The lower number of patients (Myeloid n=37; Lymphoid n=25) analysed within each 
cohort would act to reduce the statistical significance of observations but it is still 
noteworthy that a trend remained between high NK cell reconstitution at day 14 and 
relative protection from disease relapse. Therefore, any GvL effect mediated by NK 
cells in this early period post-transplant may not be entirely myeloid-specific.    
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Figure 3.8 - NK cell reconstitution at day 14 post allo-HSCT and association with disease 
relapse in patients with myeloid or lymphoid disease 
Relationship between number of peripheral blood CD56
dim
 and CD56
bright
 NK cells at day 14 
post-transplant in myeloid (A) and lymphoid (B) patients following allo-HSCT and incidence of 
relapse (RI) by two years post-transplant. The median number of cells was defined, and 
transplants were divided into those where the number of cells in the peripheral blood was 
either above (black) or below (red) this median value. Cumulative incidence analysis was 
tested using the Gray method. (Myeloid n=37, Lymphoid n=25).  
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ULBP06*01 patient genotype is associated with increased survival after allo-
HSCT 
  
The ULBPs are a family of ligands for NKG2D, an activating receptor found on T and 
NK cells.  ULPB06 polymorphisms have been associated with overall and relapse-
free survival following transplant in a cohort of T cell depleted and T cell replete HLA-
matched sibling transplants (Antoun et al. 2012). To assess whether ULBP06 
polymorphisms were important in determining outcome in a predominantly T cell 
depleted cohort I next correlated the outcomes of 62 patients undergoing allo-HSCT 
with their ULBP06 genotype obtained after sending DNA samples to LGC Genomics 
Ltd (Hoddesdon, England) (Table 2.11). Just under 40% of patients were 
heterozygous (23) with 19 ULPB06*01 and 20 ULPB06*02 homozygotes. 
At 1 year post-transplant the overall survival was approximately 82% in all groups, 
but by two years post-transplant overall survival rates began to differ with the 
ULBP06*01 homozygous patients maintaining a much higher survival rate (79%) 
than ULBP06*02 homozygotes (59%; p – 0.210) and ULBP06*01/02 heterozygotes 
(33%; p - 0.011) (Figure 3.9A). This suggests that NKG2D ligands might have a role 
in determining overall survival beyond the first year post allo-HSCT. Rates of 
relapse, aGvHD and non-relapse mortality were not significantly different between 
groups (Figure 3.9B; C and D). The heterozygous group did, however, have both the 
highest NRM and relapse-related death rates as well as the lowest aGvHD incidence 
suggesting, perhaps, both an impaired cell reconstitution and decreased alloreactive 
response. 
As ULBP06 is a ligand for NKG2D, expression of this activatory receptor on 
CD56dim NK during the first month following allo-HSCT was assessed. Expression of 
NKG2D did not differ between patients who were deceased within three years post-
transplant or not (Day 14: 60.7 vs 62.4%; p – 0.810. Day 28: 76.7 vs 78.7%; p – 
0.743) (Figure 3.10A), relapsed or not (Day 14: 59.4 vs 66.7%; p – 0.363. Day 28: 
77.2 vs 78.5%; p – 0.865) (Figure 3.10B) developed acute GvHD or not (Day 14: 
63.4 vs 60.1%; p – 0.631. Day 28: 76.7 vs 77.8%; p – 0.853) (Figure 3.10C) or died 
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from non-relapse mortality (Day 14: 65.0 vs 76.73%; p – 0.3840. Day 28: 79.2 vs 
90.3%; p – 0.1280) (Figure 3.10D). As such, the relative expression of NKG2D on 
NK cells in the early post transplant period does not appear to be a determinant of 
clinical outcome. 
A large degree of heterogeneity was seen in NKG2D expression, especially at two 
weeks post-transplant, with a small proportion of patients having less than 20% of 
their NK cell population expressing the receptor. Again, however, this did not seem 
to affect patient outcomes and by one month post-transplant NKG2D expression had 
recovered to relatively normal levels.  Together this suggests that any effect ULBP06 
polymorphisms may have on patient outcomes is not mediated by NKG2D+ NK cells 
within this early time period.  
Figure 3.9 – The association of ULBP06 genotype with patient outcome 
Analysis with 68 patients compared the presence of ULBP06 alleles with overall 
survival at three years (A), relapse incidence at two years (B), aGvHD incidence (C) 
and non-relapse mortality at three years (D)of patients undergoing allo-HSCT. OS 
Hetero/*01 p – 0.011; Hetero/*02 p – 0.273; *01/*02 p – 0.210.  RI Hetero/*01 p – 
0.543; Hetero/*02 p – 0.770; *01/*02 p – 0.421. aGvHD Hetero/*01 p – 0.160; 
Hetero/*02 p – 0.181; *01/*02 p – 0.999. NRM - Hetero/*01 p – 0.249; Hetero/*02 p – 
0.616; *01/*02 p – 0.563.  
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Figure 3.10 – Relative expression of NKG2D+ on CD56
dim
 NK cells post-transplant  
Expression of NKG2D on CD56
dim
 NK cells at two and four weeks post allo-HSCT in patients 
according to subsequent clinical outcome of survival (A), relapse (B) and aGvHD (C). Y axis 
indicates percentage of CD56dim NK cells positive for NKG2D expression. Bars charts show 
median values with interquartile range error bars. All p values calculated using a Mann Whitney 
u test, however no statistically significant differences were observed. OS Day 14 p – 0.6878; Day 
28 p – 0.1660. Relapse Day 14 p – 0.3202. Day 28 p – 0.4868.  aGvHD Day 14 p – 0.7039; Day 
28 p – 0.4510. NRM Day 14 p – 0.3840; Day 28 p – 0.1280 Day 14 n = 60; Day 28 n = 42. 
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Cell number in the stem cell graft does not determine cell count in the 
peripheral blood during the first month post allo-HSCT 
 
A large degree of heterogeneity was observed in the cellular composition between 
individual patient peripheral blood following allo-HSCT and as these cells are thought 
to be largely derived directly from the donated stem cell graft I next went on to 
determine if there was a correlation between the two. Total lymphocyte, T cell and 
NK cell number in the stem cell graft were determined and plotted against the cell 
counts of the patient at two and four weeks post-transplant (Figure 3.11). Whist there 
was a slight positive correlation in all instances, none were significantly associated.   
To determine whether the dose and number of CD34+ progenitor cells contributed 
towards the heterogeneity of patient peripheral blood composition these values were 
also compared (Figure 3.12). As engraftment and production of new cells is unlikely 
to occur within two weeks comparisons were made at one month post-transplant. 
Again no correlations between CD34+ cell dose or number in the stem cell graft and 
lymphocyte, T cell or NK cell number in patient peripheral blood at day 28 was found. 
Therefore, cellular numbers in stem cell graft do not correlate with the cell count in 
the peripheral blood during the first month post allo-HSCT. 
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Figure 3.11 - No correlation is observed between the composition of the stem cell graft 
and the number of cells in peripheral blood within the first month post-transplant 
The total number of lymphocytes, T cells and NK cells in the stem cell graft received by 
patients was calculated and correlated against the values of those same cells in the patient 
peripheral blood at two and four weeks post-transplant. A: Stem cell graft lymphocyte 
number vs day 14 lymphocytes per µl peripheral blood. B: Stem cell graft lymphocyte 
number vs day 28 lymphocytes per µl peripheral blood. C: Stem cell graft lymphocyte 
number vs day 14 T cells per µl peripheral blood. D: Stem cell graft lymphocyte number vs 
day 28 T cells per µl peripheral blood. E: Stem cell graft lymphocyte number vs day 14 NK 
cells per µl peripheral blood. F: Stem cell graft lymphocyte number vs day 28 NK cells per µl 
peripheral blood. Assessed with Pearson correlation. Week 2 n = 55; Week 4 n= 42. 
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Figure 3.12 - No correlation is observed between stem cell graft CD34+ dose and 
peripheral blood cell count in first month post-transplant 
The dose of CD34+ cells in the stem cell graft received by patients was calculated and 
correlated against the values of lymphocytes, T cells and NK cells in the patient 
peripheral blood at two and four weeks post-transplant. A: Stem cell graft total CD34+ 
cell number vs day 28 lymphocytes per µl peripheral blood. B: Stem cell graft CD34+ cell 
dose per kg patient weight vs day 28 lymphocytes per µl peripheral blood. C: Stem cell 
graft total CD34+ cell number vs day 28 T cells per µl peripheral blood. D: Stem cell graft 
CD34+ cell dose per kg patient weight vs day 28 T cells per µl peripheral blood. E: Stem 
cell graft total CD34+ cell number vs day 28 NK cells per µl peripheral blood. F: Stem cell 
graft CD34+ cell dose per kg patient weight vs day 28 NK cells per µl peripheral blood. 
Assessed with Pearson correlation. Week 2 n = 55; Week 4 n= 42. 
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Discussion  
 
Summary 
 
Lymphoid reconstitution in the first month post allo-HSCT is a highly dynamic 
process with considerable heterogeneity in cell distribution being observed between 
different patients. NK cells dominate cell number within peripheral blood for up to 
one month post-transplant whilst T cell reconstitution had a minimal contribution. No 
statistically significant correlations between T cell number and patient outcomes 
were found within the first month. However high numbers of NK cells at two weeks 
post-transplant did show a trend towards an association with protection from disease 
relapse.  
 
T cell reconstitution 
	
Overall T cell reconstitution within the first month was minimal. As such, inference of 
the relevance of T cell reconstitution dynamics with clinical outcome is difficult due to 
extremely low cell count number, technical challenges in measurement and the wide 
range of distribution. Homeostatic proliferation is the dominant mechanism of T cell 
expansion during this time and no difference was observed in CD4+ or CD8+ T cell 
reconstitution. Very few naïve T cells were identified within the first month, indicating 
that production of these cells does not occur to any significant extent within this early 
time period. Indeed some studies show that it can take up to 6 months for naïve T 
cells to begin to repopulate the host (Roux et al. 2000). T cell depleting medications 
remain at high levels in patients in the early post-transplant period, whilst the use of 
cyclosporine as a GvHD prophylaxis also suppresses T cell proliferation. 
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NK cell reconstitution 
	
NK cell reconstitution was much quicker than T cells and showed greater 
heterogeneity between patients over the first month. A trend towards higher NK cell 
number in the peripheral blood of allo-HSCT patients at two weeks post-transplant 
and a lower rate of disease relapse was found. Indeed, this association became 
almost significant in relation to the CD56dim NK cell subset and suggests that the 
cytotoxic function of these mature NK cells may play an important role during this 
early period post-transplant. As the half-life of mature NK cells is between 1-2 weeks 
it is likely that these cells are derived directly from the stem cell graft rather than 
being generated de novo following donor stem cell engraftment. Indeed, a 
comparison of patients receiving CD3/CD19 depleted stem cell grafts as opposed to 
CD34+ selected grafts found that at day 14 post-transplant there were significantly 
more NK cells in the peripheral blood of patients who received CD3/CD19-depleted 
stem cell grafts (Eissens et al. 2010). The NK cell population in patients who 
received CD34+ grafts was minimal at this time point but had recovered to similar 
levels by one month. This further supports the idea that at two weeks after 
transplant, expansion of NK cells from CD34+ progenitor cells has not significantly 
taken effect and therefore the majority of NK cells present in the patent during this 
early period have come directly from the stem cell graft.  
As these day 14 NK cells associate with protection from relapse it suggests that they 
are mediating a GvL response, which may be established within the first two weeks. 
Bacigalupo et al. showed that patients receiving low dose cyclosporine (1mg/kg) for 
20 days following transplant resulted in greater disease free survival compared to a 
higher dose (5mg/kg) which lowered aGvHD incidence, but also associated with 
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higher organ toxicity and relapse (Bacigalupo et al. 1991). Serum levels of the drug 
were only different between the two groups over the first 10 days post-transplant 
indicating that the GvL response may be established during this early time period 
and can be affected by the reconstitution of the immune environment within the first 
two weeks. 
In murine models homeostatic proliferation permits the persistence of adoptively 
transferred NK cells for more than 6 months, which actively self-renew and retain 
functionality (Sun & Lanier 2011). In humans this is less well characterised however 
the establishment of long-lived NK cells following CMV infection is well known as 
well as the beneficial disease relapse protection associated with CMV reactivation 
following allo-HSCT (Foley et al. 2012). As such, it is possible that the NK cells 
contained within the stem cell graft survive for relatively prolonged periods after 
infusion into the patient.  
Whilst this may account in part for the increased numbers in the CD56dim population 
observed in our cohort over 4 weeks, the large increase in immature CD56bright NK 
cells suggests that de novo NK cell production from the engrafted donor CD34+ 
stem cell pool is brisk. Given that high numbers of CD56bright NK cells at both two 
and four weeks were also associated with relative protection against disease relapse 
it is possible that these cells produce an indirect GvL response through the release 
of cytokines and influence on the adaptive T cell response, which is likely to also be 
established during this time. Additionally, similar trends were observed when looking 
at the myeloid or lymphoid patients separately, suggesting that an NK cell-mediated 
GvL effect may be produced in both instances. This suggestion is somewhat against 
the current general consensus that NK cells are active against myeloid malignancies 
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but that lymphoid cells are relatively resistant to the effects of NK cell-mediated lysis.    
Cells present at this early time period are likely to have been derived directly from 
the adoptively transferred stem cell graft. However, no correlation between the 
number of cells infused into patients and the number of cells in their peripheral blood 
over the first month post-transplant was found. However, assessment of the cells 
within the peripheral blood is not an ideal way to infer the total presence of immune 
cells within an individual. Lymphocytes in the peripheral blood represent only 2% of 
the total lymphocytes in the body, as the majority are located in lymphoid organs or 
various tissues, and they do not proportionally represent the same subpopulations 
present across the rest of the body. 
 
ULBP06 haplotype effect  
	
ULBP06 is a ligand for the NKG2D receptor, a powerful activatory receptor found on 
both NK cells and CD8+ T cells (Bauer et al. 1999). Tumour cells often produce 
NKG2D ligands and NKG2D-mediated killing of tumour cell lines has been 
demonstrated in vitro (Nausch & Cerwenka 2008). Our group has previously shown 
that the ULBP06 genotype within the patient has a substantial impact on patient 
outcomes (Antoun et al. 2012), potentially though enhanced NKG2D-mediated killing 
of tumour cells or indirect modulation of alloreactive immunity through lysis of host 
APC (Zuo et al. 2017). However, in my studies patients expressing the ULBP06*02 
allele had impaired two year overall survival. Furthermore, heterozygous patients 
had both the highest rate of disease related and non-relapse related death which 
may be due to less efficient NKG2D mediated killing of ULPB06 expressing cells. It 
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is important to note however that Antoun et al assessed 8 year post transplant 
outcomes in a larger cohort of HLA-matched sibling transplants, half of which did not 
receive T cell depletion or reduced intensity conditioning. Within our predominantly T 
cell depleted cohort the rates of relapse and aGvHD were not affected by ULBP06 
haplotype. Interestingly expression of NKG2D on CD56dim NK cells did not associate 
with patient outcome at two or four weeks post-transplant suggesting that any effect 
the ULBP06 haplotype may have is not mediated during the first month post-
transplant. NKG2D expression on T cells may be a more important factor as they 
begin to reconstitute to normal levels between 1-2 years post-transplant. 
Interestingly this is also around the time period when ULBP06 haplotype begins to 
associate with differences in overall survival and non-relapse related mortality, which 
may indicate a difference in the ability of patients to develop NKG2D-mediated T cell 
responses against infection. 
 
Limitations 
 
This cohort had several limitations, most notably the number of missing values. A 
potential 790 samples collected from five time points were available, however only 
49% were collected either due to patient unavailability through early discharge, 
illness or removal of consent. This meant tracking reconstitution in specific patients 
over the course of the first month post-transplant was difficult and results were 
analysed as pooled populations. In collaboration with the mathematics department a 
model to predict the missing values by using random forest analysis is being 
assessed. Random forest survival analysis works by combining lots of weak decision 
tree models utilising part of the data to predict the rest, which collectively produces a 
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stronger overall model (Ishwaran et al. 2008). This could lead to the development of 
a mathematical model of immune reconstitution during the first month post-transplant 
which can be correlated with outcomes. Initial results when performed on our data 
set confirm the protective effect of NK cell reconstitution at day 14 post-transplant. 
This does come with a note of caution due to inputted values and the precise 
methodology is still under review. Additionally, the patients consisted of a wide 
mixture of disease types and underwent vastly different transplant processing. 
Streamlining the cohort would reduce numbers and any statistical power. Likewise 
whilst reconstitution during the first month could be assessed for all patients, further 
correlations with clinical outcomes, most importantly relapse free survival and overall 
survival, could not be made in all cases, limiting the cohort. Reassessment of this 
cohort at a later time point may yield more significant results.    
 
Conclusions 
 
Overall these data highlight that assessment of the number of NK cells in the 
peripheral blood over the first month post allo-HSCT may predict patient disease 
relapse outcome. Most notably a higher number of NK cells at two weeks post-
transplant, thought to be derived directly from NK cells present within the donated 
stem cell graft, trended towards an association with lower disease relapse and 
suggests that the NK cell population collected from a HLA matched donor has the 
potential to influence patient outcomes in this T cell depleted transplant setting. 
Therefore, I was next interested to undertake further investigation into the cellular 
components, particularly the NK cell repertoire, present within stem cell grafts and 
their potential association with patient outcomes.  
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Chapter 4 – Comparison of the phenotype and function of NK cells 
from the stem cell graft and healthy individuals 
	
G-CSF mobilisation and apheresis collection is the most common method of stem 
cell graft donation for allo-HSCT. This process releases large numbers of 
haematopoietic stem cells into the peripheral blood of the donor that are collected for 
infusion in to the patient. As discussed in the previous chapter, the NK cells present 
within this stem cell graft might be able to confer a protective GvL response. 
However, the process of stem cell graft collection has been shown to modulate the 
phenotype of lymphoid cells within the graft and I therefore went on to investigate the 
functional profile of NK cells within the infusion product. 
Greater understanding of the potential changes that might occur to NK cells following 
this process could be relevant to understanding the mechanisms of NK cell 
expansion following transplant as well as for development of potential therapeutic 
methods to improve NK function in allo-HSCT. The pattern of RNA expression, 
phenotypic markers and in vitro cytotoxic function of the NK cells taken from the 
peripheral blood of healthy donors and stem cell graft samples was therefore 
performed.  
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Results 
	
Comparison of RNA expression identifies significant downregulation within 
stem cell graft NK cells 
 
To assess whether stem cell graft and peripheral blood NK cells are ‘programmed’ to 
have different functions, RNA expression using a microarray approach was initially 
examined. Dr Tracey Chan had previously acquired RNA transcriptome data for NK 
cells isolated from five stem cell grafts and four healthy donors. This data was 
reanalysed to assess gene level differential expression analysis between the two 
groups of samples. In total 1597 individual genes were found to be differentially 
expressed between stem cell graft and normal peripheral blood NK cells, using 
thresholds of fold change in expression of greater or less than two and an ANOVA p-
value < 0.05 (Figure 4.1A). The majority were coding genes downregulated in the 
stem cell graft samples (954). Several genes that encode proteins involved in 
signalling pathways were downregulated in stem cell graft NK cells such as JAK -1, 
MAP3K and PI3KR. A caveat to this however is that the lowest false discovery rate 
was 0.232 and therefore confidence in these individual gene findings cannot be 
statistically shown. To further analyse this data a gene set enrichment analysis was 
performed by Dr Wayne Croft looking at hallmark and canonical pathways 
(Subramanian et al. 2005). 
Published gene sets taken from the molecular signatures database (MSigDB) were 
compared between the healthy individual and stem cell graft NK cells. Groups within 
the hallmark gene sets, which represent well defined biological states and overall 
cellular processes, and the canonical pathways gene sets, a collection of known cell 
signalling pathways, were assessed. Differences in expression of a group of genes 
can collectively identify changes within cellular biochemical pathways with more 
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confidence than individual genes. Only gene sets with significantly different 
expression were assessed further. 
Several downregulated gene sets were identified in stem cell graft NK cells including 
those involved in cell signalling and natural killer cell mediated cytotoxicity (Figure 
4.1B). These occurred at a false discovery rate below 0.1 and a p value of below 
0.05. The IFN-g response pathway was downregulated, indicating that the functions 
of both CD56dim and CD56bright NK cells were potentially diminished. Other gene sets 
such as the p53, MAPK and PI3K pathways were also downregulated. Several KIR 
genes (KIR2DL1; KIR2DL3; KIR2DL4: KIR2DS1; KIR2DS3; KIR2DS4; KIR3DL1; 
KIR3DL2) demonstrated downregulated RNA expression within stem cell graft NK 
cells. These findings suggest that there may be considerable functional impairment 
of NK cells within the stem cell graft. 
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Figure 4.1 – Microarray data demonstrates differences in RNA expression 
between NK cells in stem cell graft and those from healthy individual   
Volcano plot showing log fold change and significance of differences in RNA expression 
between healthy individual and stem cell graft NK cells (A). Dots indicate individual gene 
RNA expression. Log fold change is in comparison to healthy individuals. Yellow 
indicates expression 1 log2 fold change increased or decreased in stem cell graft NK 
cells. Violin plots showing fold change distribution of genes from selected gene sets that 
are significantly downregulated in stem cell graft NK cells (-log10(False Discovery 
Rate)>1) (B). 
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Characterisation of the lymphocyte repertoire within haemopoietic stem cell 
grafts   
 
Having established that RNA expression of many important gene sets is 
downregulated within NK cells from stem cell grafts I next went on to investigate the 
phenotype of NK cells from the apheresis product in comparison to healthy 
individuals. Residual cells from 107 stem cell graft samples were obtained (Table 
2.2). NK cells (CD56+CD3-) were detected along with T cells (CD3+CD56-) through 
a gating strategy which identified a live lymphocyte population from which CD14+ 
monocyte and CD19+ B cells were excluded (Figure 4.2A).  
A significant decrease in the proportion of both NK and T cells as a fraction of the 
lymphocyte population was found in stem cell grafts compared to healthy donor 
peripheral blood (Figure 4.2B). The interquartile range of the T cell population was 
reduced from between 50-70% to 38-53%. A five-fold reduction was found in the NK 
population, with an interquartile range of 10-20% in peripheral blood to between 2-
6% in the stem cell graft. This change in cellular proportion demonstrates 
considerable differences in overall lymphocyte populations within the stem cell graft 
and normal peripheral blood. 
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Figure 4.2 – The percentage of T and NK cells is decreased in stem cell grafts  
PBMC were isolated from healthy individual peripheral blood and allo-HSCT stem cell 
products and immunophenotyped by flow cytometry to identify NK and T cells (A). A 
forward scatter plot (FS height v FS area) was used to gate on single cells and remove 
doublets or clumped cells. A forward scatter (FS) vs side scatter (SS) plot identified the 
lymphocyte population. Dead, CD14+ or CD19+ cells were excluded. NK cells were 
identified as CD56+CD3- whilst T cells were identified as CD56-CD3+.  Phenotypic 
analysis found statistically decreased proportions of T and NK cells in the stem cell graft 
lymphocyte pool compared to healthy individual peripheral blood (B). (T cells – p: 0.0003; 
NK cells - p: <0.0001). P values calculated with a Mann Whitney test. 
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NK cells from the stem cell graft display decreased cytotoxic capacity 
 
As the NK and T cell lymphoid fractions of healthy individual and stem cell graft 
PBMC were different I next went on to investigate whether the G-CSF mobilisation 
and apheresis processing act to modulate the phenotype of the NK cell subsets. This 
was undertaken by further immunophenotyping of samples from healthy donor 
peripheral blood and stem cell grafts (Figure 4.3). Antibodies specific for the 
activatory receptors NKp46, NKG2D, DNAM and CD16, along with a group of KIRs, 
were used to assess the expression of common signalling receptors at the cell 
surface. The functional state of the NK cells was assessed by examination of CD107 
and Ki-67 expression along with expression of the cytotoxic granules granzyme and 
perforin. Fully mature NK cells were identified by CD57 expression whilst the 
exhaustion status of the cells was assessed through PD-1 and Tim-3 expression. 
Expression of the transcription factors Eomes and Tbet was also investigated to give 
an indication as to the potential regulatory influences on the phenotype and 
functional capacity of the NK cells. Populations of total NK cells as well as individual 
CD56bright and CD56dim NK cell subpopulations could be assessed through the same 
gating strategies.   
The percentage of CD56bright NK cells was increased significantly within the stem cell 
product in comparison to peripheral blood, almost tripling from a median of 5% to 
14% (p – 0.0004) (Figure 4.4A). The reverse was seen in CD56dim cells which fell 
from 95% in peripheral blood to 86% in the stem cell graft, indicating a decrease in 
the CD56dim to CD56bright ratio. Changes in the profile of cell surface receptor 
expression were apparent with significantly decreased presence of the activatory 
receptors NKp46 (p – 0.0222), DNAM (p – <0.0001) and CD16 (p – 0.0001) on NK 
cells within the stem cell grafts (Figure 4.4B). A decrease in the proportion of NK 
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cells expressing KIRs was also found (48 – 39%; p – 0.0388). The proliferative 
capacity of NK cells from stem cell grafts was significantly increased, measured by 
an increase in the percentage of NK cells expressing Ki-67 (1.5 – 4.5%; p -<0.0001) 
(Figure 4.4C). CD107, a marker of degranulation, was also increased in stem cell 
graft NK cells (6 – 15%; p – 0.0005) which correspondingly exhibited a decrease in 
both granzyme B (46 – 33%; p – 0.0312) and perforin (68 – 46%; p – 0.0019) (Figure 
4.4C). Significant differences were observed with markers of maturity and exhaustion 
between stem cell graft and peripheral blood NK cells with a reduction of CD57 (29 – 
20%; p - 0.0149), an increase in PD-1 (3.5 – 14%; p – 0.0045) (Figure 4.4D) and a 
decrease in Tbet and Eomes dual expression (61 – 45%; p – 0.0496). 
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Figure 4.3 – Flow plots displaying comparison between NK cells in peripheral blood 
and stem cell grafts  
Example plots of extracellular and intracellular markers expressed on NK cells identified by 
immunophenotypic analysis. CD56 / CD16 (A); CD56 / DNAM (B), CD56 / KIR (C), Ki67 / 
CD107 (D), Granzyme / Perforin (E) and Tim-3 / PD-1 (F). 
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Figure 4.4 – Phenotypic differences between healthy individual and stem cell graft NK cells 
PBMC isolated from stem cell graft and healthy individual samples were immunophenotyped to 
compare percentage expression of markers within the NK cell population. Expression of CD56 NK 
cell subsets (A), activatory and inhibitory receptors (B), functional markers (C) and maturity and 
exhaustion markers (D) were assessed. Bar charts show median values with error bars displaying 
the interquartile range. Significant p values: CD56bright – 0.0004; CD56dim – 0.0004; NKp46 – 
0.0222; DNAM – <0.0001; CD16 – 0.0001; KIR – 0.0388; CD107 – 0.0005; Granzyme B – 0.0312; 
Perforin – 0.0019; Ki-67 – <0.0001; CD57 – 0.0149; PD-1 – 0.0045; Eomes/Tbet – 0.0496. (A: PB 
n= 15; SCG n=107. B: PB n=15; SCG n=107. C: PB n=15; SCG n=78. D: PB n=11; SCG n=74). 
All p values calculated using a Mann Whitney U test. 
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Sub-analysis of CD56dim and CD56bright populations of NK cells highlighted more 
specific differences. The reduced proportion of NKp46 (62 – 43%; p – 0.0174), 
DNAM (89 - 81%; p – <0.0001) and CD16 (72 – 27%; p - <0.0001) expressing cells 
was maintained within the CD56dim NK cell subset (Figure 4.5A). Interestingly the 
significant difference in KIR expression was lost when looking at the CD56dim 
population (53 -44%; p – 0.1187). Significant increases in Ki-67 (1.0 – 6.5%; p - 
<0.0001) and CD107 expression (3.5 -16%; p - <0.0001), along with decreased 
granzyme (65 -51%; p – 0.0028) and perforin (71 – 40%; p – <0.0001), were also 
notable (Figure 4.5B). The decrease in NK cell expression of maturity and 
exhaustion markers seen when the population was analysed as a whole were 
exaggerated when assessed in relation to the CD56dim NK population. Lower 
frequencies of CD57 (29 – 18%; p - <0.0001), Tim-3 (39 – 15%; p - 0.0002) and 
Eomes and Tbet (55 – 25%; p – 0.0085) expression suggest an NK population with 
fewer fully differentiated CD56dim NK cells within the stem cell graft (Figure 4.5C). 
The increase in PD-1 expression (4.5 – 25%; p – <0.0001) also highlights the 
potentially reduced cytotoxic ability of the CD56dim cells. 
In contrast, the stem cell graft CD56bright NK population did not demonstrate as 
profound a reduction in markers of cytotoxic potential (Figure 4.6). The activatory 
receptors NKp46 (93 – 82%; p – <0.0001), DNAM (91 – 88%; p – 0.0474) and CD16 
(21 – 9%; p – 0.0015) did show reduced expression (Figure 4.6A) although, 
interestingly, the expression of granzyme was increased in the CD56bright population 
(26 – 46%; p – 0.0338) (Figure 4.6B). Proliferation of CD56bright NK cells was 
increased, as assessed by Ki-67 expression (3.0 – 10%; p - <0.0001), as was the 
expression of CD107 (7.5 – 25%; p – 0.0005) (Figure 4.6B). The percentage of 
CD56bright NK cells within the stem cell graft expressing PD-1 significantly increased 
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(6.0 – 29%; p – 0.0014) whilst Tim-3 expression was significantly reduced (30 – 
20%; p – 0.0188) (Figure 4.6C).    
 
  
Figure 4.5 – Phenotypic differences between CD56
dim
 NK cells from healthy individual 
and those from the stem cell graft  
PBMC isolated from stem cell graft and healthy individual samples were immunophenotyped to 
compare percentage expression of markers within the CD56dim NK cell population. Expression 
of activatory and inhibitory receptors (A), functional markers (B) and maturity and exhaustion 
markers (C) were assessed on CD56dim NK cells. Bar charts show median values with error 
bars displaying the interquartile range. Significant p values: NKp46 – 0.0174; DNAM – 
<0.0001; CD16 – <0.0001; CD107 – <0.0001; Granzyme B – 0.0028; Perforin – <0.0001; Ki-67 
– <0.0001; CD57 - <0.0001; PD-1 – <0.0001; Tim-3 - 0.0002; Eomes/Tbet – 0.0085. (A: PB 
n=15; SCG n=107. B: PB n=15; SCG n=78. C: PB n=11; SCG n=74). All p values calculated 
using a Mann Whitney U test. 
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Figure 4.6 – Phenotypic differences between CD56
bright
 NK cells from healthy 
individuals and from the stem cell graft  
PBMC isolated from stem cell graft and healthy individual samples were 
immunophenotyped to compare percentage expression of markers within the CD56bright 
NK cell population. Expression of activatory and inhibitory receptors (A), functional 
markers (B) and maturity and exhaustion markers (C) was assessed on CD56bright NK 
cells. Bar charts show median values with error bars displaying the interquartile range. 
Significant p values: NKp46 – <0.0001; DNAM – 0.0474; CD16 – 0.0015; CD107 – 
0.0005; Granzyme – 0.0338; Ki-67 – <0.0001; PD-1 – 0.0014; Tim-3 - 0.0188. (A: PB 
n=15; SCG n=107. B: PB n=15; SCG n=78. C: PB n=11; SCG n=74). All p values 
calculated using a Mann Whitney U test. 
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The influence of donor characteristics on the composition of the stem cell 
graft  
 
As donor age and CMV status have been shown to affect the NK cell repertoire of 
healthy individuals the cohort of stem cell graft samples was analysed to assess any 
effect that these variables might have. Donor age varied from 21-66 years of age 
and a trend towards older donors supplying higher doses of NK cells was found 
(Figure 4.7A). However, there was no correlation between the percentage of 
CD56dim NK cells within the NK repertoire (Figure 4.7B). No correlation was 
observed between donor age and the number of cytotoxic NK cells within the graft.  
Interestingly comparison between CMV seronegative and seropositive donors did 
detect some differences in NK phenotype. CMV seropositive donors had a slightly 
higher proportion of CD56dim NK cells in their grafts (p: 0.0304) (Figure 4.8A). 
Furthermore a slightly higher proportion of stem cell graft NK cells from CMV 
seropositive donors showed expression of DNAM (p - 0.0190) and KIRs (p – 0.0143) 
(Figure 4.8B). No other phenotypic markers differed between CMV seropositive and 
seronegative donors (Figure 4.8C; 4.8D).  Despite these phenotypic differences 
there was no significant difference in the total number of CD56dim NK cells within 
grafts received from CMV seropositive or seronegative donors (p: 0.394). 
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Figure 4.7 – Donor age does not influence the dose of the NK cells within the 
stem cell graft 
NK cell dose and CD56
dim
 NK cell percentage in the stem cell graft was correlated with 
donor age (A). p values calculated using an unpaired t test.  
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Figure 4.8 - Phenotypic differences between NK cells within stem cell grafts from CMV 
seronegative and seropositive donors 
Stem cell graft NK cells were immunophenotyped and divided based upon whether the donor 
was CMV seropositive or seronegative. Expression of CD56 on NK cell subsets (A), 
activatory and inhibitory receptors (B), functional markers (C) and maturity and exhaustion 
markers (D) were assessed. Significant p values: CD56bright – 0.0270; CD56dim – 0.0304; 
DNAM – 0.0190; KIR – 0.0143. (A: CMV neg n =56; CMV pos n=49. B CMV neg n =56; CMV 
pos n=49. C: CMV neg n =39; CMV pos n=37. D CMV neg n =39; CMV pos n=37). All p 
values calculated using a Mann-Whitney U test. Bar charts show median values with 
interquartile range.  
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G-CSF does not affect the composition of NK cells within the lymphocyte 
fraction nor the phenotype of unprimed peripheral blood NK cells in vitro 
 
To determine whether G-CSF has a direct effect on NK cells an in vitro assay adding 
pharmacological doses of the drug to PBMC taken from healthy individuals was next 
performed. Donors receive 10μg/kg G-CSF for five days and peak serum 
concentrations within individuals receiving this dose can vary between 26-85 ng/ml 
(Stute et al. 1992). Therefore, to adequately replicate a physiological dose in vitro 
1ng, 10ng or 100ng/ml G-CSF was applied for five consecutive days to 1 x106 cells 
in a 48 well plate. After five days of culture in growth media at 370C with 5% CO2 the 
live T cell percentage had increased slightly (58.2 – 69.4%) and live NK cell 
percentage decreased (10.6 – 8.6%) as part of the lymphocyte pool, however there 
was no difference between cells exposed to G-CSF or not (Figure 4.9A; 4.9B). 
Expression of the activatory receptors NKG2D, NKp46 and DNAM at the surface of 
NK cells also remained consistent between cells exposed to G-CSF and those that 
were not (Figure 4.9C; 4.9D; 4.9E). This data suggests that exposure to G-CSF does 
not affect the composition or activatory receptor phenotype of unstimulated blood-
derived NK cells. 
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Figure 4.9 – In vitro exposure to G-CSF does not alter the phenotype of unprimed 
peripheral blood NK cells following culture 
PBMC were isolated from healthy individuals and incubated in growth media at 370C 
with 5% CO2. 1ng/ml, 10ng/ml or 100ng/ml doses of G-CSF were added every 24 hours 
over 5 days. Cell were then harvested and immunophenotyped to assess cell 
populations. No difference was observed in the proportion of T and NK cells (A), NK cell 
CD56 subsets (B) or NK cell activatory receptors NKG2D (C), NKp46 (D) and DNAM (E) 
following culture with or without G-CSF. Graphs show median values with interquartile 
ranges. (n=3). 
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The ability of NK cells taken from the stem cell graft to kill HLA-null target cells 
is reduced compared to those from healthy donors 
 
The phenotypic differences that were observed between NK cells from the stem cell 
graft and those from healthy donors suggested that they may have differing 
functional capacities. A reduced functional capacity of IL-2 activated stem cell graft 
derived NK cells has previously been shown in a 4 hour chromium release assay 
against K562 target cells at various E:T ratios (Miller et al. 1997). However, in these 
assays the killing of target cells was less than 5% at the lower E:T ratios (<0.75 E:T). 
Therefore, in order to achieve an increased efficiency of target cell lysis that was 
sufficient to allow comparisons between individual stem cell graft samples the 
incubation time with the MHC Class-I negative cell lines K562 and 721.221 was 
increased to 16 hours.  
Initially, and to compare with the previous literature, NK cells from four stem cell 
grafts were stimulated with IL-2 and incubated with K562 cells at an 0.1 E:T ratio for 
16 hours. An average of 41% killing was observed by healthy donor-derived NK cells 
but only 9% killing was seen from stem cell graft-derived NK cells (p - 0.0095) 
(Figure 4.10A).  
NK cells were then isolated from 18 stem cell grafts, stimulated with IL-2 and 
incubated for 16 hours with MHC Class-I negative 721.221 cell line target cells. NK 
cells isolated from healthy donor peripheral blood were able to eliminate an average 
of 35% 721.221 target cells when combined in a 1:10 effector to target ratio and 
incubated for 16 hours. Under the same conditions NK cells taken from stem cell 
grafts achieved a significantly reduced average lysis of 18% target 721.221 cells (p - 
0.0004) (Figure 4.10B)  
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The phenotype of NK cells is related to their ability to mediate cytotoxicity of 
an MHC Class I negative target cell line 
 
A large degree of heterogeneity was observed in the efficiency of lysis by IL-2 
activated NK cells from stem cell grafts when tested against 721.221 target cells (1 - 
31%). Having shown that these NK cells display reduced cytotoxicity compared to 
NK cells from peripheral blood, the phenotypic features of NK cells, assessed prior to 
IL-2 activation, were then compared in relation to cytotoxic activity (Figure 4.11).  
A positive correlation was observed between the percentage of NK cells from the 
stem cell graft that expressed a CD56dim phenotype and the percentage of target 
cells that were killed (R2 – 0.051; p – 0.267) (Figure 4.11A). However this did not 
reach statistical significance and may reflect the small number of samples in this 
experiment.  Non-significant positive correlations were found between the killing of 
Figure 4.10 – NK cells from healthy donors and those from stem cell graft grafts 
exhibit differential capacity for lysis of target cells 
NK cells were isolated from the peripheral blood of healthy individuals and from stem cell 
grafts, stimulated with IL-2 and incubated overnight with K562 (A) or 721.221 (B) cells in a 
0.1:1 E:T ratio. Bar charts show median values of percentage lysis with interquartile range. 
K562 p – 0.0095; 721.221 p - 0.0004 (K562: peripheral blood n=6; stem cell graft n=4. 
721.221: peripheral blood n=6; stem cell graft n=18.). P values calculated using a Mann-
Whitney U test. 
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721.221 cells and the expression of activatory receptors NKp46 (R2 – 0.118; p – 
0.127) (Figure 4.11C), DNAM (R2 – 0.122; p – 0.121) (Figure 4.11E) and CD16 (R2 - 
166; p – 0.074) (Figure 4.11F) on CD56dim NK cells, and significant positive 
correlation with the cytotoxic proteins granzyme B (R2 – 0.211; p – 0.042) (Figure 
4.11G), perforin (R2 – 0.288; p – 0.015) (Figure 4.11H) and the transcription factor 
Eomes (R2 – 0.309; p – 0.014) (Figure 4.11J), but not T-bet (R2 – 0.004; p – 0.802) 
(Figure 4.11I) were also observed. The proportions of CD56dim NK cells expressing 
NKG2D (R2 – 0.010; p – 0.672) (Figure 4.11D) and KIR (R2 – 0.0512; p – 0.311) 
(Figure 4.11B) did not correlate with target cell killing, although this was not 
unexpected as 721.221 cells do not express NKG2D ligands or MHC molecules 
(Lisovsky et al. 2015). This data suggests that the killing of 721.221 cells is 
dependent upon NK cell cytotoxic release of granzyme and perforin, whilst activation 
of that cytotoxic function in CD56dim NK cells from the stem cell graft may be due to 
expression of the activatory receptor proteins NKp46, DNAM and CD16. Interestingly 
an inverse correlation between the expression of PD-1 on stem cell graft NK cells 
and target cell killing was also observed (R2 – 0.1852; p – 0.058) (Figure 4.11K). A 
similar non-significant inverse association was observed in relation to CD107 
expression (R2 – 0.1306; p – 0.117) (Figure 4.11L).  
Overall this data fits the known associations between phenotype and function of NK 
cells. Indeed, despite differences in the phenotype and function of NK cells from the 
stem cell graft compared to those from healthy donors this correlation between 
cellular phenotype and cytotoxic function is still observed.   
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Figure 4.11 - Correlation between expression of markers on CD56
dim
 NK cells and 
cytotoxic activity 
NK cells were isolated from the stem cell graft, stimulated with IL-2 and incubated overnight 
with 721.221 target cells. Phenotypic markers of cytotoxicity measured before stimulation 
were correlated with target cell lysis. Positive correlations were seen in most cases with 
significance in granzyme B, perforin and eomes expression (n=18). Pearson correlation was 
used to measure linear association.    
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Discussion 
 
Summary 
 
NK cells within the stem cell grafts that are used in allo-HSCT display a range of 
phenotypic and functional differences compared to NK cells from the blood of healthy 
individuals that have not undergone G-CSF mobilisation or apheresis. RNA 
expression of gene sets involved in cell signalling and NK mediated cytotoxicity were 
downregulated in stem cell graft NK cells. Reduced expression of activatory 
receptors NKp46, DNAM and CD16 were also seen. The proportion of immature 
CD56bright NK cells was increased in the stem cell graft compared to peripheral blood 
and these displayed a heightened state of activation through increased CD107 
expression. The mature CD56dim NK cell population also displayed increased CD107 
expression in combination with a decrease of intracellular granzyme and perforin 
indicating degranulation and a potentially reduced cytotoxic capacity. G-CSF 
stimulation of mature NK cells isolated from healthy donors did not affect their 
phenotype suggesting that the changes observed between stem cell graft and 
peripheral blood-derived NK cells might potentially relate to the development of novel 
NK cell phenotypes that are released into the peripheral blood during mobilisation 
and apheresis. A decrease in the ability of IL-2 activated NK cells from stem cell 
grafts to kill MHC class I null target cells in vitro was also seen, however there was a 
large degree of heterogeneity in this functional analysis, which correlated with 
cellular phenotypes.   
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Transcriptome differences 
 
Microarray analysis detected considerable differences in the profile of gene 
expression between NK cells from the stem cell graft and from healthy donors. Most 
notable was the decrease in expression of genes in the ‘NK mediated cytotoxicity’ 
gene set indicating a likely reduced cytotoxic functional capacity of the stem cell graft 
NK cell population. A decrease in expression of signalling pathway genes within NK 
cells from stem cell grafts was also seen and may reflect the intracellular response to 
G-CSF stimulation. Inhibition of JAK activity leads to impaired NK cell function and a 
more immature phenotype (Schonberg et al. 2015). Similarly Pi3K and MAPK-ERK 
pathways are involved in target cell lysis, particularly NKG2D-mediated cytotoxicity 
(Jiang et al. 2000; Li et al. 2008). Downregulation of these pathways in stem cell 
graft NK cells is strongly suggestive of a functionally suppressed phenotype. A 
somewhat unexpected finding was down regulation of expression of the p53 gene in 
NK cells from stem cell graft. The p53 pathway is involved in cell cycle suppression 
and this downregulation may potentially favour a proliferative phenotype in this these 
cells  (Levine 1997).  
It was also interesting to note that the hallmark gene set involved in ‘allograft 
rejection’ was downregulated in NK cells from the stem cell graft and this is likely to 
reflect their derivation from highly activated alloreactive T cells populations. Indeed, 
within the context of allo-HSCT it is possible that this relatively suppressed functional 
phenotype of NK cells in the stem cell graft may even have a beneficial role by 
limiting the immune response against the alloreactive host. Further bioinformatic 
analysis of this dataset will be of value but a major limitation to the microarray data is 
the high false discovery rate for individual genes (FDR p value 0.3414). Additionally, 
levels of RNA transcription do not necessarily correlate with the level of protein 
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expression and this may explain the lack of a clear correlation between the 
transcriptome and cellular phenotype. Despite this, the microarray results do provide 
a range of valuable insights into the transcriptional activity of the NK cells from the 
stem cell graft. 
 
Phenotypic differences 
 
The phenotype of stem cell graft-derived NK cells was compared to those from 
healthy donor PBMC. Whilst the overall number of T and NK cells in donor peripheral 
blood increases with G-CSF treatment (Martínez et al. 1996) their frequency within 
the ‘lymphocyte gate’ on the flow cytometer decreased. This was due primarily to an 
increase in a population of CD3-CD56- cells, potentially reflecting proliferative stem 
cell progenitors produced by G-CSF administration (Lane et al. 1995; Holig et al. 
2009). 
Both mature and immature NK cell subsets in the stem cell graft showed a 
significantly increased expression of Ki-67 indicating enhanced proliferation. 
However, a slightly larger proportion of the CD56bright (10%) than CD56dim (7%) NK 
cells expressed this marker and this might explain their relative increase in number 
in the first month. The CD56bright NK cell population also showed high levels of 
CD107a expression indicating an activated functional state. 
Interestingly the CD56dim NK cell population from the stem cell graft also displayed 
higher extracellular CD107 expression indicating increased functional activity. 
However, the percentage of many activatory receptors at the surface was 
significantly lower, an observation also seen for perforin and granzyme expression 
within the cells. CD107 is a marker of both cytokine secretion and cytotoxic 
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functionality in NK cells (Alter, et al. 2004). Therefore this data suggests that NK 
cells from the stem cell graft have become activated and undergone degranulation. 
Combined with the profile of increased PD-1 expression and reduction in expression 
of the transcription factors eomes and T-bet the findings display evidence of an 
‘exhausted’ NK cell phenotype (Gill et al. 2012). The phenotypic profile of a reduced 
cytotoxic capacity from NK cells from the stem cell graft was proven in vitro by the 
comparatively weaker killing of two MHC class I null cell lines. This reduced cytotoxic 
functionality of stem cell graft NK cells has been well documented (Miller, et al. 1997; 
Su et al. 2012). 
Expression of Tim-3 was significantly reduced on both CD56dim and CD56bright NK 
cells from the stem cell graft. Whether this receptor has an activatory or inhibitory 
function on NK cells has not been totally elucidated, as in different contexts its 
effects are seemingly contradictory. Tim-3+ NK cells produce IFN-y in the presence 
of the soluble ligand galectin-9 ligand, but this is markedly reduced with removal of 
the soluble ligand or blockade on stimulatory AML cells (Gleason et al. 2012). In 
other experiments the cross-linking of Tim-3 with antibodies suppressed the killing of 
P815 or 721.221 target cells induced though NKG2D and CD16 receptors (Ndhlovu 
et al. 2012). This effect could, however, be overcome by culturing the NK cells in IL-2 
overnight. Similarly blockade of Tim-3 was found to improve the cytotoxicity of NK 
cells from melanoma patients (da Silva et al. 2014). In healthy individuals Tim-3 is 
expressed on most CD56dim CD16+ NK cells but only heterogeneously on CD56bright 
CD16- NK cells (Ndhlovu et al. 2012). The reduced expression seen in the stem cell 
graft samples may represent the more immature NK cell population present and 
contribute towards their reduced functionality. 
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Healthy donor PBMC incubated with G-CSF in vitro for five days did not demonstrate 
a resultant change in frequency of NK cells within the lymphocyte population, nor a 
change in their phenotype. Similar findings have previously been reported (Miller, et 
al. 1997). However, phenotypic and functional NK cell changes induced by IL-2 and 
IL-15 can be suppressed with the addition of G-CSF in vitro suggesting that an 
indirect effect on mature NK cells can be achieved (Schlahsa et al. 2011). The 
receptor for G-CSF is CD144 which is expressed on many cells within the bone 
marrow, but not on mature lymphocytes, indicating why direct exposure to G-CSF 
does not cause an alteration in NK cell phenotype and function. Interestingly, NK 
cells taken from G-CSF-treated donors display high GCSF receptor expression 
whereas in vitro treated cells do not (Schlahsa et al. 2011). Therefore changes to the 
immune environment and cytokine signalling caused by G-CSF mobilisation in vivo 
may result in a direct effect on mature NK cell phenotype and functionality.  
It cannot be ruled out that the physical process of aphaeresis induces apoptosis and 
death in mature CD56dim NK cells and an altered, activated phenotype in immature 
CD56bright NK cells within the final stem cell product. Indeed Miller et al. found that 
NK cells taken from the peripheral blood of G-CSF mobilised individuals displayed 
better cytotoxicity against K562 cells compared to NK cells from the apheresed stem 
cell graft, indicating that this process does alter the NK cell population in some way 
(Miller et al. 1997). Analysis of the apheresis waste product, along with donor 
peripheral blood pre and post aphaeresis, may be needed to address this question. 
Annexin-V / 7AAD staining could be used to more accurately describe the apoptotic 
cells. 
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Cytotoxic differences 
 
The CD56dim NK cell population from the stem cell graft displayed high CD107a 
expression whilst the percentage of activatory receptors at the surface was 
significantly lower compared to healthy PBMC-derived NK cells. Along with reduced 
perforin and granzyme expression this data provides an explanation as to why stem 
cell graft-derived NK cells exhibited a decreased cytotoxic capacity against target 
cell lines. These NK cells do retain partial cytotoxic activity which correlated with 
various phenotypic markers suggesting that they may have a variable ability to 
influence GvL tumour killing in vivo following allo-HSCT. 
As the cytotoxicity assay used an excess of target cells the serial killing by each NK 
cell could be estimated. An average of 3-4 target cells were killed by each IL-2 
activated healthy individual peripheral blood NK cell within a 16 hour incubation, 
however only 1-2 target cells were killed by each IL-2 activated NK cell from the 
stem cell graft. This supports the work of Bhat et al who used a 16 hour chromium 
release assay to show a similar result for healthy NK cells against 721.221 target cell 
(Bhat et al. 2007). With the use of cell labelling and microscopy visualization they 
also showed that not all NK cells within this context made multiple target cell 
contacts, but that some were hyperactive and could kill up to 6 target cells (Bhat et 
al. 2007). It was also observed that NK cell contact with a target cell would usually 
result in lysis. Therefore, it would be interesting to assess whether the decrease in 
stem cell graft NK cell cytotoxicity is due to an inability to make target cell contacts or 
whether the contacts are made but lysis is not achieved.  
 
Phenotypic markers on NK cells correlated with their ability to mediate target cell 
cytotoxic. Interestingly, expression of PD-1 on stem cell graft-derived NK cells was 
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upregulated compared to those from the blood of healthy donors. Presumably a 
consequence of the G-CSF mobilization and apheresis processing, this upregulation 
correlated with impaired killing of 721.221 target cells. PD-1 upregulation is also 
used by many tumours as an immune evasion mechanism (Benson et al. 2010). 
Therefore PD-1 blockade is being tested in several circumstances as an 
immunotherapeutic way to restore anti-tumour activity (Ansell et al. 2015; Bryan & 
Gordon 2015). To discover if PD-1 blockade of IL-2 activated NK cells from the stem 
cell graft could potentially be used to restore NK cell cytotoxicity, three high PD-1-
expressing NK cell samples from stem cell grafts were assessed for lytic activity in 
the presence or absence of PD-1 blockade. NK cells were incubated with excess 
PD-1 antibody for 30 minutes prior to incubation with 721.221 target cells which 
express PD-1 ligands. In each case, PD-1 blockade resulted in increased cytotoxicity 
against the target cell line (Figure 4.12). This indicates that NK cell cytotoxicity can 
be partially restored by blockade of inhibitory receptors and could be an important 
way to increase stem cell graft NK cell activity.    
 
Conclusions 
 
The process of G-CSF mobilization and apheresis processing is associated with 
significant alterations in the phenotype and function of NK cells in a stem cell graft, 
albeit with a large degree of heterogeneity between donors. Understanding the 
mechanisms behind this effect, their importance for clinical outcome, and potential 
mechanisms to overcome them, could be of considerable value in improving the 
outcome for patients 
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Figure 4.12 - PD-1 blockade of PD-1+ NK cells taken from the stem cell graft improves 
killing of 721.221 cells 
NK cells isolated from three stem cell graft samples with high PD-1 expression were stimulated 
with IL-2 and then incubated with 721.221 target cells at a 0.1 E:T ratio for 16 hours. The 
percentage of 721.221 target cell lysis was measured (SCG-NK). The assay was also performed 
with NK cells from the same stem cell graft samples but with PD-1 antibody added 30 minutes 
prior to incubation with target cells to block the PD-1 receptor (PD-1 Blockade). The percentage of 
721.221 target cell lysis was also measured to compare the NK cell cytotoxic function between the 
two assay conditions. N=3. One tailed Wilcoxon t test: p - 0.1667. 
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Chapter 5 – The influence of the composition of the stem cell graft 
on clinical outcome following allo-HSCT 
 
The composition of the stem cell graft products that are acquired following G-CSF 
mobilisation and apheresis can display considerable heterogeneity between donors. 
Importantly, an adequate minimum dose of CD34+ haematopoietic stem cells is 
necessary to ensure establishment of donor haemopoiesis although too high a dose 
has also been associated with the development of GvHD. The CD34+ cell dose is 
therefore measured and typically a value of 4-8 x106 cell/kg is required prior to 
infusion. However, numbers of lymphoid subsets in the stem cell graft are not 
measured and can vary substantially between donors.  
The impact that differences in graft composition can have on clinical outcomes has 
been investigated previously although with varying conclusions in different studies. 
The number of T cells, B cells, dendritic cells, NK cells, Tregs and iNKT cells have all 
been associated with relative risk of acute GvHD although these reports have been 
undertaken in different transplant settings and highlight the difficulty of making 
definitive conclusions (Impola et al. 2016; Chaidos et al. 2012; Malard et al. 2016). 
As the GvL effect is mediated by donor lymphocytes, and is believed to be 
established very early post-transplant, it is likely that the NK cell and T cell 
populations within the stem cell graft may be important determinants of the risk of 
disease relapse. Indeed, in a T cell-replete transplant setting a high dose of CD8+ T 
cells in the stem cell graft has been associated with lower relapse risk (Reshef et al, 
2015). In a T cell-depleted setting it is likely that this effect may be nullified although 
it may also be the case that any potential association with the NK cell dose may be 
relatively enhanced. 
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Therefore, I next went on to assess the impact of the composition of the stem cell 
graft on patient outcomes within a cohort of reduced intensity conditioned and T cell 
depleted allo-HSCT patients performed at our institution.  
 
Results 
 
Assessment of cellular heterogeneity within the stem cell graft  
	
A cohort of 107 consecutive patients undergoing T cell depleted allogeneic stem cell 
transplant as a treatment for a haematological malignancy was selected (Table 2.3). 
The stem cell graft composition received by each patient was examined by collecting 
the apheresis bag immediately after infusion. The bag was washed with MACS 
buffer and residual cells were collected for immunophenotyping using flow cytometry. 
A mononuclear cell and CD34+ cell count was performed as part of the clinical 
measurements of the graft before transplantation by NHSBT.  
Viable lymphocytes were measured based upon their size and granularity in a flow 
plot and were then taken as a fraction of the mononuclear cell count to calculate the 
absolute number of lymphocytes. NK and T cells were identified by a CD56+CD3- 
and CD56-CD3+ phenotype respectively from the ‘lymphocyte gate’ in which non-
viable cells, B cells and monocytes had been removed (Figure 5.1A). These values 
were then used together with the total cell count to determine absolute numbers of 
NK and T cells. These values were then divided by the patient weight to determine a 
‘cell dose’ per kg for each patient. Within this cohort the number of T cells varied 
from 0.04 to 458 million cells/kg (median 87.41; SD 84.07) whereas the comparable 
range for NK cells was from 0.03 to 99 million cells/kg with a median of 6.3 million 
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cells/kg (SD 13.57) (Figure 5.1B). Local clinical protocols aim to attain a CD34+ dose 
of between 4-8 x106 cells/kg. 
 
 
 
	  
A
B
Figure 5.1 – The number of T cells and NK cells delivered within the stem cell 
product differs greatly between patients 
Flow plots displaying how T (CD3+CD56-) and NK (CD3-CD56+) cells were identified 
through sequential gating (A). Box and whisker graph displaying dose range of T (range 
0.04 – 458 x10
6
/kg; median 87.4 x10
6
/kg), NK (range 0.03 – 99 x10
6
/kg; median 6.3 
x10
6
/kg) and CD34+ (range 1.25 -8.0 x10
6
/kg; median 4.7 x10
6
/kg) cells in the stem cell 
product received by patients in the cohort (B). 
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Assessment with patient outcomes 
 
The overall survival at two years post-transplant within the cohort was 64%, the 
relapse incidence within one year post-transplant was 27%, the incidence of aGvHD 
grade 2+ by day 100 post-transplant was 18% and non-relapse mortality at two 
years post-transplant was 23% (Table 5.1). The number of leucocytes infused within 
the stem cell graft was then examined to determine whether this was related to 
subsequent clinical outcome. The median doses of CD34+ cells, lymphocytes, T cells 
and NK cells within the stem cell graft were 4.7, 186, 87 and 6.3 x 106/kg 
respectively. Patients were divided into two groups based on receipt of a donor stem 
cell graft infusion containing values above or below the median cell dose for each of 
the four cell types. These groups were then assessed against the incidence of 
disease relapse or acute GvHD, non-relapse mortality and overall survival to 
determine whether they may impact upon these outcomes (Figure 5.2). 
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Table 5.1 – Clinical outcomes within the study cohort 
Overall number and percentages of patients with each clinical outcome were assessed, 
with and without competing risks. Overall survival was measured as patients who were 
alive or deceased at 2 years post-transplant. Relapse incidence was measured within the 
first year post-transplant. Acute GvHD incidence grade 2+ was measured within the first 
100 days post-transplant. Non-relapse mortality was measured within 2 years post-
transplant.  
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Patients who receive high numbers of NK cells within the donor graft have a 
substantial reduction in the rate of disease relapse 
 
A striking positive association was apparent between the number of NK cells infused 
and protection from disease relapse (p<0.001) (Figure 5.2A). Specifically, the 
relapse rate amongst patients who received an infusion of NK cells above the 
median dose of 6.3 x106/kg was only 6% at two years post-transplant compared to 
40% in those who received an NK cell infusion below this value.  As such, infusion of 
the higher number of NK cells was associated with a 6.7 fold decrease in the rate of 
disease relapse. Receiver operating characteristic curve analysis did not find an 
improved threshold than the median NK cell dose to distinguish relapse incidence 
(Figure 5.3). 
Patients who received an NK cell dose above the median level had an overall 
survival at two years post-transplant days of 70% compared to 58% for those in 
whom the graft composition was below the median. This difference, however, did not 
reach statistical significance (p: 0.161). Interestingly, no statistically significant 
differences were observed in the risk of acute graft versus host disease or non-
relapse mortality in association with the NK cell dose in the stem cell graft.  
In addition, no associations were observed between high or low doses of infused 
CD34+ cells, lymphocytes or T cells and any of the clinical outcomes (Figure 5.2B; C; 
D). 
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Figure 5.2 – The dose of NK cells in the stem cell product is protective against disease 
relapse 
Relationship between the dose of four different cell subsets administered within the stem cell 
infusion and clinical outcome. The median number of CD34+ cells, lymphocytes, T cells and 
NK cells was defined and transplants were divided into those where the infusion contained a 
cell dose either above (black) or below (red) this median value. Clinical outcome measures 
were incidence of relapse (A), aGvHD (B), non-relapse mortality (C) and overall survival (D). 
This demonstrates that NK cell dose influences disease relapse (p. <0.0001).  Cumulative 
incidence analysis was tested using the Gray method. Log-Rank tests were used to analyse 
Kaplan-Meier survival curves.  
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AUC:		0.736				
P:	0.001
 
 
 
 
 
 
 
 
A protective effect of NK cells against relapse was also seen when assessing the 
absolute number of NK cells in the bag. Patients receiving above the median value 
of 0.487 x109 NK cells showed a powerful association with protection from disease 
relapse (p: <0.0001) indicating the strong correlation between absolute number of 
cells and dose received (Figure 5.4A). Similarly the percentage of NK cells as a 
fraction of the lymphocyte gate was also protective as patients receiving transplants 
from donors over the median of 3.33% NK cells displayed a significantly reduced 
disease relapse incidence (p: 0.0135) (Figure 5.5A). Clearly the NK cell frequency, 
absolute number and dose within the graft are all linked and the fact that they all 
display the same association highlights the confidence of the findings.  
Absolute numbers of CD34+ cells, total lymphocytes and T cells did not associate 
with relapse or acute GvHD incidence (Figure 5.4) and nor did the T cell percentage 
(Figure 5.5). Interestingly a high absolute number of CD34 cells in the graft did 
correlate with protection from non-relapse mortality (p: 0.0258). Patients receiving 
Figure 5.3 – Receiver operating curve of NK cell dose and incidence of relapse 
This receiver operating curve indicates that the median value is the most accurate 
threshold for differentiating the risk of relapse. (6.3 x10
6
/kg:  Sensitivity - .870; 1-
Specificity - .377) 
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Figure 5.4 – The absolute number of NK cells in the stem cell product is protective against 
disease relapse 
Relationship between the absolute number of four different cell subsets administered within the stem 
cell infusion and clinical outcome. The median number of CD34+ cells, lymphocytes, T cells and NK 
cells was defined and transplants were divided into those where the infusion contained either above 
(black) or below (red) this median value. Clinical outcome measures were incidence of relapse (A), 
aGvHD (B), non-relapse mortality (C) and overall survival (D). This demonstrates that total NK cell 
number influences disease relapse (p. <0.0001). Cumulative incidence analysis was tested using the 
Gray method. Log-Rank tests were used to analyse Kaplan-Meier survival curves.  
lower than 0.39 x109 CD34+ cells had a 38% NRM incidence which was more than 
double that found in patients receiving a higher number of cells (Figure 5.4C).   
 
164	
	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.5 – The percentage of NK cells in the stem cell product is protective against 
disease relapse 
Relationship between the percentage of T and NK cell subsets administered within the 
stem cell infusion and clinical outcome. The median percentage T cells and NK cells was 
defined and transplants were divided into those where the infusion contained either above 
(black) or below (red) this median value. Clinical outcome measures were incidence of 
relapse (A), aGvHD (B), non-relapse mortality (C) and overall survival (D). This 
demonstrates that NK cell percentage influences disease relapse (p. 0.0135).  Cumulative 
incidence analysis was tested using the Gray method. Log-Rank tests were used to 
analyse Kaplan-Meier survival curves.  
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Multivariate analysis confirms that infusion of a stem cell graft with an NK cell 
dose that is above the median value is a determinant of the risk of relapse 
 
In addition to NK cell dose within the stem cell graft, several additional patient 
characteristics were found to be associated with the risk of disease relapse at a 
statistical significance of <0.2 on univariate analysis (Table 5.2). These included 
patient age, donor type, type of T cell depletion, patient haemopoietic stem cell 
transplant comorbidity index (HCT-CI) and total lymphocyte dose. The predictive 
power of NK cell dose was assessed within multivariate models that included these 
parameters (Table 5.3). Clinical outcomes with competing risks were assessed with 
a Fine and Gray model while overall survival was assessed by a Cox proportional 
hazards model. 
Unrelated donor transplantation, low HCT-CI, the nature of T cell depletion and high 
NK cell dose all remained as independent predictors of protection against disease 
relapse following multivariate analysis. Importantly, the relative risk of relapse in 
patients who received an NK cell infusion greater than 6.3 x 106/kg compared to 
those who received less than 6.3 x 106/kg was 0.097, representing a 90% reduction 
in relapse risk. 
Several variables were associated with risk of developing acute GvHD of grade 2 or 
greater but only HLA mismatch and full intensity conditioning remained significant 
upon multivariate analysis. HLA mismatch was also the only independent predictor of 
non-relapse mortality.  Finally, HLA mismatch between patient and donor, HCT-CI, 
type of T-cell depletion and NK dose were also found to be significant in univariate 
analysis of predictors for OS but only HLA mismatch and HCT-CI remained as 
independent predictive risk factors following multivariate analysis.  
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    RI aGvHD NRM OS 
Age <56 30.4 19.6 14.3 66.1 
>56 13.7 13.7 25.5 62.7 
p. 0.0445 0.4393 0.1431 0.612 
Disease Lymphoid 27.0 14.3 22.2 58.7 
Myeloid 18.4 23.7 15.8 68.4 
p. 0.5602 0.2162 0.2555 0.716 
Gender Other 22.4 14.1 17.6 65.9 
Female to 
Male 22.7 27.3 27.3 59.1 
p. 0.8915 0.1270 0.2814 0.488 
CMV at risk Not at risk 24.2 13.6 16.7 62.1 
At risk 19.5 22.0 22.0 68.3 
p. 0.5283 0.2805 0.7222 0.865 
Conditioning RIC 21.5 12.9 17.2 64.5 
Full 28.6 42.9 28.6 64.3 
p. 0.4657 0.0081 0.4291 0.503 
Mismatch No  21.6 13.4 16.5 68.0 
Yes 30.0 50.0 50.0 30.0 
p. 0.4531 0.0019 0.0105 0.0561 
Donor Type MUD 18.8 20.0 21.3 65.0 
Sibling 33.3 7.4 14.8 63.0 
p. 0.1818 0.1428 0.4636 0.91 
T Cell 
Depletion 
ATG 32.1 0.0 17.9 50 
Alemtuzumab 19.0 22.8 19.0 69.6 
p. 0.1816 0.0061 0.5245 0.0942 
HCT-CI Low 15.0 18.8 16.3 71.2 
High 44.4 11.1 25.9 44.4 
p. 0.0013 0.3293 0.3459 0.0039 
CD34 Dose <median 17.8 22.2 24.4 62.2 
>median 20.0 17.8 17.8 68.9 
p. 0.7240 0.0754 0.5779 0.746 
Lymphocyte 
Dose 
<median 29.4 21.6 17.6 60.8 
>median 15.7 11.8 23.5 66.7 
p. 0.0984 0.1835 0.4582 0.415 
T Cell Dose <median 28.0 22.0 22.0 60.0 
>median 18.0 12.0 18.0 68.0 
p. 0.2535 0.1753 0.7227 0.419 
NK Dose <median 40.0 18.0 14.0 58.0 
>median 6.0 16.0 26.0 70.0 
p.  <0.0001 0.7604 0.2148 0.161 
  
Table 5.2 – Univariate analysis of patient characteristics and cell doses 
Variables known to have a potential influence on transplant outcomes were 
assessed via univariate analysis. Variables with a p value <0.2 (in bold) were 
included in subsequent multivariate analysis. 
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    p value Hazard Ratio 
CI 
(2.5%) 
CI 
(97.5%) 
RI 
> 56 Years Old 0.069 0.477 0.22 1.06 
Alemtuzumab T cell Depletion 0.018 0.424 0.21 0.87 
Sibling Transplant <0.001 4.588 1.99 10.60 
High HCT-CI <0.001 4.097 1.82 9.24 
Lymphocyte Dose > Median 0.730 1.148 0.52 2.55 
NK Dose > Median <0.001 0.097 0.03 0.33 
          
aGvHD 
Female to Male Transplant 0.320 2.049 0.49 8.52 
Mismatched Unrelated Donor 
(9/10) 0.030 7.988 1.23 51.96 
Sibling Transplant 0.720 0.649 0.06 7.02 
Full Intensity Conditioning 0.006 11.414 2.01 64.73 
CD34 Dose > Median 0.130 0.341 0.08 1.39 
Lymphocyte Dose > Median 0.860 1.176 0.19 7.21 
T Cell Dose > Median 0.820 1.207 0.23 6.30 
          
NRM 
> 56 Years Old 0.360 1.530 0.61 3.84 
Mismatched Unrelated Donor 
(9/10) 0.014 2.970 1.24 7.10 
          
OS 
Mismatched Unrelated Donor 
(9/10) 0.012 3.449 1.32 9.02 
Alemtuzumab T cell Depletion 0.127 0.560 0.27 1.18 
High HCT-CI 0.008 2.525 1.27 5.03 
NK Dose > Median 0.102 0.547 0.27 1.13 
  
Table 5.3 – NK cell dose remains an independent predictor of relapse incidence 
in a multivariate analysis. 
Multivariate analysis. Patient characteristics or stem cell product cell dose with a 
univariate p value <0.2 association with a clinical outcome were included to assess 
independent predictors in a regression model. Fine and Gray regression method was 
used for RI, aGvHD and NRM to take competing risk into account. Cox proportional 
hazard regression analysis was used to identify independent associations with overall 
survival.  
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The number of CD56dim NK cells within the stem cell graft is the predominant 
determinant of the risk of disease relapse 
 
To investigate the mechanisms underlying the association between infusion of a high 
NK cell dose and relative protection from disease relapse it was determined whether 
a specific NK cell subset was associated with this effect. The mean NK cell dose that 
had been given in the stem cell graft in patients who went on to suffer disease 
relapse was 4.9 x 106/kg compared to an average of 11.5 x 106/kg in patients who 
did not relapse following allo-HSCT (Figure 5.6A). This was mirrored by the lower 
average total NK cell number (0.39 x 109) and frequency of NK cells (3.2% of all 
lymphocytes) received in the stem cell graft by patients who relapsed compared to 
those who did not (0.91 x109 and 5.7% of all lymphocytes respectively).  
The expression level of CD56 is used to divide NK cells into immature CD56bright and 
mature effector CD56dim NK cells. Having previously found an increased ratio of 
CD56bright : CD56dim NK cells within stem cell products the numbers of these cells 
within the stem cell infusion was assessed in relation to relapse risk. The risk of 
disease relapse was not influenced by infusion of doses of CD56bright NK cells above 
or below the median value (Figure 5.6B). Importantly however, the relapse incidence 
at two years post-transplant for patients who received at least the median dose of 
5.7 x 106/kg CD56dim NK cells was only 8.3% compared to 43% in those who 
received a dose below this value (p<0.0001) (Figure 5.6B). In relation to average 
values, patients who went on to relapse had received lower doses of both CD56bright 
(0.65 x 106/kg) and CD56dim cells (4.3 x 106/kg) compared to those who did not 
relapse (1.2 x 106/kg (p: 0.0241) and 10.4 x 106/kg (p: 0.0004) respectively) (Figure 
5.6C). These observations indicate that the number of mature cytotoxic effector 
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CD56dim NK cells infused within the stem cell graft is a powerful determinant of the 
strength of the graft versus leukaemia effect following allogeneic transplantation. 
Figure 5.6 –CD56
dim
 NK cells within the stem cell product are the major contributing factor 
to the association with disease relapse risk. 
Relationship between the number of CD56
bright 
and CD56
dim
 NK cells administered within the 
stem cell infusion and relapse incidence. The cohort was split into patients who relapsed or not 
within two years post transplant to assess absolute number (n=100), dose (n=100) and 
percentage (n=107) of total NK cells within the stem cell product (A). The median dose of both 
subsets was defined and transplants were divided into those where the infusion contained a cell 
dose either above (black) or below (red) this median value (B). The dose of CD56
bright 
and 
CD56
dim
 NK cells received by patients who relapsed or not within two years post transplant was 
also assessed (n=100) (C). All NK cell groups proved to be significantly reduced in relapse 
patients. p values calculated using a mann-whitney u test. Cumulative incidence analysis was 
tested using the Gray method. 
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The influence of the NK cell dose on clinical outcome in patients with myeloid 
or lymphoid disease 
 
Several studies have shown that donor NK cells appear to have a protective 
influence on relapse for patients with myeloid malignancy following allo-HSCT, 
however this has been difficult to also demonstrate in patients with lymphoid 
malignancy (Giebel et al. 2003; Cooley et al. 2010; Ruggeri et al. 2015). 
Therefore, I next went on to assess the effect of NK cell dose on the clinical outcome 
of different disease subtypes. Patients were divided into those who received an allo-
HSCT for a myeloid or lymphoid malignancy and comparisons were made on the 
importance of NK cell dose with patient outcomes in both settings (Figure 5.7). 
Interestingly, in both cases patients receiving a high dose of NK cells in the stem cell 
graft had a lower incidence of disease relapse (Figure 5.7A; 5.7B).  
No significant differences were seen in the incidence of acute GvHD or non-relapse 
mortality incidence with high or low NK cell dose with either myeloid or lymphoid 
malignancies. Similarly no significant effect on overall survival was found although a 
trend towards greater protection in association with higher dose of NK cells was 
clear for patients with both types of disease. Together these findings suggest that the 
NK cells within the stem cell graft have an important influence on clinical outcome of 
many disease subtypes in allo-HSCT.  
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Figure 5.7 – NK cell dose effect in myeloid and lymphoid allo-HSCT patients 
Patients were split based upon whether they were receiving allo-HSCT for a myeloid or a 
lymphoid malignancy to determine whether the effect of NK cell dose was different in each case. 
The median number of NK cells was defined and transplants were divided into those where the 
infusion contained either above (black) or below (red) this median value. Clinical outcome 
measures were incidence of relapse (A/B), aGvHD (C/D), non-relapse mortality (E/F) and overall 
survival (G/H). The protective effect of a high NK cell dose was seen in both myeloid and 
lymphoid disease. Cumulative incidence analysis was tested using the Gray method. Log-Rank 
tests were used to analyse Kaplan-Meier survival curves.  
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Validation in a secondary cohort trends towards an association between high 
NK dose in the stem cell graft and protection from relapse 
 
In order to provide further validation of these findings I next went on to assess the 
influence of NK cell dose within the stem cell graft on disease relapse in a second 
cohort of 30 patients (Table 2.4). However, only five patients relapsed in this study 
(17%) and this number is too low to draw statistically significant findings from the 
data. Despite this, a trend towards a correlation between the NK cell dose and 
protection from relapse was observed as four out of the five patients who went on to 
relapse received less than the 6.3x106 NK cells/kg threshold that was established in 
the previous cohort (Figure 5.8A). At two years post-transplant the probability of 
relapse when receiving an NK cell dose below the median level was 35% compared 
to only 5% in patients receiving greater than the median dose (Figure 5.8B). This 
compares well with the comparable values of 40% to 6% seen in the initial cohort. 
Figure 5.8 – A trend towards a protective effect of a high NK cell dose in the stem cell 
graft and protection from disease relapse is observed in a second patient cohort 
The number of NK cells within the stem cell graft was assessed in a further 30 patients and 
correlated with the incidence of disease relapse. A trend was observed towards a protective 
effect of a high NK cell dose and protection from disease relapse (A). p value calculated 
using a Mann-Whitney t test. Patients were divided into those where the infusion contained 
either above (black) or below (red) the previously measured threshold of 6.3x10
6
 NK cell per 
kg and compared against instance of relapse (B). Analysis was tested using the Gray 
method. 
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Discussion 
  
Summary 
 
My work has uncovered a strong association between the infusion of high numbers 
of donor NK cells within the stem cell graft and relative protection from disease 
relapse. This was shown both in univariate and multivariate models and the effector 
CD56dim NK cell population was found to be the phenotype most highly associated 
with this effect. Patients with both myeloid and lymphoid disease benefitted from this 
protective effect and a smaller second cohort of patients also showed the same 
trend.  
 
Impact of NK cell dose on the strength of the GvL effect post-transplant 
 
These findings indicate that the number of NK cells infused at the time of transplant 
is a strong determinant of the potency of the graft versus leukaemia effect of 
allogeneic transplantation. Healthy individual NK cells have a half-life of around two 
weeks although they will undergo homeostatic proliferation following transfer into a 
lymphodepleted host and this may further extend their lifespan (Prlic et al. 2003; 
Ullah et al. 2016). As such, relatively modest differences in the number of NK cells 
within the initial infusion might translate into relatively profound differences in tumour 
cell lysis within the first few weeks following transplantation.  
The mechanisms that might underlie this association are unclear at the current time. 
The most straightforward explanation is that donor NK cells have a direct lytic activity 
against residual tumour cells within the patient (Ruggeri et al. 2002; Porgador et al. 
1997). NK cells demonstrate a range of cytotoxic and immunomodulatory functions 
however our data showed the critical importance of the CD56dim NK cell subset 
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suggesting that the cytotoxic activity of NK cells is a predominant factor in providing 
protection against relapse. NK cells have potent activity against transformed cells 
and purified NK cell infusions have been shown to demonstrate anti-tumour efficacy. 
High NK cell dose would result in a more beneficial effector to target cell ratio 
potentially resulting in greater killing of residual tumour cells. Alternatively, NK cells 
might exert an indirect effect on the priming, expansion or activity of the alloreactive 
T cell immune response that develops in the early post-transplant period. As such, 
larger number of NK cells might act to boost T cell activation, perhaps through 
mechanisms such as stimulation of host dendritic cells or suppression of inhibitory 
cell subsets (Vivier et al. 2008; Olson et al. 2010). This may be the more likely 
situation as previous data showing the beneficial effect of NK cell reconstitution and 
alloreactivity has been primarily in myeloid malignancies rather than lymphoid 
(Savani et al 2007; Velardi 2008). This is thought to be due to the enhanced NK cell 
resistance of lymphoid cells indicating that a direct GvL response in these cases may 
not occur (Romanski et al. 2005). However, I did not see a difference in the effect of 
the stem cell graft NK cell dose on the relapse incidence of myeloid or lymphoid 
disease, suggesting that these NK cells may not be killing the tumour directly but are 
influencing the immune environment. Alternatively, the relative activation level of NK 
cells within the first two weeks post-transplant may result in enhanced capacity for 
lysis of lymphoid cells. Further detailed assessment of the phenotype and function of 
NK cells in the early post-transplant period may help to identify a more precise 
mechanism of NK cell involvement in relapse protection.    
 
NK cells dominate the lymphocyte repertoire during the early phase of immune 
reconstitution. Therefore the clinical impact of the NK cell infusion at the time of 
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transplant will most likely have greatest effect during the first month (Dunbar et al. 
2008). The substantial use of alemtuzumab for T cell depletion in our transplant 
cohort is likely to enhance the dominance of NK reconstitution post-transplant and 
may also increase their relative clinical importance in relation to GvL. When the 79 
patients who received alemtuzumab were analysed alone the protective effect of the 
high NK cell dose was still statistically powerful (p: 0.0008) (Figure 5.9A). In addition, 
removing the HLA-mismatched patients and those receiving full intensity conditioning 
left a 60 patient cohort of RIC alemtuzumab T cell depleted HLA-matched 
transplants and this still demonstrated significant protection from relapse when a 
higher than median dose of NK cells was received, with a tenfold difference in 
relapse incidence between those receiving high or low NK cell doses (Figure 5.9B). 
The remarkable nature of these findings has not been shown previously in other 
cohorts.        
Figure 5.9 – The NK cell dose remains protective for patients who received an 
alemtuzumab-conditioned transplant 
Cohort analysis was limited to those patients who received alemtuzumab for T cell depletion 
(A) (n=79) or those who underwent a reduced intensity conditioned, HLA matched and 
alemtuzumab-incorporting transplant regimen (B) (n=60). Patients were divided into those 
where the infusion contained either above (black) or below (red) the previously measured 
threshold of 6.3x10
6
 NK cell per kg and this was related to incidence of disease relapse. In 
both instances a high NK cell dose was highly predictive of disease relapse protection. 
Analysis was tested using the Gray method. 
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Impact of T cell depletion 
 
Anti-thymocyte globulin (ATG) acts primarily to deplete T lymphocytes but can also 
reduce the numbers of B and NK cells in the peripheral blood (Mohty 2007). Within 
the secondary lymphoid tissues of animal models high doses of ATG, comparable to 
those used in clinical allo-HSCT, were seen to result in depletion of B and NK cells 
along with T lymphocytes (Mohty 2007). Alternatively in another murine model of 
allo-HSCT, comparable clinical doses of alemtuzumab significantly depleted 
circulating lymphocytes but did not substantially affect the number of cells in 
secondary lymphoid organs (Hu et al. 2009). Indeed, even tenfold increases in the 
treatment dose did not achieve total removal of T cells from the thymus and spleen. 
If these findings translate directly to humans it suggests that there could be a 
disparity in the clearance of lymphocytes within patients receiving alemtuzumab and 
ATG, in which alemtuzumab does not achieve such a profound T-cell lymphopenia 
within secondary lymphoid organs. Consequently, the clinical correlations that I 
observed between NK cell dose and clinical outcome in patients who had received 
alemtuzumab may not necessarily translate directly into cohorts which incorporate 
ATG. Alemtuzumab is a CD52-specific monoclonal antibody and may partly exert its 
effects through ADCC in a process mediated by NK cells (Hu et al. 2009). This could 
potentially aid in NK cell activation by providing ‘easy’ targets for the cells to kill and 
priming them for more efficient serial killing (Choi et al. 2013). The expression level 
of CD52 varies on different lymphoid subsets, with B cells expressing the highest 
level and NK cells the lowest (Figure 5.10). An in vitro assay that I undertook to 
assess killing of healthy PBMC found no dose dependent effect on NK cell depletion, 
compared to a linear correlation between the dose of alemtuzumab and T cell 
depletion (Maggs, 2013, MRes Thesis). Greater understanding of how alemtuzumab 
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and ATG affect early immune cell reconstitution following allo-HSCT, and the clinical 
importance of NK stem cell dose in each setting, may help to describe the 
mechanisms of protection.   
 
 
 
 
 
 
 
 
 
 
 
 
Overall survival 
 
Whilst the difference in relapse incidence between the two groups was substantial 
this did not transform into a significant difference in overall survival. A trend towards 
greater survival with a higher dose of infused NK cells was seen and is presumably 
related to a lower rate of relapse-related deaths in these patients. However, of the 
patients who did relapse, only 75% of those who received a low NK cell dose went 
on to die due to their disease compared to 100% of the patients who relapsed 
***
**
**
Figure 5.10 – Expression of CD52 on lymphocytes in stem cell graft samples 
PBMC isolated from stem cell graft samples were stained for lymphocyte markers (anti-
CD19 PE-Cy7 [SJ25C1] - eBioscience; anti-CD3 PB [OKT3] – eBioscience; antiCD56 
APC-Cy7 [HCD56] - Biolegend) and CD52 surface expression (anti-CD52, FITC [HI186] - 
Biolegend). (N=13). Bar chart compares mean fluorescence intensity (MFI) of CD52 on 
stem cell graft lymphocytes. All p values calculated using a Mann-Whitney U test. Bar 
charts show median values with interquartile range. P values: B – NK <0.0001;  B – T 
0.0007; T – NK 0.0008. 
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following receipt of a high NK cell dose, potentially indicating a greater severity of 
disease within these patients which higher numbers of NK cells were unable to 
control. The use of intervening treatments should also be noted, such as donor 
lymphocyte infusions (DLI) to convert mixed chimerism or restore remission. This 
was given to 14 patients, however in the three patients who also relapsed only one 
did not die of their disease. Interestingly the patients receiving a higher dose of NK 
cells also showed a trend towards higher incidence of non-relapse related mortality. 
Whilst this was not significant it is important to note as it may indicate poorer 
infection control in these patients.  
 
An association between a high number of CD34+ cells in the graft and protection 
from non-relapse mortality is likely to reflect more effective haemopoietic 
engraftment, subsequent improvement in immune function and lower infection risk. 
In most cases within our cohort (91%) the dose of CD34+ cells given to the patient 
was kept between 4-8 x106 cells per kg as a measure to improve overall survival 
(Törlén et al. 2014). This limited variability may explain why no significant differences 
in non-relapse mortality or overall survival were found in relation to the CD34+ cell 
dose. However, an association was observed in relation to the absolute number of 
CD34+ cells and may potentially reveal a dissociation between correction for patient 
weight and the finite limit in bone marrow capacity. As such the absolute number of 
CD34 cells may potentially provide a more accurate predictive correlate for 
protection from transplant related mortality in similar transplant cohorts.       
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Other influences on the frequency of disease relapse 
 
Multivariate analysis found that several patient characteristics were independent 
predictors of protection from disease relapse in addition to the dose of NK cells in the 
stem cell graft. Low HCT-CI, indicating a patient has minimal comorbidities likely to 
affect the transplant outcome, has been shown to impact on overall survival and non-
relapse mortality but not specifically on relapse (Sorror et al. 2005).  Here low HCT-
CI was found as an independent predictor of protection against relapse as well as 
overall survival.  
Additionally, patients receiving alemtuzumab as opposed to ATG as their source of T 
cell depletion had a lower incidence of relapse. The choice of these anti-T cell 
antibodies is down to Consultant preference, centre experience or participation in a 
clinical trial. T cell depletion is used to prevent occurrence of GvHD but this is also 
known to result in an increase in the rate of disease relapse compared to 
unmanipulated transplants (Soiffer et al. 2011). Soiffer et al did not find a significant 
difference between relapse rates in patients receiving ATG or alemtuzumab at three 
years post allo-HSCT, albeit the majority of patients did receive ATG. Interestingly 
use of alemtuzumab correlated with greater overall survival compared to ATG and 
univariate analysis showed a similar association within our cohort.  
Patents who received a transplant from a matched unrelated donor as opposed to a 
sibling donor were found to have relative protection from disease relapse. It is likely 
that the increased ‘histoincompatibility’ that is present following use of an unrelated 
donor acts to enhance the allogeneic immune response, although this has been 
difficult to substantiate (Weisdorf et al. 2002). A ten out of ten HLA-matched 
patient/donor pairing only compares HLA-A, -B, -C, DRB1 and -DQB1 however there 
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are many other HLA and non-HLA genes which could remain mismatched and 
influence patient outcome. For instance, HLA-DPB1 matching between patient and 
donor is associated with lower risk of aGvHD but greater risk of relapse (Shaw et al. 
2007) and suggests that HLA-DPB1 can act as a restriction element for alloreactive 
T cells. Further classification can divide HLA-DPB1 mismatched pairs into those that 
are potentially tolerable (‘permissive’) or ‘non-permissive’ based upon matching or 
mismatching of T cell epitope groups. Non-permissive mismatches are associated 
with significantly lower rates of disease relapse compared to permissive mismatches 
which suggests a greater alloreactive T cell-mediated GvL (Fleischhauer et al. 2014).     
Similarly, KIR-ligand mismatch between donor and patient has been shown to impact 
upon disease relapse (Cooley et al. 2014). KIR genotyping could offer another 
opportunity to improve donor selection but these potential advantages must be 
traded against further limitation of donor availability and financial cost.    
Correlative trends towards higher donor age and the NK cell dose as well as a 
protective effect of the percentage of CD56dim cells in the graft were found but did 
not significantly affect patient outcomes. An interquartile range of 22 years is 
probably too small to allow an accurate assessment of the impact of donor age in 
this study.  
Previous infections may represent an important influence on donor NK cell repertoire 
and function (Strauss-Albee et al. 2015). This is clearly true for CMV as seropositive 
donors showed a trend towards having higher frequencies of CD56dim NK cells, 
however this did not result in a difference in the doses received by patients. Further 
in depth analysis of donor NK cell repertoires, potentially using techniques such as 
CyTOF analysis, may prove more predictive for allo-HSCT outcome.     
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My analysis of these findings in a second cohort revealed comparable findings to the 
first study but this was too small to achieve statistical significance. In addition, due to 
time constraints on analysis of the clinical outcomes these patients had only reached 
at least six months post-transplant. Four out of the five patients who relapsed within 
this time received less than the 6.3x106 NK cells/kg median of the main cohort and it 
will be interesting to see how this data matures during follow up.   
 
Conclusions 
 
The magnitude of the impact that the NK cell ‘dose’ has on the risk of disease 
relapse after allo-SCT was striking and the findings could have considerable impact 
for clinical practice. Within the context of T cell depleted allo-HSCT, stem cell grafts 
containing at least 6.3x106 NK cells/kg are associated with 6.7 fold reduction in the 
risk of relapse, without increasing the risk of clinically significant aGvHD or non-
relapse mortality. CD34+ cell dose is already measured within stem cell donations 
and it would be relatively straightforward to also assess the number of the CD3-
CD56dim cells. Where the NK dose is inadequate it is likely to be possible to add 
more cells from processing of residual apheresis product. Alternatively, up to 2x107 
NK cells/Kg can be obtained following a single donor lymphopheresis. 
These findings indicate the profound influence that the initial NK cell infusion has on 
determining the clinical features following allogeneic stem cell transplantation. 
Further investigation of the mechanism that underlies this association has the 
potential to uncover new insights into NK cell biology and may have the potential to 
greatly improve the clinical outcome of patients undergoing this procedure.  
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Chapter 6 - Phenotypic and functional analysis of stem cell graft 
NK cells 
 
My previous work had revealed that a higher dose of mature CD56dim NK cells within 
the stem cell graft was associated with relative protection from disease relapse. I 
next went on to assess the phenotypic and functional profile of NK cells within the 
stem cell product. This was considered to be important as there is extensive 
heterogeneity within the NK cell repertoire of different individuals and as shown 
previously G-CSF mobilisation and apheresis processing impacts on the phenotype 
and functional capacity of NK cells within the stem cell graft.   
A variety of inhibitory and activatory receptors on each NK cell receive signals from 
target cells and the local microenvironment which are integrated in order to 
determine the overall cellular response. The pattern of receptor expression on 
different NK cells is related to NK cell differentiation status and is also influenced by 
genotype and environmental factors such as infection history.  
Differences in the functional capacity of NK cell populations from different donors 
may influence patient outcomes following HLA matched T cell depleted allo-HSCT. I 
therefore decided to determine the phenotype and cytotoxic function of NK cells 
within the stem cell grafts and related this to clinical outcome.     
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Results 
	
Phenotypic analysis of NK cell markers within the stem cell graft and their 
association with incidence of relapse within the patient 
	
Stem cell grafts received by 107 patients undergoing stem cell transplantation were 
analysed for phenotypic differences (Table 2.2). Associations were investigated with 
four clinical outcomes in the patient and a Bonferroni correction was therefore 
applied, reducing the significance value to <0.0125.  
Initially comparison with relapse incidence was assessed by examining the NK cell 
population within the stem cell graft and dividing them into those received by patients 
who did not go on to relapse (NR) and those who did (R). An increased percentage 
of CD56dim cells (87.3 vs 83.1%) and lower percentage CD56bright (12.7 vs 16.9%) 
NK cells was found to have been given to patients who did not go on to relapse 
compared to those who did (p - 0.027) (Figure 6.1A). Patients who relapsed also 
received NK cells with a significantly lower percentage expression of the activatory 
receptor DNAM compared to those that remained in remission (72.7% vs 84.5; p - 
0.0013) (Figure 6.1B). A similar trend was seen in relation to the activatory receptors 
NKp46 (37.1% vs 43.2%; p – 0.1734) and CD16 (15.6% vs 31.1; p – 0.0373) but 
these did not reach significance. KIR expression was detected on an average of 
28.3% of NK cells in the stem cell grafts that were administered to patients who went 
on to relapse compared to a value of 42.9% in patients that remained in remission 
(p- 0.0007).  
The proliferation status of NK cells, as measured by Ki-67 expression, was very 
similar between the groups (5.1% vs 5.2% for NR and R respectively; p – 0.97). A 
trend towards higher percentage expression of the degranulation marker CD107 was 
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seen in relapse patients (14.9% (NR) vs 23.4%(R); p - 0.22). Patients who went on 
to relapse also received NK cells with a reduced expression of the cytotoxic proteins 
granzyme B (33.5% (NR) vs 21.9% (R); p - 0.096) and perforin (47.5% (NR) vs 
17.0% (R); p - 0.029) (Figure 6.1C). Markers of NK cell maturity and exhaustion 
displayed large variation between patients but did not show any significant 
differences between the relapse and non-relapse groups (NR vs R - CD57: 20.1% vs 
16.1%; p – 0.14; PD-1: 18.6% vs 20.7%; p – 0.45; Tim-3: 40.1% vs 32.4%; p - 0.89. 
Eomes/Tbet: 45.4% vs 44.6%; p – 0.2749) (Figure 6.1D).  
As clear differences had been observed in the phenotypic profile of NK cells within 
the stem cell graft and the relative rate of relapse, I next went on to determine 
whether these differences were specific to either the immature or mature NK cell 
subsets by analysing them as separate populations (Figure 6.2). As expected, 
overall differences in activatory and inhibitory receptors were mainly observed within 
the CD56dim population, with DNAM (83.2% vs 71.7%; p - 0.0012) and KIR (47.1% 
vs 30.5%; p - 0.0012) expression significantly reduced in the relapse cohort. 
Reduced DNAM expression was also seen to a lesser extent in the CD56bright 
population (89.1% vs 79.7%; p - 0.097) whilst the KIR disparity was not (11.1% vs 
8.5%; p – 0.038). Differences in granzyme and perforin did not reach significance 
when split into CD56bright and CD56dim cells, nor were any differences observed in 
relation to expression of markers of maturity or exhaustion.  
In conclusion, patients who went on to relapse received grafts containing a lower 
CD56dim to CD56bright NK cell ratio. The mature effector CD56dim cells they did 
receive also had significantly reduced expression of DNAM and KIRs. This suggests 
that the NK cells received by patients who go on to relapse displayed reduced 
cytotoxic potential compared to those given to patients who remained in remission.   
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Figure 6.1 – Phenotypic analysis of NK cells within the stem cell graft in patients who 
remained in remission and those who relapsed 
Stem cell graft NK cells were immunophenotyped and results analysed based upon whether 
patients who received the cells went on to relapse or remained in remission within two years post 
transplant. Expression of CD56 (A), activatory and inhibitory receptors (B), functional markers 
(C) and maturity and exhaustion markers (D) were assessed. Bonferroni correction was applied 
reducing the significance cut off to <0.0125. Significant p values: DNAM – 0.0013; KIR – 0.0007; 
Perforin – 0.0285. (A: NR n=68; R n=24. B: NR n=68; R n=24. C: NR n=62; R n=16. D: NR n=60; 
R n=13). All p values calculated using a Mann-Whitney U test. Bar charts show median values 
with interquartile range.  
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Figure 6.2 – Phenotypic analysis of CD56bright and CD56dim NK cells within the stem cell 
graft in patients who remained in remission and those who relapsed 
Stem cell graft CD56
bright 
and CD56dim NK cells were immunophenotyped and analysed 
based upon whether patients who received the cells went on to relapse or not. Expression of 
activatory and inhibitory receptors on CD56
bright 
(A) and CD56
dim
 (B) NK cells, functional 
markers on CD56
bright 
(C) and CD56
dim
 (D) NK cells and maturity and exhaustion markers on 
CD56
bright 
(E) and CD56
dim
 (F) NK cells were assessed. A Bonferroni correction was applied 
reducing the significance cut off to <0.0125. Significant p values: CD56
dim
DNAM – 0.0012; 
CD56
dim
KIR – 0.0012. (A/B: NR n=68; R n=24. C/D: NR n=62; R n=16. E/F: NR n=60; R 
n=13). All p values calculated using a Mann-Whitney U test. Bar charts show median values 
with interquartile range.  
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Association between NK cell phenotype in the stem cell graft and additional 
clinical outcomes 
	
I next assessed how NK cell phenotype in the stem cell graft was related to the 
three-year post-transplant overall survival, incidence of aGvHD and non-relapse 
mortality. Patients with competing risks were removed. In all circumstances there 
were no statistically significant differences between the NK cell populations received 
within the stem cell graft and outcome (Figure 6.3; 6.4; 6.5). As such NK cell 
phenotype within the stem cell graft appears to be exclusively associated with 
relapse incidence.  
Validation that low expression of DNAM and KIR on CD56dim NK cells within 
the stem cell graft is associated with an increased risk of disease relapse 
	
Initial findings suggested that the number and phenotype of CD56dim NK cells plays 
an important role in regulating the risk of disease relapse. Further analysis of this 
specific population was made within a separate cohort of patients who had all 
undergone a T cell-depleted conditioning regimen (Table 2.3).  As had been seen in 
the initial cohort, expression of NKG2D and NKp46 on CD56dim NK cells did not vary 
between patients who did not relapse compared to those who did (78.2% vs 76.6%; 
p – 0.6381 and 41.6% vs 35.4%; p – 0.4087 respectively) (Figure 6.6A and B). 
However, a lower percentage of cells expressed KIR proteins (45.0% vs 34.2%; p - 
0.016) and the transmembrane activatory glycoprotein DNAM (74.9% vs 58.6%; p - 
0.0013) in patients who went on to suffer disease relapse (Figure 6.6C and D).  
This validates the finding that the expression level of DNAM and KIR on NK cells 
within the stem cell graft associates with disease relapse rate in two cohorts of allo-
HSCT. 
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Figure 6.3 – Association between the phenotype of NK cells within the stem cell graft 
and overall survival 
Stem cell graft NK cells were immunophenotyped and divided based upon whether patients 
who received donor infusions were alive at three years post allo-HSCT or deceased. 
Expression of CD56 NK cell subsets (A), activatory and inhibitory receptors (B), functionality 
markers (C) and maturity and exhaustion markers (D) were assessed. A Bonferroni correction 
was applied reducing the significance cut off to <0.0125. (A: Alive n=60; Deceased n=47. B: 
Alive n=60; Deceased n=47. C: Alive n=45; Deceased n=33. D: Alive n=44; Deceased n=29). 
All p values calculated using a Mann-Whitney U test. Bar charts show median values with 
interquartile range.  
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Figure 6.4 – Association between the phenotype of NK cells within the stem cell graft 
and acute GvHD 
Stem cell graft NK cells were immunophenotyped and divided based upon whether patients 
who received the donor infusion acquired grade 2 or above aGvHD within 100 days following 
allo-HSCT or not. Expression of CD56 NK cell subsets (A), activatory and inhibitory receptors 
(B), functionality markers (C) and maturity and exhaustion markers (D) were assessed. A 
Bonferroni correction was applied reducing the significance cut off to <0.0125. (A: None n=59; 
aGvHD n=45. B: None n=59; aGvHD n=45. C: None n=40; aGvHD n=35. D: None n=39; 
aGvHD n=31). All p values calculated using a Mann-Whitney U test. Bar charts show median 
values with interquartile range.  
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Figure 6.5 – Association between the phenotype of NK cells within the stem cell graft 
and non-relapse mortality 
Stem cell graft NK cells were immunophenotyped and divided based upon whether patients 
who received donor infusions died of non-relapse related causes following allo-HSCT or not. 
Expression of CD56 NK cell subsets (A), activatory and inhibitory receptors (B), functionality 
markers (C) and maturity and exhaustion markers (D) were assessed. A Bonferroni 
correction was applied reducing the significance cut off to <0.0125. (A: Alive n=58; NRM 
n=30. B: Alive n=58; NRM n=30. C: Alive n=42; NRM n=20. D: Alive n=41; NRM n=18). All p 
values calculated using a Mann-Whitney U test. Bar charts show median values with 
interquartile range.  
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Figure 6.6 – Patients receiving NK cells with high DNAM
+
 or KIR
+
 CD56
dim
 expression 
within stem cell graft demonstrate a reduced incidence of disease relapse 
A separate T cell depleted cohort of patients undergoing T cell depleted allo-HSCT was 
divided into those who relapsed or remained in remission within two years post transplant.  
Populations of CD56dim NK cells from the stem cell graft received by patients were examined 
by immunophenotyping. Expression of NKG2D (A) and NKp46 (B) did not associate with 
relapse but DNAM (C) and KIR (D) expression did. (n=71 for all phenotypic markers). All p 
values calculated with a Mann-Whitney U test. Bar charts show median values with 
interquartile range.  
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The pattern of co-expression of activatory markers on NK cells in the stem cell 
graft and clinical outcome 
 
I next went on to assess the pattern of co-expression of individual markers on the NK 
cell subsets. In particular, a sequential series of defined Boolean parameters was 
used to calculate the proportion of cells expressing multiple markers. This analysis 
was applied to the activatory receptors DNAM, NKG2D and NKp46 to determine 
their overlapping expression on NK cells received by patients who went on to relapse 
and patients who did not (Figure 6.7). The proportion of NK cells expressing all three 
receptors was lower in stem cell grafts received by the relapse group at 3% 
compared to 8% in the non-relapse patients. Decreases in the double positive 
NKp46+DNAM+ cells (4% vs 1%) and single positive DNAM+ NK cells (25% vs 14%) 
were also observed. Interestingly, NKG2D+DNAM+ and single-positive NKG2D+ 
subsets were found in higher proportions in the relapse group.   
 
 
  
Non-relapse Relapse
Sum	of	NKp46+NKG2D+DNAM- Sum	of	NKp46+NKG2D+DNAM+ Sum	of	NKp46+NKG2D-DNAM-
Sum	of	NKp46+NKG2D-DNAM+ Sum	of	NKP46-NKG2D+DNAM- Sum	of	NKp46-NKG2D+DNAM+
Sum	of	NKp46-NKG2D-DNAM+
Figure 6.7 – The pattern of co-expression of activatory receptors on NK cells within 
the stem cell graft in relation to clinical outcome of relapse or non-relapse 
Stem cell graft NK cells were split into those received by patients who went on to relapse 
and those that did not. Single, double and triple expression of activatory receptors 
NKp46, NKG2D and DNAM was assessed via Boolean gating (Non relapse n=40; 
Relapse n=17).  
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The influence of donor CMV serostatus on NK cell phenotype within the stem 
cell graft 
 
As donor age and CMV status had been shown to influence the NK cell repertoire in 
the stem cell graft I next went on to examine their influence on DNAM expression. 
Donor age had no effect on the percentage of DNAM+CD56dim NK cells found in 
donor stem cell grafts (R2 – 0.010; p – 0.477) (Figure 6.8A). CMV seropositive status 
in the donor was associated with an almost 12% higher percentage of 
DNAM+CD56dim NK cells compared to CMV seronegative donors (75.5% vs 85.7%; 
p: 0.021) (Figure 6.8B). However, this did not translate into a significantly different 
dose of DNAM+CD56dim NK cells within the seronegative or seropositive grafts (3.2 
vs 5.4 x106 cells/kg; p – 0.082) (Figure 6C). 
CMV seropositive individuals have higher numbers of CD57+NKG2C+ ‘memory’ NK 
cells within the blood and it has been suggested that they may play a role in 
mediating protection from relapse in association with an episode of CMV reactivation 
following allo-HSCT (Cichocki et al. 2015). CMV seropositive donors did display a 
small increased proportion of these cells (0.46% in CMV seronegative vs 1.11% in 
seropositive; p - 0.0097) (Figure 6.8D). However there was no association between 
this CD57+NKG2C+ NK cell population and protection from relapse post-transplant 
(p: 0.4713) (Figure 6.8E).  
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Figure 6.8 – The influence of age and CMV serostatus on NK cell phenotype within 
the stem cell graft 
Specific stem cell graft NK cell phenotypes were correlated with donor age and CMV 
serostatus. DNAM
+
CD56
dim
 NK cell expression did not change in relation to donor age 
(A). CMV seropositive donors did express higher proportions of DNAM
+
CD56
dim
 NK cells 
(B), however this did not result in a statistically significant higher dose delivered to the 
recipient (C). NKG2C+CD57+ NK cells were also found at a higher frequency in CMV 
seropositive donors (D) but the expression of these cells in the stem cell graft was not 
related to risk of subsequent relapse (E). (n=59). All p values calculated using a Mann-
Whitney t-test. 
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The pattern of chemokine receptor expression differs on NK cells within stem 
cell grafts received by patients who go on to relapse 
 
A final phenotypic panel was added to measure chemokine receptor expression in 
order to determine whether the potential trafficking of NK cells within the stem cell 
graft could be associated with clinical outcome. CCR6 and CCR9 promote trafficking 
to the skin and gastrointestinal tract respectively (Inngjerdingen et al. 2001). 
ChemR23 and CX3CR1 are found on CD56dim NK cells and promote migration to 
inflamed peripheral sites whilst CXCR3, CXCR4 and CCR7 are found predominantly 
on CD56bright cells and promote migration to secondary lymphoid organs 
(Maghazachi 2010). The chemotaxis and distribution of these cells within the body 
immediately following infusion may be important in mediating an effective GvL 
response. 
There was variation in the expression of chemokine receptors between stem cell 
grafts, however there were no significant differences in the phenotype of NK cells 
given to patients who went on to develop aGvHD and those that did not (Figure 
6.9A). In contrast NK cells received by patients who relapsed showed a significantly 
higher expression of CXCR4 (9.5% vs 21.1%; p - 0.010), CCR7 (5.6% vs 12.8%; p - 
0.046), and CCR9 (2.3% vs 6.7%; p - 0.016) compared to those that did not relapse 
(Figure 6.9B).  
When analysis was split into the CD56bright and CD56dim subsets the differences seen 
in relation to relapse risk were diminished. No differences in CD56bright NK cell 
chemokine receptor expression and clinical outcome were detected (Figure 6.10A). 
However, on CD56dim NK cells a higher proportion of cells expressing CXCR4 was 
found on NK cells received by patients who went on to relapse (7.1% vs 16.6%. p – 
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0.0422) whilst overall a large degree of heterogeneity was seen in chemokine 
receptor expression on these cells (Figure 6.10B).  
  
Figure 6.9 – Chemokine receptor expression on NK cells within the stem cell 
graft and association with subsequent outcome 
Expression of chemokine receptors was determined by immunophenotyping of stem 
cell graft NK cells. These were then analysed in patients according to the development 
of aGvHD (A) or relapse (B). Bar charts show median values with interquartile range. 
Significant p values: RI CCR9 - 0.0190; RI CXCR4 - 0.0160; RI CCR7 – 0.0358. (A: 
No aGvHD n= 16; aGvHD n=11. B: Non–relapse n=20; Relapse n=7). All p values 
calculated using a Mann Whitney u test.  
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Figure 6.10 – Chemokine receptor expression on NK cell subsets within the stem 
cell graft and association with subsequent risk of relapse 
Expression of chemokine receptors was determined by immunophenotyping of stem 
cell graft CD56
bright
 (A) and CD56
dim
 (B) NK cells. This was assessed against relapse 
incidence within the first year following allo-HSCT. Bar charts show median values with 
interquartile range. Significant p values: CD56dim NK cells CXCR4 - 0.0422. (Non–
relapse n=20; Relapse n=7). All p values calculated using a Mann Whitney u test.  
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No difference in NK cell killing between cells received by patients who went on 
to relapse and those that did not 
 
As NK cells received by patients who went on to relapse showed reduced DNAM 
and KIR receptor expression it was felt important to assess if this correlated with less 
efficient killing of target cells in vitro. NK cells were isolated from stem cell graft 
samples of patients who either went on to relapse (R) or did not (NR) and stimulated 
with IL-2 prior to incubation with 721.221 cells at an E:T ratio of 0.1 for 16 hours. No 
difference was found between the two groups in the elimination of these cells (NR – 
12.02%; R - 14%. p – 0.8125) (Figure 6.11). Therefore, the ability of activated NK 
cells from stem cell grafts to kill an MHC class I null target cell line is not related to 
subsequent risk of relapse.     
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Figure 6.11 – The capacity of NK cells from stem cell grafts to kill MHC class I null 
target cell line does is not related to subsequent relapse incidence 
NK cells were isolated from stem cell grafts, stimulated with IL-2 and incubated for 16 
hours with 721.221 cells at 0.1 E:T. The ability to kill target cells was then related to 
clinical outcome of relapse or not. No difference was seen in the ability of NK cells 
received by patients who went on to relapse and those that did not in the ability to kill 
721.221 target cells (p – 0.8125). Non-relapse n = 7; Relapse n = 10. p value calculated 
using a Mann Whitney U test. 
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Assessment of NK cell cytotoxicity against AML target cells in vitro 
 
In order to further evaluate the potential basis for a direct GvL response by NK cells 
against residual tumour in allo-HSCT, the potential capability of NK cells taken from 
the stem cell graft to kill tumour cell lines was further assessed. Previous work had 
shown that IL-2 activated stem cell graft NK cells can kill K562 and 721.221 HLA-null 
cell lines (Figure 4.10) and, as the positive associations between NK cells in allo-
HSCT have been predominantly seen in myeloid disease, I next went on to assess 
their capability to kill AML cell lines. 
 PL-1 and Kasumi AML cell lines were donated from Professor Constanze Bonifer’s 
laboratory and combined at a 0.1 E:T with IL-2 stimulated healthy donor derived NK 
cells for 16 hours. In comparison to the MHC Class-I negative cell lines (K562 – 
44.8%; 721.221 – 33.7%) the percentage of PL-21 and Kasumi cells killed (3.9% and 
9.2% respectively) were significantly reduced (compared to K562; 721.221 p – 
0.212, PL-21 p – 0.037, Kasumi p – 0.004) (Figure 6.12A).   
Similarly, to test whether NK cells are functionally effective against primary tumour 
targets, three primary AML blast samples were acquired at the point of diagnosis 
from Professor Mark Drayson. NK cells from healthy donors exhibited some degree 
of lysis on cells from all three samples (8.9%, 14% and 4.2% respectively) when 
stimulated with IL-2 and incubated at a 0.1 E:T ratio for 16 hours (Figure 6.12B). The 
observation that NK cells are able to directly kill AML cells adds support for the 
theory that NK cells within the stem cell graft may act directly to eliminate residual 
tumour cells in the immediate post-transplant period. 
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Figure 6.12 – The ability of NK cells to lyse AML cell lines and primary AML 
cells  
NK cells were isolated from healthy donors, stimulated with IL-2, and incubated for 
16 hours with target cells at 0.1 E:T. Target cells included HLA class I-negative 
cell lines and AML cell lines (PL-1 and Kasumi) (A) as well as primary AML blasts 
(AML1-AML3) (B).  p values calculated using a Mann Whitney U test. 
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DNAM inhibition significantly reduces NK cell cytotoxicity against AML target 
cells in vitro 
 
The association between a high number of DNAM-positive NK cells within the stem 
cell graft and protection from disease relapse suggested that DNAM-mediated 
cytotoxicity is involved in an effective GvL response. As direct killing of tumour cells 
is a potential mechanism for GvL I next went on to assess whether this could be 
DNAM dependent.  
Expression of the DNAM ligands CD155, and CD112 was assessed by flow 
cytometry on the cell lines K562 and Kasumi as well as primary AML cell samples 
(Figure 6.13A). Expression of both ligands was higher on K562 cells compared to 
Kasumi cells (K562 MFI: CD112 – 0.74; CD155 - 0.69; Kasumi MFI: CD112 – 0.29; 
CD155 - 0.58) and was particularly low on primary AML samples (MFI: CD112 – 
0.08; CD155 - 0.11). 
To assess the potential importance of DNAM in the killing of these target cells, IL-2 
stimulated NK cells were incubated with excess DNAM antibody for 30 minutes prior 
to incubation with the target cell in order to inhibit signalling from the receptor. The 
NK cells were then incubated for 16 hours with target cells at an E:T ratio of 0.1. 
K562, Kasumi and AML sample 2 were chosen as they demonstrated the greatest 
susceptibility to NK killing. DNAM inhibition significantly reduced lysis of all three 
target cells.  K526 (40.8% (without incubation) vs 26.6% (with incubation); p - 
<0.0001), Kasumi (9.3% vs 3.2%; p – 0.0304) and AML sample 2 (13.9% vs 9.2%; p 
- 0.0321) (Figure 6.13B).  
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Together this data is supportive of a hypothesis that residual AML cells could be 
partially eliminated in the early post-transplant period by CD56dim NK cells in a 
DNAM-specific manner. 
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Figure 6.13 – NK cells can kill AML cells in a manner that is partially dependent on 
DNAM-specific lysis  
Expression of CD33, a myeloid specific marker, and DNAM ligands (CD155 and CD112) 
was examined on target cells K562, Kasumi and AML blasts (A).  Black – isotype control; 
Grey – test sample. NK cells from healthy donors were isolated, stimulated with IL-2 and 
inhibited with DNAM antibody. Cells were then incubated for 16 hours with a target cell 
line at 0.1 E:T (B). DNAM inhibition significantly reduced target cell killing of K562, 
Kasumi and primary AML cells. All p values calculated using a Mann Whitney U test. 
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Discussion 
 
Summary 
 
The phenotype and function of NK cells within the stem cell graft were assessed for 
potential association with subsequent patient outcomes post-transplant. Whilst there 
was a large degree of heterogeneity in the phenotypic properties of NK cells from 
different donors, the only positive associations with outcome were related to low 
expression of DNAM, KIRs and perforin on NK cells received by patients who went 
on to relapse. A slightly higher expression of several chemokine receptors was also 
seen on these populations. The cytotoxic ability of NK cells within stem cell grafts 
was not shown to be different in relation to whether patients subsequently went on to 
relapse. However, DNAM inhibition was able to significantly reduce NK cell killing of 
primary AML target cells indicating that a lack of DNAM expression in vivo may 
hinder NK cell killing of residual tumour cells.   
 
The potential importance of DNAM in relation to the mechanisms of GvL  
 
Whilst the number of NK cells within the stem cell graft is important for protection 
from relapse, the phenotype of these NK cells also has an impact on this outcome. In 
particular, my data show the critical importance of the CD56dim subset, indicating that 
cytotoxic activity of NK cells may be the predominant factor in providing protection 
against relapse. It was further observed that DNAM expression by CD56dim NK cells 
may be a mechanism of tumour cell targeting and protection from relapse following 
transplant.   
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DNAM is a dominant activatory molecule involved in T and NK cell mediated 
cytotoxicity (Shibuya et al. 1996). The DNAM ligands CD155 (also known as PVR 
and NECL5) and CD112 (also known as nectin 2) are members of the nectin and 
nectin-like molecule family and are known to be variably expressed by AML blast 
cells (Pende et al. 2005; Bottino et al. 2003). Moreover, DNAM-dependent killing of 
AML cell lines has been shown in vitro (Kearney et al. 2016) as well as here in 
primary AML cells. Decreased expression of DNAM has been demonstrated on NK 
cells taken from patients with AML and is believed to be induced as a mechanism of 
tumour evasion (Sanchez-Correa et al. 2012). Therefore, an infusion of donor 
CD56dim NK cells which express high levels of DNAM would be expected to have the 
potential to directly lyse CD112 or CD155 expressing tumour cells.  
Interestingly, the expression of DNAM was increased on CD56dim NK cells from CMV 
seropositive donors but donor CMV status was not found to be a pre-transplant 
factor influencing transplant outcome. CMV reactivation following allo-HSCT has 
previously been associated with protection from relapse (Elmaagacli et al. 2011; 
Green et al. 2013) and it is possible that the induction of DNAM expression by NK 
cells in response to CMV viremia may influence GvL. It is also known that CMV 
reactivation post-transplant produces an increase in CD56dimCD57+NKG2C+ NK 
cells and associates with reduced relapse incidence (Cichocki et al. 2015). 
Interestingly within this cohort, stem cell grafts from CMV seropositive donors had 
significantly higher percentages of CD57+NKG2C+ NK cells (p: 0.0097) indicating 
the lasting effect of their primary infection. This difference however did not impact on 
relapse rates suggesting that CMV reactivation may be an additional necessary 
factor to deliver the beneficial expansion of these cells.  
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The expression of multiple activatory receptors on NK cells received by patients that 
went on to relapse was lower compared to those that did not. NK cell killing usually 
requires two signals to be initiated and synergy between activation of NKG2D, 
NKp46 or DNAM is usually required for efficient lysis (Bryceson et al 2006). As such 
this finding may represent an important topic for further study.  
 
The potential importance of KIR expression on NK cells and risk of relapse 
 
Expression of a group of predominantly inhibitory KIRs (KIR2DL1/DS1; 
KIR2DL2/DL3; KIR3DL1) was assessed on NK cells within the stem cell graft. Their 
collective expression was reduced on CD56dim NK cells in patients who went on to 
relapse. The impact of KIRs in allo-HSCT has previously been reported as patients 
receiving grafts from KIR haplotype B donors show greater relapse protection in the 
T cell replete transplant setting (Cooley et al. 2009). This was particularly relevant 
when patients and donors exhibited a HLA-C mismatch, which was thought to 
stimulate development of alloreactive NK cells (Cooley et al. 2014). A similar effect 
on patient outcomes in a large cohort of T cell depleted transplants has not been 
shown however. Group B haplotypes contain one or more of the following genes 
which encode primarily activatory receptors; KIR2DL5, KIR2DS1, KIR2DS2, 
KIR2DS2, KIR2DS5 and KIR3DS1 (Uhrberg et al. 1997; Hsu et al. 2002). Haplotype 
A is defined by containing primarily inhibitory KIRs and lacks the activatory genes 
and genetic variability associated with haplotype B. Distinguishing donor haplotype 
based upon the immunophenotyping data was not possible due to the use of anti-
KIR2DS1 within the pan-KIR antibody mixture. Individual KIR genotyping of patients 
and donors will be necessary to ascertain whether the relevance of the reduced KIR 
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expression observed on stem cell derived CD56dim NK cells is secondary to a 
predominance of KIR haplotype B in this cohort.  
Although most patients and donors were HLA-matched, the variability in KIR 
expression within an individual’s NK cell population may produce some alloreactive 
NK cells. A greater population of KIR+ NK cells might represent a possibility of more 
alloreactive NK cells in this setting whilst the reduced expression of KIRs received by 
patients who went on to relapse may also indicate a greater population of un-
licenced NK cells with less responsiveness to residual tumour. 
    
Chemokine receptor expression and risk of disease relapse  
 
Immunophenotyping also revealed higher expression of several chemokine 
receptors on NK cells received by patients who went on to relapse. In particular this 
was seen for CXCR4 and CCR7 which stimulate NK cell migration towards potential 
tumour sites in the bone marrow and lymph nodes respectively (Bernardini et al. 
2008; Förster et al. 2008). This may however be representative of a more immature 
NK cell phenotype which is generated during the G-CSF mobilisation and apheresis 
processing donors undergo. Interestingly CD56dim cells showed high levels of 
CXCR3, CXCR4 and CCR7 expression which is not normally reported on this subset 
in healthy donors. As such, when infused into the host these NK cells may traffic to 
tissue sites before undergoing differentiation into fully mature effector NK cells and 
this may limit their immediate GvL potential within the first two weeks post-transplant. 
This is a challenging hypothesis to investigate in vivo and would require invasive 
tissue biopsies or, potentially, radiolabelling of cells prior to infusion. Previous reports 
have also shown that the chemokine receptor expression of the NK cell population 
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within the donor grafts is different to that seen within normal peripheral blood and 
may impact upon the NK cell role in relapse protection (Inngjerdingen et al. 2001; 
Maghazachi 2010). As such, manipulation of chemokine-mediated cell migration may 
represent an important determinant of clinical outcome.  
 
Conclusions 
 
The phenotype of NK cells received by patients as part of their stem cell graft 
appears to play an important role in the incidence of disease relapse. Direct killing of 
residual target cells produced by CD56dim DNAM+ NK cells present in the stem cell 
graft is a viable mechanism of GvL and the associated protection from disease 
relapse.  
 
T-cell depletion was used in this patient cohort and as such NK cells therefore 
dominate the lymphoid repertoire during the early phase of immune reconstitution. 
However, T and NK cell reconstitution correlated positively with each other (Figure 
3.2B) and therefore both compartments may have influence over the other. One 
mechanism by which NK cells may regulate the T cell response is via the killing of 
immature dendritic cells which promote immune tolerance and suppression via Tregs 
(Dickinson et al. 2017; Ghadially et al. 2014). This dendritic cell editing is therefore 
useful when initiating an immune response, resulting in an increase in effector T cells 
(Morandi et al. 2012; Ferlazzo & Moretta 2014). Within the context of allo-HSCT an 
infusion of cytotoxic CD56dim NK cells which can kill host dendritic cells might 
enhance the allogeneic immune response. Our finding that DNAM expression is 
important in relapse protection also supports this hypothesis of GvL as DNAM 
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ligands are highly expressed by dendritic cells and DNAM-mediated killing of 
immature dendritic cells is well documented (Pende et al. 2006). Furthermore, Treg 
cells have been shown to suppress both T and NK cell cytotoxicity through 
expression of TGF-β in murine models (Ghiringhelli et al. 2005). High numbers of NK 
cells may therefore compete with T cells for this regulation, which may allow a more 
effective T cell-mediated GvL effect. This data supports a hypothesis that DNAM-
mediated killing of recipient cells by stem cell derived NK cells may also represent a 
valid mechanism for the GvL effect following T cell depleted allo-HSCT.  
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Chapter 7 – General Discussion 
 
 
Summary  
 
This thesis investigated primarily the role of stem cell graft derived NK cells in 
determination of the clinical outcome of adult T cell depleted allo-HSCT. It was found 
initially that the reconstitution of higher numbers of both CD56dim and CD56bright NK 
cells in the peripheral blood of patients by day 14 post-transplant was associated 
with relative protection from disease relapse. As these NK cells are likely to be 
derived directly from the stem cell graft, assessment of the cellular components 
within this infusion product was then undertaken.  
NK cells within the stem cell graft are phenotypically and functionally different to 
peripheral blood NK cells from healthy individuals. In particular, CD56dim NK cells 
display a reduced cytotoxic capacity with decreased expression of activatory 
receptors and cytotoxic proteins which resulted in less efficient killing of MHC class I 
null cell lines. In contrast, CD56bright NK cells from the stem cell graft are increased in 
frequency compared to circulating blood of healthy individuals and displayed a more 
activated and proliferative phenotype. As such, the NK cells received by patients are 
generally of a more immature phenotype and display reduced cytotoxic potential. A 
large degree of variability in the number of cells collected, and their phenotypic 
expression, was also observed between donors. 
In a T cell deplete allo-HSCT setting a cohort of 107 patients demonstrated a strong 
association between the infusion of high numbers of donor NK cells in the stem cell 
graft and relative protection from disease relapse (Maggs et al. 2017). This was 
shown both in univariate and multivariate models. This suggests a role for stem cell 
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graft derived NK cells in establishing a GvL response and it is likely that this is 
mediated in the very early post-transplant period.   
Mature effector CD56dimDNAM+ NK cells transferred within the graft were strongly 
associated with protection from disease relapse indicating that cytotoxic function 
appears to be important in mediating an effective GvL response. In order to explore 
this concept I was also able to demonstrate DNAM-mediated NK cell killing of 
primary AML blasts. 
Whilst the number of the cellular components within the stem cell graft did not 
correlate with the number of cells in patient peripheral blood over the first month 
post-transplant, the influence of NK cell number on disease relapse rate was also 
seen throughout this early time period. It is therefore highly likely that NK cells within, 
and derived from, the stem cell graft influence the allogeneic immune response in 
patients and are indeed beneficial for establishing a GvL response immediately 
following T cell depleted allo-HSCT.    
 
NK cells and the allogeneic immune response post allo-HSCT 
 
These data support a hypothesis that donor derived NK cells in the stem cell graft 
contribute directly towards a GvL response and result in a lower incidence of disease 
relapse. DNAM-mediated killing of recipient target cells occurring within the first two 
weeks post-transplant is one viable mechanism as to how this effect may be 
mediated. 
Killing of residual tumour cells would be the most direct way through which these NK 
cells might mediate GvL. This would require that NK cells can identify tumour cells 
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for elimination, receive appropriate signalling and mediate effective cytolytic function. 
Receiving a higher number of NK cells in the stem cell graft might therefore be 
beneficial simply by increasing the ‘effector:target ratio’ of NK cell activity.    
Haploidentical transplants are widely used for treatment of myeloid leukaemia and 
increased GvL responses have been reported in association with KIR receptor ligand 
mismatch (Ruggeri et al. 1999). Host HLA mismatch with donor KIR will limit 
inhibitory signalling and a resultant increase in alloreactive NK cells may mediate the 
protective clinical effect (Ruggeri et al. 2015b). Within the context of HLA-matched 
allo-HSCT the probability of KIR-ligand mismatch is less, however the variability in 
KIR expression within an individual’s NK cell repertoire would suggest that a 
subpopulation of the cells are likely to exist that carry alloreactive potential. 
Determining if these cells are indeed present and confer such a response is, 
however, difficult.  
Beneficial associations between KIR ligand mismatch and survival and relapse rates 
were seen in a study of 130 patients receiving unrelated donor transplants (Giebel et 
al. 2003), although this has not been corroborated in other studies with unrelated 
donors, albeit using differing conditioning, T cell depletion and stem cell graft 
sources (Davies et al. 2002; Bornhäuser et al. 2004; Rocha et al. 2016). Whilst our 
data did not assess potential KIR mismatch between patient and donor, it was 
observed that patients who did not subsequently relapse received NK cells with a 
higher expression of KIR receptors. Interestingly the protective effect of NK cell KIR 
expression on relapse incidence was seen in both myeloid and lymphoid 
malignancies (Lymphoid: 45.8% vs 34.2%, p -0.0241; Myeloid 42.47% vs 27.67%, p 
– 0.0017) (Figure 7.1A; 7.1B). This may be representative of an NK population with 
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increased alloreactive activity as well as more responsive ‘licenced’ NK cells that are 
capable of tumour cell killing. 
AML patients receiving T cell replete unrelated transplants from KIR B genotype 
donors, which express more activatory KIRs, have lower relapse rates and greater 
survival that those receiving KIR A genotype infusions (Cooley et al. 2009). This 
indicates that NK cell alloreactivity may be less influential in this transplant setting 
but that the degree of activatory receptor expression is in fact more important. NK 
cell killing of tumour cells requires a priming and a triggering signal to be received, 
usually via downregulation of a MHC molecule and the expression of an activatory 
receptor ligand (Brenner et al. 2010). NK resistant B-ALL cell lines are thought to 
mediate this phenotype due primarily to deficiencies in NK cell activation rather than 
any inhibitory mechanism failures (Romanski et al. 2005). Interestingly, loss of 
DNAM ligand expression by AML cell lines results in poorer DNAM-mediated killing 
(Kearney et al. 2016). In out cohort lower NK cell DNAM expression was significantly 
associated with disease relapse incidence for patients with a myeloid but not 
lymphoid malignancy, indicating that the importance of DNAM-mediated killing in 
GvL may vary in different circumstances (Lymphoid: 84.1% vs 77.0%, p -0.4009; 
Myeloid 85.1% vs 70.0%, p – 0.0013) (Figure 7.1C; 7.1D).  
Indeed, the importance of tumour NK-ligand expression on clinical outcome of AML 
has recently been demonstrated following chemotherapy. The balance of activating 
or inhibitory ligands on tumour cells in a cohort of AML patients receiving induction 
chemotherapy was an important determinant of outcome, with a higher ‘overall 
activating NK ligand phenotype’ being associated with improved two year overall 
survival and lower relapse rate (Mastaglio et al. 2018). 
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Figure 7.1 – The phenotype of NK cells in the stem cell graft is correlated with 
disease relapse at 1 year 
Patients with a lymphoid or myeloid malignancy were separated. The percentage 
expression of KIR (A/B) and DNAM (C/D) on NK cells within the stem cell graft was 
assessed in each group and correlated with whether or not the patient went on to 
relapse within 1 year post-transplant. Decreased KIR expression was associated 
with relapse in both instances whereas decreased DNAM was associated only with 
relapse for myeloid patients. Lymphoid: NR n=21; R n=8. Myeloid: NR n=42; R 
n=16. All p values calculated using a Mann-Whitney U test. Bar charts show median 
values with interquartile range.  
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The presence of greater numbers NK cells that are both more functionally active and 
‘primed’ may be a main factor in achieving direct killing of residual tumour cells after 
allo-HSCT. However, it would be naïve to suggest that NK cells are the sole 
mediator of the GvL response in this circumstance. Uharek et al. showed over 20 
years ago in a murine model of HLA-matched transplantation that whilst elimination 
of malignant disease resistant to NK cell killing could be enhanced by ex vivo 
cytokine activation, this did not compensate for the loss of CD3+ T cells (Uharek et 
al. 1998). 
A more reasonable suggestion is that that NK and T lymphocytes mediate differential 
GvL responses, the importance of which may vary at different times post-transplant. 
NK cells may also be beneficial by exerting an indirect effect on the priming, 
expansion, or activity of the alloreactive T cell immune response that develops 
(Dickinson et al. 2017). As such, larger numbers of NK cells may act to regulate T 
cell activation. Despite this, some studies show that NK cells may actually suppress 
the alloreactive response. The mechanism behind NK cell suppression of the 
alloreactive T cell response is still unclear, although killing of immature dendritic cells 
is thought to be involved (Ferlazzo & Moretta 2014). 
Conventional dendritic cells are known to be necessary for presenting alloantigen to 
donor T cells following allo-HSCT in order to initiate the alloreactive immune 
response that leads to GvHD (Shlomchik 2007; Markey et al. 2009). Dendritic cells 
can also take up tumour cells and cross present leukemic-specific antigens to T 
cells, as shown in murine post-transplant models (Toubai et al. 2014; Markey et al. 
2018). These processes rely on the presence of mature activated dendritic cells 
whilst immature dendritic cells may be detrimental in alloreactive immune induction 
due to their promotion of immune tolerance and regulatory T cells (Ichim et al. 2003; 
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Fairchild & Waldmann 2000). Dendritic cell editing by NK cells may adjust this 
balance by lysing immature dendritic cells which have a low expression of HLA class 
I molecules and increasing the proportion of residual mature cells (Ferlazzo & 
Moretta 2014; Morandi et al. 2012; Ferlazzo et al. 2001).  
Ghadially et al. observed in a murine model of splenocyte transfer that absence of 
the activatory receptor NKp46 resulted in increased GvHD, thought to be mediated 
by reduced control of immature dendritic cells expressing the unknown NKp46 ligand 
(Ghadially et al. 2013; Ghadially et al. 2014). However the expression of NKp46 on 
NK cells in the stem cell graft was not associated with GvHD or GvL in our cohort. 
The NKp30 receptor is an important mediator of the regulation of immature dendritic 
cells in humans and NK and dendritic cell engagement through NKp30 can either kill 
the immature dendritic cell or trigger the release of IFN-γ and TNF-α to promote 
dendritic cell maturation (Vitale et al. 2005). 
A role for DNAM in NK cell mediated dendritic cell editing is less well established, 
however does have some basis. Pende et al. showed the involvement of DNAM in 
the killing of dendritic cells in vitro through the expression of DNAM ligands CD112 
and CD155 (Nectin-2 and PVR) on dendritic cells (Pende et al. 2006). NK cells with 
low level expression of NKp30 could maintain suitable dendritic cell editing through 
DNAM-mediated killing. Therefore within the context of human allo-HSCT, DNAM 
and NKp30 expression on stem cell graft NK cells may have a large impact upon 
dendritic cell editing. In contrast to NKp30, the role of DNAM in dendritic cell editing 
is restricted to target cell lysis rather than cytokine release (Pende et al. 2006). This 
may fit with my finding that DNAM expression on cytotoxic CD56dim NK cells was 
most relevant in relation to subsequent relapse rate.  
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Interestingly dendritic cells can in turn promote the activation and priming of NK cells 
which may also be important to consider when assessing NK cell activity post-
transplant (Ferlazzo et al. 2002; Lucas et al. 2007). A model is emerging in which 
CD56bright NK cells appear to be important in the initial cytokine-mediated activation 
of dendritic cells, which in turn primes NK cells and leads to killing of immature 
dendritic cells leaving an ‘edited’ population of mature dendritic cells that can 
effectively promote an alloreactive T cell response. Whether or not the number of NK 
cells that a patient receives in the stem cell graft would impact upon this process 
would require tracking of cell populations to patient lymph nodes and determination 
of the functional and phenotypic subtypes of the dendritic cells present. 
In murine models NK cells post-transplant have been reported to protect against 
acute GvHD whilst maintaining GvL (Asai et al. 1998; Ruggeri et al. 2002). Similarly, 
high NK cell reconstitution following allo-HSCT in patients with haematological 
malignancies has been found to associate with lower occurrence of acute GvHD (B 
N Savani et al. 2007; Ullah et al. 2016). Recently the presence of high numbers of 
IL-10 producing NK cells at day 14 has been associated with protection from GvHD 
(Chan et al. 2017). IL-10 is produced by CD56bright NK cells and suppresses T cell 
proliferation and the development of antigen-specific immunity (Akdis & Blaser 
2001). No correlation was observed between the number of NK cells received in the 
stem cell graft and reconstitution of cells in the peripheral blood of patients within the 
first month post-transplant in our cohort. Nevertheless, the complicated dynamics of 
lymphoid reconstitution may not be identifiable through assessment of peripheral 
blood. GvL is likely to be mediated primarily within bone marrow, whilst acute GvHD 
affects the skin and gut tissues (Dickinson et al. 2017; Shlomchik 2007). Migration of 
donor derived NK cells to these sites is presumably necessary for a direct effect to 
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occur. Chan et al. found that NK cell aGvHD protection at day 14 correlated with 
expression of chemokine receptors to both lymphoid and peripheral sites (Chan et al. 
2017). As such the first two weeks following T cell deplete allo-HSCT seems to 
represent a short window during which the NK cells from the stem cell graft can have 
a powerful influence.  
Indeed the establishment of GvHD and GvL responses within this very early time 
period post-transplant has been recognised through the effects that differing doses 
of cyclosporine have on patient outcomes following HLA matched allo-HSCT where 
higher serum levels during the first 10 days post-transplant are associated with 
higher relapse rates (Bacigalupo et al. 1991). The effect of cyclosporine on NK cell 
activity is less marked than that on T cells, with no major influence on functional 
cytotoxicity and even an increase in the numbers of NK cells derived from CD34+ 
progenitor cells in vitro (Wang et al. 2007). Proliferation of NK cells cultured with 
cyclosporine however is inhibited, with CD56dim NK cells affected more so than 
CD56bright cells (Wang et al. 2007).  
Within our cohorts nearly all patients received cyclosporine at 2.5mg/kg twice daily 
until around 90 days post-transplant. At this point the dose starts to be tapered, 
usually reducing every couple of weeks until either the patient is off the 
immunosuppression or they develop GvHD. This may therefore have an adverse 
effect on the homeostatic proliferation of the infused donor NK cells and as such 
affect the numbers of CD56dim NK cells within the first two weeks post-transplant. 
It is also important to note the difference in function between CD56bright and CD56dim 
NK cells. Immature CD56bright NK cells generally produce cytokines which can 
influence the immune environment, whilst cytotoxic CD56dim cells can directly 
eliminate target cells (Caligiuri 2008). Protection from relapse was conferred by stem 
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cell grafts containing a higher percentage of CD56dim NK cells, whilst at day 14 the 
frequency of both subsets within the peripheral blood was relatively similar. 
CD56bright cells are the main population of NK cells in the lymph nodes where they 
have a major influence on the development of the adaptive immune system (Dalbeth 
et al. 2004). The presence of such a high frequency of CD56bright NK cells in the 
peripheral blood during patient reconstitution suggests that they are likely to play an 
influential role in the development of the GvL response.       
Immature CD56bright NK cells have a predominantly cytokine producing function and 
the secretion of chemokines and cytokines by activated NK cells will further impact 
upon immune function. Cell to cell contact between NK cells and dendritic cells 
through the NKp30 receptor can result in the release of TNF-α and IFN-γ, promoting 
the maturation of the dendritic cells (Vitale et al. 2005; Walzer et al. 2005). Within 
lymph nodes NK cell release of IFN-γ helps to promote a TH1 phenotype for naïve 
CD4+ T cells (Martín-Fontecha et al. 2004). Together these cytokines can enhance 
NK cell cytotoxicity against targets and act to promote tumour elimination (Ikeda et 
al. 2002; Balkwill 2009). Measuring the presence of cytokines in patients post-
transplant provides interesting data, especially in terms of GvHD prediction where 
increased TNF-α and IL-10 levels have both been associated with aGvHD onset 
(Visentainer et al. 2003; Zhang et al. 2017). Foley et al. also showed that the 
functional activity of reconstituting NK cells, in relation to cytotoxic activity or 
chemokine expression, were not always strongly correlated following allo-HSCT 
(Foley et al. 2011). However, how this effect may impact upon patient outcomes is 
not yet clear.   
Together these studies, along with my findings, lead to a hypothesis that NK cells 
produce a GvL response in the early period after a T cell depleted allo-HSCT and 
219	
	 	
that this operates through CD56dim-mediated killing of residual tumour cells and 
potential indirect killing of immature dendritic cells. This would explain why receipt of 
greater numbers of NK cells in the stem cell graft is beneficial in protection against 
disease relapse (Maggs et al. 2017). Additionally, CD56bright NK cell expansion 
following transplant may act to protect against acute GvHD by suppression of an 
alloreactive T cell response (Ullrich et al. 2016; Chan et al. 2017).     
No significant associations were found between the stem cell graft NK cell dose or 
phenotype and overall survival or non-relapse mortality in our cohort. Similarly, trials 
of adoptive transfer of purified NK cells have typically been shown to reduce relapse 
rates and improve disease free but not overall survival (Rubnitz et al. 2010; Stern et 
al. 2013; Curti et al. 2016). This supports a hypothesis that T cell depletion within a 
transplant setting may provide the ideal environment for stem cell derived NK cells to 
mediate a direct GvL effect and suppress an alloreactive T cell GvHD response, but 
their ultimate benefit can only be considered in relation to the composition of the 
whole stem cell graft.   
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Hypothesis 
 
The data collected in this project add to the growing understanding surrounding the 
role of NK cells in T cell depleted HLA-matched allo-HSCT. The results indicate that 
the stem cell graft NK cell ‘dose’, phenotype and function are linked with relapse 
incidence but that this does not necessarily associate with significant effects on 
aGvHD, NRM or OS. The impact of NK cells on the GvL effect is likely to occur very 
early following T cell depleted allo-HSCT as NK cells are the predominant 
lymphocyte population at this period. A threshold of ‘cytotoxic capacity’ may need to 
be met in order to prevent disease relapse whereby the two-step activation of the NK 
cells is achieved. This may well be influenced by the residual tumour burden, the 
pattern of NK-ligand expression and both the number of NK cells transferred with the 
stem cell graft (NK cell dose) and their phenotype (CD56dimDNAM+ frequency) 
(Figure 7.2).  
 
 
High	Relapse	Risk
Low	Relapse	Risk
Medium	Relapse	Risk
Relapse
%	of	DNAM+	NK	cells
CD56dim	NK	
Cell	Dose
Figure 7.2 – Model of the potential beneficial effects of CD56
dim 
stem cell 
graft dose and DNAM expression frequency    
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It is currently unclear whether or not the role of stem cell graft NK cells on GvL is 
primarily direct killing of residual tumour cells, indirect influence over the alloreactive 
T cell GvL response or a combination of the two (Figure 7.3). The individual 
circumstances of each patient and their treatment will be important determinants of 
this response.  
 
Figure 7.3 – NK cells from the stem cell product may act in either a direct or 
indirect manner to produce a GvL effect.  
Residual tumour cells may potentially be eliminated via engagement of DNAM on NK 
cells with ligands on the tumour cell.  In addition, NK cells may act indirectly to boost the 
alloreactive T cell response by influencing the immune environment through cytokine 
release or modulation of host regulatory cell function.   
NK	Cells
DNAM
CD112/CD155
Treg Cells
APC
CD8+	T	Cells
Tumour
Cytokine
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Acquisition of optimal NK cell grafts for patients undergoing allo-HSCT 
	
Allogeneic haematopoietic transplant in adults is a complicated and highly variable 
treatment and whilst I have shown an association between NK cells and relapse 
incidence it is important to state that a finding of this magnitude has not been shown 
previously. Small differences in transplant procedure as well as donor selection and 
patient variation may have large effects on the cellular dynamics achieved following 
the transplant and therefore the potential clinical outcomes. As such my findings 
require validation and any potential association in clinical cohorts with different 
transplant protocols will be interesting to observe. 
 
G-CSF mobilisation is the most commonly used method of donor stem cell graft 
collection but, as shown, this affects the phenotype and function of NK cells received 
by the patient. Maintaining normal levels of receptor expression at the surface of the 
NK cells and retaining a high proportion of CD56dim NK cells may be important for 
relapse protection. As such the generation of new haematopoietic stem cell 
mobilisation agents presents a new factor to consider (Cashen et al. 2007; Devine et 
al. 2008). Plerixafor, a CXCR4 antagonist which blocks the binding of SDF-1, a 
chemokine expressed by bone marrow stromal cells, is now widely used to mobilise 
CD34+ cells into the peripheral blood (De Clercq 2003). Plerixafor can promote 
mobilisation of donor CD34+ cells in hours rather than days and has been used as a 
strategy to improve the yield of stem cells from donors where mobilisation with G-
CSF was insufficient (Devine et al. 2008; Hauge et al. 2014; Gattillo et al. 2015). 
Whilst plerixafor presents a potentially beneficial method of hematopoietic progenitor 
cell collection its effect on the other stem cell graft cellular components needs to be 
elucidated. Lundquist et al. found that T cell phenotype and function were not altered 
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in healthy donors mobilised with plerixafor and this resulted in higher rates of GvHD 
in a murine transplant model (Lundqvist et al. 2013). Plerixafor preferentially 
mobilises B cells, then T cells and finally NK cells of the lymphocyte compartment 
however a direct effect on NK cells has not been investigated. Currently plerixafor 
use in allo-HSCT is predominantly as a method to rescue poorly G-CSF mobilised 
donors. In comparison between donors receiving G-CSF alone or G-CSF and 
plerixafor there was no difference in the number of NK cells collected (Rutella et al. 
2014). The effect on patient outcome also does not seem to be affected by the 
addition of plerixafor in a trial of haploidentical HSCT (Jaiswal et al. 2018). Together 
this suggests that plerixafor has little effect on the NK cell population collected in the 
stem cell graft.  
It is also important to note that analogues of G-CSF exist which can produce differing 
effects on the cellular composition of a donor product and can influence GvHD and 
GvL responses (Morris et al. 2004; Morris et al. 2005). Pegylated G-CSF has a 
polyethylene glycol molecule attached which prolongs the half-life of the drug, whilst 
also making it capable of mobilising murine CD34+ and PBMC to a greater number 
and in a shorter timeframe than normal G-CSF (Molineux et al. 1999). When this 
long acting G-CSF analogue is given to wildtype mice it results in the generation of 
IL-10 producing regulatory T cells, which inhibit the alloreactive T cell response 
following transplant and provide greater protection from GvHD compared to normal 
G-CSF (Morris et al. 2004). Similarly, G-CSF analogues have been found capable of 
expanding the donor NKT cell population, which when transferred in a murine model 
of allogeneic transplantation enhanced host dendritic cell activation and T cell 
alloreactivity (Morris et al. 2005). Multi-pegylated G-CSF improves this effect even 
further, inducing greater numbers of progenitor and invariant NKT cells and 
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improving leukemic clearance in an in vivo murine model (Banovic et al. 2009). The 
clinical outcomes from use of these long acting G-CSF analogues in humans is less 
well studied. Pegylated-G-CSF is capable of mobilising CD34+ cells, albeit with 
differential molecular and functional properties in comparison to unconjugated G-
CSF (Bruns et al. 2008). The effect on NK cells seems to be minimal and no 
difference in the size of the NK cell population was seen in a small cohort of patients 
with gynaecological malignancies who received normal or pegylated-G-CSF 
(Bonanno et al. 2010). Multi-pegylated G-CSF had no greater effect on the number 
of NK cells collected compared to the peg-G-CSF in mice (Banovic et al. 2009). This 
suggests that whilst long acting G-CSF analogues may not impact upon the NK cell 
population their ability to alter the donor T and NKT populations, which are beneficial 
to a GvL response, may be of value. Trials using stem cell grafts from donors treated 
with pegylated G-CSF have been performed, showing the feasibility and 
comparability to normal G-CSF (Hill et al. 2006). However, the beneficial effects 
seen in mice have not been shown in humans and therefore peg-G-CSF is not 
commonly used in allo-HSCT.    
Ensuring that alternative methods of stem cell graft collection also produce a 
beneficial population of NK cells that will produce a GvL effect should be considered 
before they are introduced into routine practice.   
 
Influence of T cell depletion method on NK cell number and function  
 
Another important consideration is the method used for T cell depletion. 
Alemtuzumab and ATG are two commonly used approaches and the use of these 
different drugs may have a differential effect on the NK cell population infused into 
the patient. Murine models suggest that ATG may lyse more lymphocytes within 
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secondary lymphoid tissues compared to alemtuzumab (Mohty 2007; Hu et al. 
2009). This might therefore be expected to affect the role of NK cells in interacting 
with residual tumour cells and other immune cells at these sites. Alemtuzumab 
markedly depletes T cells within the peripheral circulation and is highly effective at 
reducing rates of GvHD whilst maintaining some degree of GvL.  
T cell depletion was given directly to the patient in our cohort (in vivo depletion) and 
therefore contrasts with direct ex vivo T cell depletion of the stem cell graft which can 
also be used as a GvHD prophylaxis method (Novitsky et al. 2005). Use of 
alemtuzumab with this latter method of T cell depletion may potentially have a more 
detrimental effect on the NK cell population within the stem cell graft despite 
expression of CD52 on NK cells being lower than on other lymphocytes (Figure 
5.10). PBMC taken from filgrastim (a recombinant form of G-CSF)-mobilised donors 
and subjected to increasing concentrations of alemtuzumab in vitro for 30 minutes 
effectively depleted CD3+ T cells at a 0.001mg/ml dose whilst also reducing the NK 
cell population by around 50% (Novitsky et al. 2013). The concentration of 
alemtuzumab used ex vivo is usually 10-20mg, which would create a far higher 
concentration than that shown in vitro and is therefore likely to lower the dose of NK 
cells received by patients within the stem cell graft. However higher concentrations 
did not further diminish the NK cell population in Novitsky’s experiments, which may 
reflect the lower CD52 expression on NK cells. Additionally, whilst the serum 
concentration of alemtuzumab can remain at high levels post-transplant for a longer 
period of time when given in vivo rather than when received with the graft, NK cell 
reconstitution is clearly still able to thrive in this environment (Morris et al. 2003). 
Together this suggests that the use of ex vivo T cell depletion within the stem cell 
graft may suppress the beneficial effects against disease relapse mediated by 
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inadvertently reducing the initial dose of NK cells present. As shown, T cell depletion 
in vivo does allow a beneficial stem cell graft NK cell effect to occur in a dose 
dependent manner. An adequate comparison of the two methods of T cell depletion 
would be needed to test their influence over the NK cell population in the early post-
transplant period. 
Alternative methods of stem cell graft manipulation ex vivo that do not deplete the 
NK cell population may be more effective. For example, the use of αβ+ T cell and 
CD19+ B cell-depleted stem cell grafts, which retain mature alloreactive NK cells, 
are in clinical trials after proving to be a viable transplant regimen with beneficial 
patient outcomes in the haploidentical paediatric transplant setting (Locatelli et al. 
2017).   
  
Impact of post-transplant factors on NK cell function 
	
As mentioned before, CMV reactivation has been found to associate with a reduced 
rate of disease relapse in some AML cohorts, but this effect has not generally been 
observed with other malignancies (Green et al. 2013). CMV reactivation leads to an 
increase in the number of  CD56dim NK cells with a memory phenotype within the 
blood (Foley et al. 2012; Della Chiesa et al. 2013). This is one example of how an 
environmental influence can shape the peripheral NK cell repertoire post-transplant 
and it is therefore important to consider potential factors that could modulate the 
activity of the NK cell populations that are infused at the time of transplant.  
The chimerism status of the host is one such factor that needs to be considered. 
Within a variable time period following successful allo-HSCT, the patient’s immune 
system will come to be either fully derived from the donor or develop a mixture of 
host and donor cells termed ‘mixed chimerism’. This is particularly common within 
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the T cell compartment where mixed chimerism is frequently present following T cell 
depleted RIC allo-HSCT and is thought to confer greater protection from GvHD as a 
weaker alloreactive T cell response is produced (Huss et al. 1996). The effect of 
mixed chimerism on the rate of disease relapse however is less clear. In some 
instances mixed chimerism has been found not to impact upon relapse rates, 
whereas in others it has (van Besien et al. 2009; Nikolousis et al. 2013; Koreth et al. 
2014). These differences may be due to the extent of T cell depletion received and 
the time point at which the chimerism was measured, however a detrimental effect 
on alloreactive T cell response is certain. It is possible that the increased ratio of 
regulatory T cells to effector cells that is observed in early mixed chimerism, and 
which prevents activation of dendritic cells, may suppress GvL (Kinsella et al. 2018 – 
manuscript in preparation). In such circumstances NK cell expansion might then be 
sub-optimal, further limiting establishment of a GvL effect. (Toubai et al. 2014).  
Kinsella et al recently assessed a cohort of 212 T cell-depleted RIC allo-HSCT 
patients based upon total PBMC and T cell chimerism at one to two months post-
transplant (Kinsella et al. 2014). Patients who had PBMC chimerism >99%, but T-cell 
chimerism <98% were termed ‘split chimerism’ and displayed similar overall survival 
to the full chimerism patients whilst the mixed chimerism group (<98% in both PBMC 
and T cell compartments) displayed significantly worse outcomes. Mixed chimerism 
patients at day 50 post-transplant also showed a significantly higher risk of relapse. 
The difference between the split and mixed chimerism patients could relate to 
differential activity within the NK cell population of the PBMC compartment and this 
is currently under investigation.  
Chan et al. performed microsatellite NK cell chimerism in three patients at our 
institution at day 14 post-transplant (Chan et al. 2018). The NK cells present in the 
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peripheral blood of all patients were entirely donor. Jiang et al. tracked NK cell 
chimerism following allo-HSCT in a cohort of 153 patients (Jiang et al. 2015) and 
observed a significant drop off in donor chimerism of peripheral blood NK cells one 
or two weeks prior to relapse in non-B-ALL patients. Therefore, monitoring the NK 
cell chimerism following allo-HSCT may be an important factor for predicting patient 
outcomes and our understanding of their effect on GvL.  
It is also important to note that post-transplant donor lymphocyte infusions (DLI) may 
be utilised when patients are in mixed chimerism as this is associated with a 
reduction in the risk of disease relapse (Marijt et al. 2006; von dem Borne et al. 
2007). The role that NK cells play in DLI-associated responses needs to be 
assessed however. Within our cohort only 15 patients received a DLI. Of those 12 
received DLI due to the presence of mixed chimerism with the remaining three 
receiving the cells due to molecular disease relapse. Of the three patients who 
received the DLI due to relapse all subsequently were deceased within a year, two 
from disease relapse and one from GvHD. The impact of receiving a DLI for mixed 
chimerism on disease relapse within this cohort was seemingly quite positive. Ten 
out of the twelve patients were alive at two years post-transplant. Four of the twelve 
patients received an original transplant with a low NK cell dose, only one of whom 
went on to relapse. Determining the impact that the NK cell dose plays in this context 
is currently unclear but represents an exciting opportunity for future study. A large 
cohort in which assessment of the DLI composition was undertaken, and correlated 
with clinical response, could provide more insight into this question.  
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Potential clinical applications 
	
The potential benefits of using NK cells in the treatment of haematological 
malignancies are clear, yet evaluating suitable strategies to harness these effects 
are still under intense investigation (Cooley et al. 2018; Bachanova & Miller 2014). 
The data presented in this thesis has the potential to influence donor selection, stem 
cell graft composition and the ability to predict patient relapse within two weeks of 
allo-HSCT. It also provides insight into further ways to manipulate adoptively 
transferred NK cells and our understanding of the role NK cells play in producing a 
GvL effect.  
Firstly, it may be worth applying a NK cell threshold of 6.3 x 106 cells per kg for 
patients undergoing T-cell depleted allo-HSCT within the context of a prospective 
clinical trial. Harvested donor CD34+ haemopoietic stem cells are already 
enumerated following collection, and the additional assessment of CD3-CD56+ cells 
should therefore be feasible. Where NK cell dose is inadequate, a second 
aphaeresis procedure may be possible, as up to 2 x 107 NK cells per kg can be 
obtained from a single donor lymphapheresis (Miller et al. 2005). As mentioned 
above, the use of G-CSF would be necessary to achieve this. Alternatively the 
production of large numbers of activated NK cells expanded ex vivo could be used 
as an ‘off the shelf’ treatment alongside allo-HSCT (Baggio et al. 2017; Boyiadzis et 
al. 2017).  
NK cells for adoptive transfer can be sourced in several ways, either directly from 
cord or peripheral blood, or differentiated from CD34+ progenitor cells. NK cells 
differentiated from cord blood CD34+ cells are effective killers of target cells when 
either resting or following CTV-1 tumour cell line priming or IL-2 stimulation in vitro, 
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comparable to peripheral or cord blood NK cells (Domogala et al. 2017). They can 
be produced in large numbers, retain their function following cryopreservation and 
have longer telomeres and a less terminally differentiated phenotype than peripheral 
blood NK cells, suggesting they may continue to proliferate well in vivo.  
Alternatively, cell lines established from patients with clonal NK cell lymphoma 
provide a source of cytotoxic and genetically manipulatable NK cells. In particular 
NK-92 has been safely given to patients and has been shown to confer a clinically 
significant response in several solid tumours and haematological malignancies 
(Klingemann et al. 2016). This population of pure and activated continually growing 
NK cells that can easily be manipulated to acquire specific targeting potential 
provides an ‘off the shelf’ adoptive NK cell transfer option that has several 
advantages over NK cells collected from patient or donor peripheral blood.    
Determining the best time to give additional NK cells is also important. NK cells given 
in isolation are capable of persisting when patients receive intense conditioning 
(Miller et al 2005). When received as part of the stem cell graft they can also persist 
but as in vitro culture of NK cells with leukemic blasts leads to the downregulation of 
DNAM, it suggests that donor NK cells in the presence of residual tumour within the 
host may eventually succumb to immune evasion mechanisms (Sanchez-Correa et 
al. 2011). Therefore the infusion of additional NK cells post-transplant may also 
prove beneficial enhancing upon the work performed by the initial stem cell graft NK 
cell population and could be used as a rescue strategy for patients with poor NK cell 
reconstitution. NK cells can be safely given in this context however larger trails are 
needed to prove the effectiveness of this procedure (Shaffer et al. 2016).   
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It is also worth noting that weight-based dosing may not be the best method of 
determining the quantity of cells that should be given. Immune cells are not a drug 
that may diffuse evenly throughout the body, they will traffic to different locations and 
can accumulate differentially in various tissues. As shown there was not a correlation 
between the dose of cells given and the numbers in the peripheral blood at two 
weeks post-transplant. The ability for cells to be accepted within the host requires 
there to be ‘space’ available, which is determined by patient-specific factors and the 
effectiveness of the conditioning regimen used.  
I am interested in the potential to create a mathematical model that could predict 
patient outcomes based upon early immune cell reconstitution dynamics. If validated, 
clinicians could use this to estimate a patients’ recovery following allo-HSCT and 
intervene to prevent aGvHD or relapse at an early stage should the model indicate 
that an event is likely to occur. This could potentially be based on assessment of cell 
number, cellular phenotypes and cytokine serum levels. Whilst this could be an 
effective way to give a general estimate of the probability of a patient outcome, it 
would need to be proven to be highly predictive for individual patients.    
Enhancement of the priming of NK cells is another method where a beneficial 
application could potentially be developed. The identification of DNAM as an 
important NK cell receptor for protection against relapse post allo-HSCT makes it an 
ideal therapeutic target. Donor selection based upon high DNAM expression, or the 
application of immunotherapeutic methods to enhance DNAM specific killing, are 
worthy of further investigation. Similarly, attempts to increase DNAM ligand 
expression in patients could be explored. Nitric oxide can increase CD155 
expression on multiple myeloma tumour cell lines although it is also thought to 
negatively regulate haematopoietic progenitor cell proliferation and would therefore 
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require careful consideration in the allo-HSCT setting (Fionda et al. 2015; Michurina 
et al. 2004). Bortezomib, a proteozome inhibitor used in the treatment of multiple 
myeloma, has been shown at low doses to increase the expression of DNAM and 
NKG2D ligands on the surface of multiple myeloma cell lines. This causes increased 
NK cell functionality against them (Niu et al. 2017). Application of this drug in 
combination with stem cell transplantation may therefore lead to enhanced DNAM 
specific killing of tumour cells.  Alternatively T cell immunoreceptor with Ig and ITIM-
domains (TIGIT) is an inhibitory receptor expressed on NK cells which shares the 
same ligands as DNAM (Yu et al. 2009; Stanietsky et al. 2009). Blockade of TIGIT 
can improve NK cell cytokine secretion and cytotoxicity in a murine model and could 
therefore also be used as a way to increase the effectiveness of DNAM in allo-HSCT 
(Stanietsky et al. 2013).  
Donor KIR and recipient MHC class I expression mismatching is thought to result in 
a population of alloreactive NK cells. This criteria is often taken into account when 
determining patients for haploidentical transplantation. KIR typing has been available 
for over 20 years, but this method does not reliably pick up on subtle allelic 
differences (Uhrberg et al. 1997). The development of high throughput, next 
generation sequencing methods allow more in depth KIR typing and once brought 
into the clinical setting may allow for greater donor patient selection for HLA matched 
allo-HSCT (Maniangou et al. 2017). 
Similarly, the isolation and expansion of specific NK cell products for patients with 
discrete KIR genotypes could provide an immediate source of alloreactive NK cells 
that could be administered as an immunotherapy. This source of NK cell therapy is 
being explored in an autologous transplant setting for treatment of multiple myeloma. 
HLA mismatched NK cells expanded from umbilical cord blood can safely be 
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administered to patients receiving high dose melphalan, which allows space for 
homeostatic proliferation, and lenalidomide which is thought to provide an activating 
effect to the infused NK cells (Snowden & Hill 2017; Shah et al. 2017). The 
adoptively transferred NK cells could be detected at 26 days, a time frame within 
which our data suggests is suitable for a GvL response to be influential. This therapy 
may provide elimination of residual tumour whilst carrying no risk of GvHD. The 
curative potential however is still under consideration and requires greater numbers 
of patients to power the study.     
 
Cytokines have been effectively used to activate NK cells when adoptively 
transferred, in particular IL-2 given intravenously following the infusion (Miller et al. 
2005). The addition of IL-2 promotes changes in cytokine and NK cell population 
dynamics, however the effectiveness of patients receiving IL-2 stimulation compared 
to those whose NK cells are unstimulated has not been definitively shown to impact 
upon clinical outcomes (Brehm et al. 2011). IL-2 administration also results in an 
expansion of host Treg cells which may have a detrimental effect on the immune 
response (Bachanova & Miller 2014). IL-15 is also an effective activator of NK cells 
and can rapidly expand NK cell numbers in the peripheral blood, but does not initiate 
the same Treg stimulation (Conlon et al. 2015). The use of IL-15 alone or the IL-15-
based superagonist ALT-803 following adoptive transfer of NK cells is under 
investigation (Wong et al. 2013; Davis et al. 2015). 
Alternative ways to activate and enhance NK cells besides the use of cytokines 
include NK cell priming through prior exposure to tumour cells such as leukaemia 
cell lines (North et al. 2007; Sabry et al. 2011). This priming occurs via NK cell CD2 
binding to a CD15 ligand on the tumour cell. These cells can be given safely and in a 
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trial of seven patients who received NK cells from haploidentical donors primed in 
this way a GvL effect was potentially produced in four cases (Kottaridis et al. 2015). 
The rapid maturation of NK cells to create a population of CD57+ cells, which are 
functionally more cytotoxic and greater producers of TNF-α and IFN-γ, can be 
achieved through inhibition of GSK3 kinase and expansion with IL-15 (Cichocki et al. 
2017). Adoptive transfer of a population of mature or ‘memory-like’ NK cells may 
have the same potential benefit as the expansion of CD56dimCD57+NKG2C+ NK 
cells seen in CMV infection and protection from disease relapse when reactivation 
occurs post-transplant (Green et al. 2013; Cichocki et al. 2015).  
The artificial activation of NK cells to create an expanded population of primed cells 
is thought to contribute towards beneficial outcomes through the improved 
cytotoxicity and a greater number of cells expanded within the host. Our data 
supports this from an unstimulated standpoint however further manipulation of stem 
cell graft or post-transplant cytokine application may be able to enhance the effect of 
NK cells in allo-HSCT. 
 
Tumour cell killing can also be enhanced by the blockade of inhibitory receptors at 
the surface of NK cells when the target cells still express MHC class I (Vahlne et al. 
2010). Attempts to improve outcomes in AML and multiple myeloma patients through 
KIR2D blockade, potentially creating a population of alloreactive NK cells, have 
shown clinical safety and increased cytokine and NK cell activation but no outcome 
effects so far (Vey et al. 2012; Benson et al. 2012; Korde et al. 2014). Similarly 
blockade of the CD94:NKG2A receptor is also under investigation as it has been 
shown to improve NK cell cytotoxicity of CLL patients as well as haploidentically 
transferred NK cells in vitro (Nguyen et al. 2005; McWilliams et al. 2016).  
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The use of PD-1 blockade has been shown to produce a beneficial GvL response in 
pre-clinical murine models (Koestner et al. 2011; Michonneau et al. 2016). This has 
led to PD-1 blockade being utilised across a range of haematological malignancies 
(Ansell et al. 2015; Younes et al. 2016; Lesokhin et al. 2016). In the context of allo-
HSCT anti-PD-1 monoclonal antibodies are being tested as a treatment strategy in 
relapsed patients following transplant (Haverkos et al. 2017). In these circumstances 
the PD-1 blockade is used primarily as a way to improve T cell antitumor response, 
however this is often accompanied by increased GvHD related mortality. The effects 
this has on the NK cells present are less well studied. Our data suggests that PD-1 
expression on NK cells in G-CSF mobilised stem cell grafts is generally increased 
and that this has a negative impact on the cytotoxic capability of these cells. 
Therefore, pre-infusion graft manipulation or application of PD-1 blockade early post-
transplant could provide beneficial functional effects to the NK cells while not 
influencing the poorly reconstituted T cell compartment. Indeed adoptive transfer of 
NK cells expanded from peripheral blood have been shown to produce improved 
killing of multiple myeloma cells in a murine model with PD-1 blockade (Guo et al. 
2016). This strategy needs to be tested in an allo-HSCT transplant setting but could 
have the potential to improve the NK cell related GvL effect. 
Expression of CD16, the low affinity Fc receptor, on NK cells can also be 
manipulated to influence NK cell function and patient outcomes. Differing allotypes of 
this receptor produce different affinities for IgG however and this can result in 
functional effects. NK cells from VV and VF versus FF genotype donors show 
greater affinity for rituximab the anti-CD20 IgG1 monoclonal antibody utilised in 
several B cell lymphomas (Congy-Jolivet et al. 2008). Therefore donor selection of 
appropriate FcR genotype may improve the ADCC ability of NK cells infused at the 
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time of allo-HSCT. Expression of CD16 on stem cell graft NK cells was significantly 
reduced in comparison to peripheral blood cells. ADAM17 is a metalloprotease which 
is required for CD16 shedding from the cell surface (Romee et al. 2013). Inhibition of 
ADAM17 retains CD16 and results in increased CD16-mediated ADCC. Use of 
ADAM17 inhibition could be tested in donors receiving G-CSF mobilisation to 
establish whether it could maintain the presence of CD16 at the surface of NK cells 
within the apheresis product. However CD16 expression on stem cell graft NK cells 
did not have an effect upon patient outcome which may indicate that ADCC does not 
have a significant role to play in an lymphodepleted individual early post-transplant. 
Therefore a greater propensity for stem cell graft NK cells to perform ADCC may 
only be likely to improve patient outcome in allo-HSCT when combined with 
monoclonal antibody therapy.  
CD16 is also being utilised in the production of bi-specific killer engagers (BiKEs). 
These ex vivo generated molecules comprise of two variable antibody regions, one 
which binds to a tumour antigen and the other to a receptor on the NK cell surface. 
In particular antiCD16xCD33 has been effectively tested against myeloid tumour 
cells in vitro (Gleason et al. 2014; Wiernik et al. 2013). Further development of this 
molecule with the addition of IL-15 produces a trispecific killer engager (TriKE) which 
improves the functional, proliferative and survival capabilities of NK cells in a murine 
model of AML (Vallera et al. 2016). A CD16/IL-15/CD33 TriKe for CD33+ 
haematological malignancies is currently in clinical trials. The use of TriKEs in 
combination with ADAM17 inhibition could be an effective way to enhance stem cell 
graft NK cells in allo-HSCT. 
The development of chimeric antigen receptor (CAR) technology, which has 
predominantly been applied to T cells also has potential with NK cells. In fact CAR 
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NK cells actually have several advantages over CAR T cells such as a shorter life 
span in vivo, less potency to cause a GvHD reaction, they are not CAR restricted in 
their killing mechanism and they are capable of serial target cell killing (Klingemann 
2014). By genetically engineering synthetic receptors into immune cells it can greatly 
improve their specificity against a defined ligand. This is achieved through 
transfection of DNA which can be performed on peripheral blood NK cells, NK cell 
lines or NK cells derived from pluripotent stem cells (Hermanson & Kaufman 2015). 
The efficiency of viral transfection in peripheral blood NK cells however is relatively 
poor (Sutlu et al. 2012). The NK-92 cell line is more easily transfected than primary 
cells and several CAR engineered NK-92 cells have been produced against varying 
targets with successful results in vitro. Anti-CD19-CAR NK-92 cells that are effective 
killers of CD19 expressing leukaemia targets with no change in their cytotoxicity 
against CD19 negative cells have been produced (Romanski et al. 2016). Similarly 
CAR engineered NK-92 cells have been created against target ligands found on 
lymphoid malignancies, multiple myeloma and several solid tumours (Boissel et al. 
2013; Müller et al. 2008; Yang et al. 2005; Chu et al. 2014). Several CAR NK cell 
therapies are currently in clinical trials including one against NKG2D-ligand 
expressing cancer cells. Whilst the transfer of CAR NK cells against specific cancer 
ligands may assist in the treatment of haematological malignancies a DNAM-ligand 
targeting CAR NK cell may also produce longer term beneficial effects in 
combination with allo-HSCT.  
It may also be important to regulate any NK cells that are being adoptively 
transferred, especially if they have been modified in some way. They may be useful 
in producing a GvL response and providing protection from infections in the 
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immediate aftermath of allo-HSCT but their continual persistence may have a 
detrimental effect on healthy reconstitution.  
Most of the current trials involving the adoptive transfer of NK cells are looking to 
harness a short term GvL effect where the NK cell given are primed and therefore 
more adept at directly eliminating residual tumour in the host. Data presented in this 
thesis adds to the backing of this theory, however also suggests that treatments to 
enhance the longer term reconstitution of NK cells within a patient influencing the 
overall immune response may be the key to curing patients rather than just a short 
term beneficial effect. Adoptive transfer of NK cells alone does not seem to produce 
substantial long term results suggesting that the beneficial effects of allo-HSCT as a 
whole are also important and that the role of NK cells in the stem cell graft are 
necessary to allow time for this to generate and promote their effects. 
 
Allo-HSCT is developing towards a much more individualised treatment and it is 
becoming clear that stratification of transplant conditioning and post-transplant 
management can help to improve clinical outcomes. This may benefit from 
assessment of immune measures that optimise NK cell engraftment. However, 
determining the best method of harnessing the beneficial effect of NK cells in allo-
HSCT still requires more understanding of their basic biology and the fundamental 
mechanisms of GvL.    
 
Strengths and limitations of this study 
 
My access to a large and relatively uniform cohort of T cell depleted transplant 
recipients and ability to collect clinically relevant samples was excellent. Peripheral 
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blood samples collected during the first month post-transplant allowed for 
measurement of reconstitution during this early time period. However, the low 
cellularity at these early time points and ethical restrictions on the volume of blood to 
be collected meant that calculations of cell numbers, at day 0 and day 7 particularly, 
must be treated cautiously.  
Residual cells collected from the infusion bag following transfer into the patient were 
used to assess the cellular composition of the stem cell graft. The cells in these 
samples were often adhesive to one another and would on occasion require filtering, 
especially following cryopreservation. This complicated analysis of some flow 
cytometric panels and the ability to obtain sufficient cells for cytotoxic assays. 
Obtaining “fresh” stem cell graft samples prior to infusion would reduce this concern 
but would require further ethical approval.  
All samples were collected over the course of three years and therefore correlations 
with clinical outcomes were limited by the time since transplantation. Whilst aGvHD, 
by definition, develops within 100 days post allo-HSCT, relapse usually occurs 6 
months to a year later (Tauro et al. 2005). Within my analysis cohort, survival could 
be assessed for all patients at 1-year post transplant which will capture most 
episodes of relapse. Despite this, assessment of survival over a longer time period 
would be a valuable measurement. 
This project benefited from being able to use clinically relevant samples from a 
relatively large cohort of patients undergoing allo-HSCT, however it must also be 
noted that there was a large range of disease, patient and donor characteristics. 
Over the course of the study transplant procedures at the hospital have been 
consistent, as well as the leading personnel who decide upon the actions for each 
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patient, maintaining a level of reliability in transplant management. Whilst many 
clinical factors are beyond the control of the researcher it is important to be aware of 
them when trying to undertake analysis.  
The majority of data acquired in the research was obtained through multicolour flow 
cytometry. Whilst this permits analysis of many thousands of cells per sample, the 
major limitation is the finite number of markers that can be analysed and the 
complicated compensation entailed, plus the subjective nature of the analysis which 
accompanies increases in this number. Whilst the analysis was validated, some 
degree of human error is likely. In future analyses, the development of automated 
flow gating software to more reliably assess the data, especially with increases in 
markers identified, will be useful to remove the subjective element of analysis 
(Verschoor et al. 2015).  
 
Overall findings 
 
It was hypothesised that the impact of NK cells on transplant outcome was most 
likely to be observed during the first month after T cell-depleted transplantation. 
We set out to appraise this and found that: 
• NK cells reconstitute quicker and in greater volume than T cells after T cell 
deplete allo-HSCT, with high numbers of NK cells in the peripheral blood at 
two weeks associating with protection from relapse. 
• NK cells derived from the stem cell graft are phenotypically and functionally 
different to those derived from the peripheral blood of healthy individuals with 
reduced cytotoxic capacity and an enhanced immature population.      
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• High CD56dim NK cell dose in the stem cell graft associates with protection 
from disease relapse following allo-HSCT, suggesting an NK cell mediated 
role in GvL produced by these cells. 
• High frequency of DNAM expression on CD56dim NK cells in the stem cell 
graft associates with relapse protection following allo-HSCT, indicating that an 
effective GvL effect may by partially produced through DNAM mediated 
cytotoxicity.    
My findings therefore support the beneficial effect of using large numbers of NK cells 
within a stem cell graft during T cell depleted allo-HSCT.  
 
Concluding remarks 
	
The ethical and logistical restrictions of translational research make it a challenging 
undertaking, but an incredibly rewarding one when progress is achieved. Allogeneic 
hemopoietic stem cell transplantation is a complicated treatment given for a large 
range of haematological malignancies. The large degree of variability in this process 
can produce seemingly contradictory results and separating out the differing effects 
and influences of the factors involved is important in improving our knowledge of how 
best to apply this treatment. Compiling and sharing information from transplant 
centres across the world is the only way to continually improve this treatment which 
benefits the lives of thousands of patients worldwide each year. The work in this 
thesis has hopefully made a useful contribution to this scientific area which can be 
built upon to improve patient outcomes.  
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